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ABSTRACT
Around 20% women of reproductive age are found to have polycystic ovaries 
(PCO) during ultrasound examinations and approximately 10% have symptoms of 
polycystic ovary syndrome (PCOS), which is associated with multiple risk factors 
for cardiovascular disease. The aim of this thesis was to investigate arterial 
mechanical properties and responsiveness to vasoactive stimuli in young women 
with PCOS, PCO and controls, using non-invasive ultrasound techniques. The 
influence of PCOS-related endocrine and metabolic perturbations on aortic function 
was investigated in a mifepristone-treated rat model of PCOS.
The carotid artery pulsatility index was decreased in PCO and PCOS women and 
there was a paradoxical vasoconstrictor response to a dilator stimulus in these 
women relative to controls. Vascular compliance was decreased in the internal 
carotid artery in PCO and PCOS women; PCOS women also exhibited increased 
intima-media thickness (IMT) of the common carotid and common femoral arteries 
compared with controls. In the cutaneous microcirculation, the response to the 
vasodilator acetylcholine (ACh) was depressed in PCOS women, whilst the 
response to sodium nitroprusside (SNP; nitric oxide donor - NO) was unaffected.
Mifepristone-treated rats exhibited increased serum luteinising hormone, 
testosterone, and polycystic ovaries. Ultrasound analysis indicated that aortic 
diameter and blood flow in vivo were unaffected in treated rats, but aortic 
compliance was reduced.
In-vitro assessment of endothelial and vascular smooth muscle function of rat aorta 
demonstrated decreased relaxation with ACh, which was not abolished by L-NAME, 
however, the effect of SNP was greater, a finding which raises the possibility of an 
alternative dilator mechanism that may be independent of NO system.
Since increased IMT, endothelial dysfunction and abnormal reactivity are independent 
risk factors for cardiovascular disease, these results also provide evidence of preclinical 
atherosclerotic surrogate markers in women with PCOS and PCO. These findings 
increase the likelihood of an association between PCOS (and probably PCO) and 
cardiovascular morbidity and mortality.
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CHAPTER 1
GENERAL INTRODUCTION
20
1.1 Background
The definition of polycystic ovary syndrome (PCOS) is now much wider than that 
originally described by Stein and Leventhal (1935) of ‘oligo/amenorrhoea, 
hirsutism, obesity and enlarged ovaries with multiple cysts and thickened tunica’ 
(Taylor, 1998). Traditionally, the diagnosis of PCOS was based primarily on the 
typical appearance on histological examination of bilateral sclerotic ovaries with 
thickened stroma, i.e. polycystic ovaries (PCO), in women presenting with 
anovulation, hirsutism or both (Goldzieher and Green, 1962). In the 1970s, the 
introduction of radioimmunoassay techniques caused a shift away from histological 
diagnosis, to the use of serum biochemical markers characteristic of PCOS, such as 
elevated concentrations of luteinising hormone (LH), testosterone (T) and/or 
androstenedione (A), low or normal levels of follicle stimulating hormone (FSH), 
and decreased sex hormone binding globulin (SHBG) (Conway et al, 1989; Franks, 
1989). The advent of ultrasound technology in the 1980s led to a definition based 
on non-invasive ovarian imaging (Swanson et al, 1981; Parisi et al, 1982; Adams et 
al, 1985). Although the ultrasound criteria for the diagnosis of PCO have never 
been universally agreed until 2004, the initially accepted characteristic features in 
PCO were an increase in the size (volume) / number of follicles and stromal 
volume within an ovary relative normal ovaries (Dewailly, 1997).
Until recently, there was no consensus about which criteria (clinical, morphological
or endocrine) best characterised PCOS. The predominantly European definition
required PCO morphology on ultrasound (Adams et al, 1985), associated with
menstrual disturbance (usually oligo- or amenorrhoea) and/or clinical signs of
hyperandrogenism (hirsutism, acne or alopecia). No serum hormonal parameters
21
were required to make the diagnosis. In contrast, the definition proposed by the 
National Institute of Health of the USA (1990) did not include ultrasound features 
of PCO, but stipulated that clinical symptoms such as anovulation and/or 
hyperandrogenism should serve as the selection criteria, with serum hormonal 
results used to exclude other conditions, such as diseases of the adrenals or pituitary 
including adult-onset congenital adrenal hyperplasia, hyperprolactinaemia and 
androgen secreting neoplasms (Zawadzki and Dunaif, 1992).
The lack of universally accepted and used diagnostic criteria for defining PCOS has 
made the comparison of studies assessing cardiovascular risk difficult. At a recent 
joint American Society of Reproductive Medicine/European Society of Human 
Reproduction and Embryology (ASRM/ESHRE) consensus meeting (The 
Rotterdam ESHRE/ASRM-Sponsored Consensus Workshop Group, 2004), refined 
diagnostic criteria for PCOS were agreed, which should have worldwide 
acceptability. The criteria require two out of three of the following to support a 
diagnosis of PCOS:
1. Symptoms -  menstrual disturbance, anovulation
2. Clinical and/or biochemical signs of hyperandrogenism (hirsutism and/or acne)
3. Ultrasound appearance of PCO
Although there have been no specific population-based prevalence studies, the
incidence of PCOS has been estimated at 5% to 10%, making it one of the most
common endocrine disorder in women of reproductive age (Dunaif, 1997). This
estimate was based on the upper limit of the prevalence of around 20% in self
22
selected normal women with PCO on ultrasound (Adams et al, 1985; Poison et al, 
1988; Clayton et al, 1992); the lower estimate was based on the prevalence of 
androgen excess and chronic anovulation in a random population (Dewailley,
1997).
A spectrum of clinical and endocrine variations in PCOS has not only been reported 
within a population (Clayton et al, 1992), but there appears to be ethnic diversity as 
well. For example in the USA, the prevalence of PCOS in Caribbean-Hispanic 
women is twice that in African-American and Caucasian women (Weiss et al, 
1987). In contrast to women in the USA or Italy, Japanese women with PCOS 
exhibit a lesser degree of hirsutism (Carmina et al, 1997), whilst in the British 
population hirsutism is present in 14% of women with PCOS (Clayton et al, 1992). 
A major difference between the Asian, i.e. women from the Indian subcontinent 
(Rodin et al, 1998), and the Caucasian groups is related to menstrual patterns 
(Clayton et al 1992). In the Asian population nearly 50% of women with PCOS 
have menstrual irregularity, whilst menstrual irregularities occur much less 
commonly in the Caucasian group (24%; Clayton et al, 1992).
PCOS was not considered to affect general health until 1980, when it was found to
be associated with insulin resistance (Burghen et al, 1980). Hyperinsulinaemia is
frequently present in 18% -  20% of obese PCOS women and has an important
influence on symptomatology, affecting menstrual cyclicity and the severity of the
clinical signs of hyperandrogenism (Dunaif, 1997). In addition to obesity (Evans et
al, 1988; Pasquali et al, 1993) and insulin resistance (Dunaif, 1992), the syndrome
is also associated with dyslipidaemia (Wild et al, 1985; Conway et al, 1992, Talbott
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et al, 1998), impaired glucose tolerance (Dunaif et al, 1987; Conway et al, 1990; 
Robinson et al, 1993) and hypertension (Conway et al, 1992, Talbott et al, 1995; 
1998), suggesting that PCOS women might be at increased risk of cardiovascular 
disease (Wild et al, 1990; Guzick et al, 1996; Birdsall et al, 1997; Talbott et al,
1998).
Insulin resistance which in turn is associated with risk factors for cardiovascular 
disease is often seen in association with a cluster of abnormalities in the Metabolic
' j
Syndrome such as obesity (body mass index (BMI) > 30 kg/m ) particularly 
abdominal obesity ((W/H > 0.88), hypertension (systolic blood pressure (SBP) > 160 
mmHg or diastolic blood pressure (DBP) > 95 mmHg or drug treatment for 
hypertension), elevated fasting serum triglyceride (> 1.70 mmol/L), fasting HDL 
(>1.20 mmol/L), hyperinsulinaemia (fasting insulin levels > 13.0 mU/L) (Reaven, 
19.95). The fact that women with PCOS exhibit features of the Metabolic Syndrome is 
therefore suggestive that they be at an increased risk of developing coronary heart 
disease or stroke. It therefore appears that hyperinsulinaemia could be involved in the 
pathogenesis of a wider spectrum of diseases than originally anticipated.
Long-term follow-up studies have shown that women with PCOS are at an
increased risk (3-7 fold) of developing type II diabetes, relative to the general
female population, (Dahlgren et al, 1992a; Pierpoint et al, 1998; Wild et al, 2000,
Cibula et al, 2000) and exhibit a greater than 7-fold increased risk of cardiovascular
disease (Dahlgren et al, 1992b). However, the relationship between cardiovascular
disease and PCOS was challenged by Pierpoint in 1998 in the only mortality study
in women with PCOS performed to date, which showed no increase in deaths from
24
heart disease related to PCOS.
As previously stated, some there are studies suggest that women with PCOS have 
extensive cardiovascular disease. Wild et al (1990) reported that both pre- and post­
menopausal women with coronary artery stenosis on cardiac catherisation exhibited 
an increased prevalence of hirsutism, increased waist-to-hip ratio (W/H), diabetes 
and hypertension than women without coronary artery lesions. Furthermore, Guzick 
et al (1996) reported increased intima-media thickness (IMT) in the carotid artery 
in PCOS women relative to controls, this being an early indication of subclinical 
atherosclerosis. Similarly, in a larger study, Talbott et al (1998) reported increased 
IMT in PCOS women aged 45 years or more compared to controls, even after 
adjusting for age and body mass index. However, in women aged less than 45 
years, no significant difference in IMT was found between those with PCOS and 
controls, although a higher proportion of those with PCOS had an increased 
atherosclerotic index (the mean IMT measured at eight sites) compared to controls. 
Although the progression of disease from increased IMT, through plaque formation 
to alteration in blood flow is lacking, increased IMT is viewed as an early 
indication of atherosclerosis. Further evidence of an association with 
atherosclerosis was provided by Birdsall et al, (1997), who reported that women 
with ultrasound detected PCO had more coronary artery segments exhibiting > 50% 
stenosis, and a trend towards greater severity of ischaemic heart disease, than 
women with normal ovaries.
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There is evidence of circulatory changes in women with PCOS (Battaglia et al, 
1995; Aleem and Predanic, 1996), though haemodynamic studies outside the pelvis 
are limited. Using two dimensional, M-mode and pulsed Doppler echocardiography 
in 26 women with PCOS (menstrual irregularity, hirsutism -  elevated T, raised LH 
and decreased SHBG concentrations and PCO on ultrasound, as described by 
Adams, 1985) and 11 healthy non-hirsute age-matched control women with regular 
ovulatory cycles, Prelevic reported decreased flow velocity over the aortic arch 
(Prelevic et al, 1995) and higher resting forearm flow (Prelevic et al, 1996) in 
women with PCOS.
It is generally accepted that the endothelium plays an active role in regulating
vascular tone and in modulating vascular smooth muscle cell migration and growth
(Cannon, 1998; Quyyumi, 1998). Intact endothelium is required to prevent
premature atherosclerosis, and impaired endothelial function has been associated
with increased risk of cardiovascular disease (Li and Fostermann, 2000). There is
increasing evidence of endothelial dysfunction in women with PCOS (Wild, 2002).
In obese PCOS women (exhibiting elevated free serum T levels, hirsutism and
amenorrhoea or oligomenorrhoea < 6 periods per year), methacholine chloride
(MCh) induced dilatation in leg blood flow (measured using a thermodilution
catheter placed in the femoral vein) was impaired relative to obese controls
(Steinberg et al, 1996). This was suggestive of endothelial dysfunction since MCh
requires active endothelium to mediate its effect. Furthermore, the impairments
correlated directly with insulin resistance and hyperandrogenaemia in PCOS
women (Steinberg et al, 1996), and returned to normal with insulin sensitising
agents (Paradisi et al, 2001), suggesting that PCOS is associated with endothelial
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dysfunction may be associated with elevated serum T and/or insulin concentrations.
It is apparent that women with PCOS exhibit a number of hormonal, metabolic and 
vascular abnormalities that may increase their risk of premature cardiovascular 
disease. The process of macro-and micro-arterial dysfunction may start at an earlier 
stage in the reproductive life of women with PCOS, indicating that the vascular 
function is different in young women with PCOS and that they might be ‘older’ 
from the circulatory point of view.
The hypothesis under study in this thesis is that women with PCOS have vascular 
and haemodynamic abnormalities, similar to those seen in Type II diabetes, which 
are consequently associated with an increased risk of developing cardiovascular 
disease.
To test this hypothesis the aims of this thesis are to assess:
1. Vascular resistance and vascular reactivity in the common and internal 
carotid in women with PCOS, asymptomatic women with PCO and age- 
matched control women.
2. Viscoelastic properties in the common and internal carotid arteries in 
women with PCOS, asymptomatic women with PCO and age-matched 
control women.
3. IMT in muscular and elastic arteries in women with PCOS, asymptomatic 
women with PCO and age-matched control women.
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Endothelial function in the skin microcirculation in young women with 
PCOS and age-matched control women.
Mechanical vascular properties, and endothelial and vascular smooth 
muscle function, in a rat model of PCOS.
CHAPTER 2
POLYCYSTIC OVARY SYNDROME
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2.1 Introduction
Numerous biochemical parameters and ultrasound appearances together with a 
combination of clinical features have been reported in the diagnosis of PCOS, but 
until recently no universally accepted criteria have been adopted for clinical and 
research purposes (Homburg, 2002). Since the first international conference on 
PCOS (1990) at the National Institute of Health in Bethesda, Maryland, it has 
become apparent that the syndrome encompasses a broader spectrum of signs and 
symptoms of ovarian dysfunction than was defined by the original diagnostic 
criteria (Zawadski and Dunaif, 1992). The recent 2003 Rotterdam Consensus 
workshop on the diagnostic criteria for PCOS bridges the gap between biochemical 
marker-based diagnosis, predominantly used in the US and Canada, and the 
European reliance on ultrasound detection of PCO morphology. The diagnostic 
criteria agreed at this workshop may eliminate the selection bias caused by the 
variable definitions previously used and also contribute much to future work, 
especially the long-term consequences of this most common endocrinopathy.
2.2 Diagnosis of Polycystic Ovary Syndrome
As described earlier, although the first description of the condition now known as
PCOS dates back to the mid 1930s (Stein and Leventhal, 1935), a consensus
definition (clinical, morphological and/or endocrine) which best characterises the
syndrome was only reached in 2003 (Balen and Michelmore, 2002; Homburg,
2002; Balen et al, 2003). The range of presentation extends from the sole finding of
PCO on pelvic ultrasound in the absence of other symptoms or signs of the
syndrome (Jacobs, 1987), to women with symptoms of hyperandrogenism,
menstrual irregularity and endocrine disturbances which occur either singly or in
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combination (Balen et al, 1995).
Biological evidence of hyperandrogenism is generally accepted as a sensitive 
marker for PCOS (Hopkinson et al, 1998); however, the serum levels of T and A 
are dependent on the body mass index (BMI), with increased levels in obese 
individuals (Dewailly, 1997). The use of clinical signs of menstrual disturbance or 
androgen excess in the diagnosis of PCOS is limited by the findings of PCO on 
ultrasound in around 20% of normal ovulatory women and in 50-87% of regularly 
menstruating women with hirsutism (Michelmore et al, 1999). The first 
descriptions of the syndrome were based on the macroscopic appearance of the 
ovary (Stein and Leventhal, 1935), but this is now not essential for the diagnosis, 
since the development of high-resolution ultrasound equipment allows non-invasive 
diagnosis of polycystic morphology, in a manner well correlated with 
histopathological diagnosis. On the other hand, as described before, the National 
Institute of Health (1990) definition did not include ultrasound features, but 
stipulated that clinical symptoms such as anovulation and/or hyperandrogenism be 
used as diagnostic criteria for PCOS, with serum hormonal estimates used to 
exclude conditions such as tumours of the adrenals and/or pituitary, congenital 
adrenal hyperplasia and hyperprolactinaemia (Zawadzki and Dunaif, 1992).
2.2.1 Clinical presentation
The seven women described by Stein and Leventhal in 1935 in the index study of
PCOS had symptoms of hirsutism, obesity, infertility and had enlarged polycystic
ovaries. The accepted clinical definition of PCOS is the association of
hyperandrogenism with anovulation without any underlying disease of the adrenal
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or pituitary glands (Zawadzki and Dunaif, 1992). Hyperandrogenism presents as 
hirsutism, acne, and/or male-pattem alopecia and the degree of hirsutism can be 
assessed by the Ferriman-Gallwey score (1961), a simple, semi-quantitative method 
for recording the distribution and severity of excess body hair. Anovulation 
manifests as menstrual disturbance such as amenorrhoea, oligomenorrhoea and 
infertility. Obesity is common but not usually a presenting symptom. The variation 
in clinical presentation is related to the degree of endocrine disturbance (Conway et 
al, 1989; Balen et al, 1995). The majority of women will however present with only 
one or two clinical manifestations, and in clinical practice women with PCOS are 
seen for three major reasons: infertility (mean incidence of 50-75%), menstrual 
irregularity (mean incidence of amenorrhoea 70%) and androgen excess (mean 
incidence of hirsutism 66%; Harrington and Balen, 1996).
In. 1989, Franks analysed 300 patients with clinical features i.e. hirsutism, 
infertility, acne, ultrasound (Adams et al, 1985, 1986) and endocrine features 
(raised serum LH concentrations) of PCOS and 60 volunteers with normal ovarian 
morphology on ultrasound with no history of menstrual irregularity and clinical 
signs of hyperandrogenism. Disturbance of menstrual cycle was a common 
presenting feature, with 52% of women complaining of an irregular cycle or 
oligomenorrhoea, 28% having amenorrhoea and 42% with infertility. On clinical 
examination, 64% of women were found to be hirsute (increased free T levels), 
27% had acne and 35% were overweight (BMI > 25 kg/m2).
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Conway et al (1989) studied 556 women with PCOS (clinical -  
hyperandrogenemia, menstrual irregularity, infertility; ultrasound ovarian 
morphology of Adams, 1985 and endocrine features -  raised LH) and 23 volunteers 
with normal ovaries on ultrasound and with no history of menstrual irregularity or 
hyperandrogenism. They also reported disturbance of the menstrual cycle to be the 
most common presenting feature, 45% of women exhibited irregular cycles, 26% 
amenorrhoea, and 29% complained of infertility. Sixty one percent of women were 
hirsute (increased free T levels), 24% had acne and 35% were overweight (BMI > 
25 kg/m2).
The similarities in the prevalence of symptoms in these two studies (Franks, 1989; 
Conway et al, 1989) in which ultrasound was used as the primary method of 
diagnosis and that of the classic review (Goldzieher and Green, 1962), in which the 
diagnosis was based on histological features of ovaries following wedge resection, 
is shown in Table 2.1. The higher prevalence of infertility in the older series almost 
certainly reflects different criteria for selection, i.e. clinical symptoms at the 
extreme end of the PCO spectrum, which sufficed to justify surgical intervention.
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Table 2.1 Clinical features of the Polycystic Ovary Syndrome (Modified from 
Franks, 1989).
Feature
Diagnostic Criteria
Ultrasonographic 
(Franks, 1989)
(N = 300)
Ultrasonographic 
(Conway et al, 1989)
(N = 556)
Histologic
(Goldzieher and 
Green, 1962)
(N = 1009)
percent frequency
Hirsutism 64 61 69
Acne 27 24 -
Obesity 35 35 41
Infertility 42 29 74
Amenorrhoea 28 26 51
Oligomenorrhoea § 52 45 29
Regular menstrual cycle 20 25 15
§ Values include women with abnormal pattern of uterine bleeding.
2.2.2 Endocrine profile in PCOS
With the advent of radioimmunoassay in the 1970s, the diagnostic criteria for 
diagnosis of PCOS were changed to include the use of serum biochemical markers 
of the syndrome. As described in Chapter 1, numerous endocrine parameters have 
been reported in the diagnosis of PCOS including increased circulatory levels of 
LH, LH/FSH ratio, T, A, free androgen index (FAI), normal or increased levels of 
FSH and decreased SHBG levels (Yen et al, 1970; Franks, 1989; Conway et al, 
1989; Pache et al, 1993; Holte et al, 1998). Such endocrine profiles have been 
reported in women with PCOS that include oligomenorrhoea and amenorrhoea, 
obese and non-obese women, hirsute and non-hirsute, high and normal LH, high 
and normal T, after surgery and following treatment. However, controversy was
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still present until recently as to which endocrine parameter, single or in 
combination, best describes the syndrome.
As described before, in Frank’s (1989) study of 300 patients with PCOS and 60 
volunteers, the overall serum endocrine results of women with PCOS were similar 
to that described in the classical Stein-Leventhal syndrome: raised concentrations 
of LH, T and A. The serum concentrations of LH (>10 IU/L), T (> 2.6 nmol/L), 
and A (> 2.6 nmol/L) were significantly higher in women with PCOS than in 
normal subjects in the early to mid-follicular phase of menstrual cycles. Of 
particular interest was that, although both hirsute and non-hirsute women had raised 
total serum concentrations of T and A, the differences between these two groups 
were not statistically significant. Women with PCOS also had lower concentrations 
of SHGB, and therefore increased FAI compared to control women. Although there 
was a wider distribution of prolactin concentrations in the PCOS women, no 
detectable (radiological) abnormalities of the pituitary were noted and the serum 
concentrations of LH and T were not associated with prolactin concentrations. 
There were no significant differences in FSH concentrations between the two 
groups.
Conway et al (1989) studied 556 women with PCOS and 23 volunteers with normal 
ovaries and reported raised levels of LH, T, A and FAI, and low concentrations of 
SHBG and normal FSH levels in women with PCOS. This study revealed that 44% 
(n = 244) of women with serum LH concentrations > 10 IU/1 had a higher incidence 
of infertility than those with serum < 10 IU/1, and that oligomenorrhoea was 
significantly more common in the high LH group than in the normal LH group. 
Secondly, 22% of women (n = 110) had serum T concentrations exceeding 3.0
35
nmol/1; hirsutism was more prevalent in this group than in those with normal serum 
concentrations. The prevalence of menstrual disturbances was not different between 
these two groups.
Until recently no consensus had been agreed on the definitive biochemical 
definition of the syndrome. Most women with PCOS have evidence of 
hyperandrogenism, and it has also been suggested that circulating androgen levels 
may represent an inherited marker for androgen excess (Legro et al, 1998). 
However, there is evidence that a proportion of women with PCOS may be 
asymptomatic (Balen et al, 1995). The limitations in defining androgen excess 
include the wide variability in the normal population; age and BMI have not been 
considered when assessing androgen levels. Multiple androgen definitions have 
also been reported (Bili et al, 2001), together with the inaccuracy and variable 
laboratory methods often used (Vermeulen et al, 1999).
With regards to LH, both the absolute level of circulating hormone as well as its 
relation to FSH levels is significantly elevated in PCOS women compared with 
controls (Fauser et al, 1991). Increased LH concentrations have been reported in 
around 60% of women with PCOS (Van Santbrink et al, 1997), whereas LH/FSH 
ratio may be elevated in as many as 95% women (Taylor et al, 1997). The 
limitations of using LH as a diagnostic endocrine parameter is that ovulation 
normalises its concentration, is higher in lean women and is also influenced by the 
assay system used.
With these limitations, The Rotterdam ESHRE/ASRM-Sponsored Consensus 
Workshop Group recommended the measurement of free T or FAI as the most 
sensitive method of assessing PCOS (Cibula et al, 2000) and the measurement of 
the serum LH was not considered necessary for clinical diagnosis of PCOS. LH
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concentration should only be used as a secondary parameter, especially in lean 
women with amenorrhoea or in research.
2.2.3 Ultrasound in the diagnosis of PCO
Although ultrasound had already been used in therapy and was proposed for 
diagnosis in 1937, no successful attempt to apply the echo-sounder principle to 
medical diagnostics was made until the early 1950s. X-ray pelvic pneumography 
(air introduced in the peritoneal cavity followed by x-ray examination) was first 
used to visualise the ovaries (Edwards et al, 1961). Although the ovarian outline 
was well described, pneumography provided no information regarding the internal 
morphology of the ovary. In the mid 1960s, Prof. Ian Donald developed 
ultrasonography as a technical aid for gynaecological diagnosis. The static B- 
scanners of the mid 1960s allowed visualisation of ovarian enlargement and cysts 
measuring greater than 1 cm in diameter (Fleming et al, 1999). The poor resolution 
of the ultrasound equipment used in the early 1970s only permitted visualisation of 
the ovarian outline, and the diagnosis of PCO was based upon increased maximum 
length (> 4.0 cm).
However, the use of a single dimension may lead to false positive results when the 
full bladder compresses the ovary or false negative results when the ovaries are 
spherical rather than ovoid. In fact the PCO tends to be more spherical in shape so 
that the sphericity index, expressed as ovarian width to ovarian length ratio < 0.7 
and decreased uterine width to ovarian length ratio < 1.0, have also been reported in 
the diagnosis of PCO (Ardaens et al, 1991). Thereafter, the development of grey
scale equipment in the 1970s and of real-time sector scanners in the 1980s
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improved resolution, and for the first time cysts less than 1 cm could easily be 
recognised (Swanson et al, 1981).
In 1981, Swanson and colleagues reviewed, over a 12-month period, 863 female 
patients referred for pelvic ultrasound examination. Among 863 scans performed 
(3.5 MHz transabdominal (TA) approach), 22 women showed evidence of PCO. 
The ovaries were symmetrically enlarged with a mean ovarian volume of 12.5 cm3 
(range 6 - 3 0  cm3), three times the normal ovarian volume as reported by Sample et 
al (1977). Swanson et al (1981) described two patterns of follicular distribution in 
PCO. The characteristic multiple cysts, measuring 2 - 6  mm in diameter, were 
either uniform in size and arranged in a 'necklace' distribution around the periphery, 
or were of variable size and scattered throughout the ovarian parenchyma. 
Although the number of follicles was recorded, the ovarian stromal characteristics 
were not described.
In a study by Parisi et al (1982) of 78 women who presented with clinical 
symptoms of the syndrome (amenorrhoea, oligomenorrhoea, hirsutism, obesity or 
infertility), symmetrically enlarged ovaries on ultrasound examination were 
apparent in only nine cases and were surgically confirmed in four cases (mean 
ovarian volume = 17 cm ). In the four cases in which surgery was carried out, the 
symmetrical enlargement of the ovaries corresponded to the ultrasound findings. 
The remaining 68 patients had ovaries of normal size and were affected by other 
endocrinopathies.
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The importance of ovarian size as an ultrasonographic criterion of PCO has 
decreased as various groups showed that about one-third of patients with PCO had 
ovaries of normal volume (Orsini et al, 1985; Nicolini et al, 1985). This is because 
the later studies exhibited a wide range of clinical and endocrine abnormalities, 
whereas Swanson (1981) and Parisi (1982) included women with enlarged ovaries 
and classic Stein and Leventhal syndrome, which therefore represented the extreme 
end of the clinical spectrum. The presence of an increased number of cysts has 
become an important ultrasound criterion of PCO, particularly when the ovary is of 
normal size (Franks, 1989). In 1985, Adams and colleagues, in their study of 76 
women referred for either menstrual irregularity, infertility, hirsutism or acne and 
17 control women with regular ovulatory cycles and normal ovaries on 
transabdominal (TA) ultrasound, refined the ultrasound diagnosis of PCO to 
include the presence of 10 or more cysts measuring 2-8 mm in diameter arranged 
peripherally or scattered around an echo dense stroma. Ovarian volumes were 
found to be higher in PCO (14.6 ± 1.1 cm3) than in either multicystic (8.0 ± 0.8 
cm3) or normal ovaries (6.4 ± 0.4 cm3).
Because of the increased prevalence of PCO in anovulatory women and in those with 
hirsutism (Adams et al, 1986), Poison and colleagues (1988) performed ultrasound 
examination on 257 volunteers (clinical and secretarial staff) who considered 
themselves to be in good health and had not found it necessary to consult a doctor for 
menstrual disturbance, infertility or acne. These women had previously completed a 
detailed menstrual history questionnaire and this was checked at the time of 
presentation for a scan. Ninety-nine women were taking oral contraceptives and were
excluded from the study. Of the remaining 158 women, PCO were found in 36 (23%).
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The Adams criteria have remained in widespread use even after the introduction of 
transvaginal scan (TVS) a decade later. TVS has largely superseded TA ultrasound 
because of its greater resolution and in many cases patient preference. The TVS 
approach provides a more accurate view of the internal structures of the ovaries, 
particularly in obese women. TVS allows visualisation of follicles < 5 mm in diameter 
and the echogenic stroma (Figure 2.1), which corresponds closely to the characteristic 
histopathological changes (Figures 2.2 and 2.3)
Figure 2.1 Transvaginal image of a polycystic ovary showing peripheral distribution of follicles
(arrows)
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Figure 2.2 Correlation between histological and ultrasonic features of 
polycystic ovary. This photograph sets artificially side-by-side the ultrasonic 
(lower part) and the histological (upper part) pictures of polycystic ovary.
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Figure 2.3 Stained longitudinal section of a polycystic ovary showing numerous 
small peripheral cysts.
42
There have been at least four definitions of PCO using TVS, the most recent by Fox 
(1999) and Atiomo (2000). In the study by Fox et al (1999) of 60 women with PCO, 
the ovarian volume was 17.6 cm3 with more than 15 follicles of 2—5 mm diameter. In 
contrast, the study of 70 women with PCO by Atiomo et al (2000), reported the 
ovarian volume as > 9 cm3 with more than 10 follicles of 2-8 mm in diameter. A large 
study of 80 oligo-/amenorrhoeic women with PCO compared with 30 control women 
using TVS reported the cut-off values of ovarian volume as 13.21 cm , based on mean 
± SD data from the control group (Fulgheseu et al, 2001). A recent study designed to 
assess variability in the detection of polycystic and normal ovaries utilised four 
experienced practitioners, who independently reviewed recordings of 27 pairs of 
ovaries. The intra-observer agreement was 69.4% and inter-observer agreement 51% 
(Amer et al, 2002). Polycystic ovaries were defined as the presence of > 10 follicles (2 
- 8mm diameter), ovarian volume > 12 cm and bright echogenic stroma. These results 
suggests either that these criteria are too subjective or their measurement too 
insensitive.
Quantification of features of the polycystic ovary
Surface volume
It is necessary to identify each ovary and measure the maximum diameter in each
of the three planes (longitudinal, anteroposterior and transverse). It is appreciated
that, because of the irregular shape of the ovary, any calculation of the volume is an
estimate. Modem ultrasound equipment can calculate the ovarian volume in three
planes, using the ellipsoid formula or by drawing an ellipse round the ovary. The
ultrasound software for this calculation has been shown to be accurate (Balen et al,
2003). In clinical practice ovarian volume is calculated using the simplified ellipse
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formula (0.532 x length x width x thickness) (Swanson et al, 1981). It is noteworthy 
that numerous parameters of ovarian volumes have been reported in the literature 
(Adams et al, 1985; Fox et al, 1999; Atiomo et al, 2000; Fulghesu et al, 2001; Amer 
et al, 2002). It is recognised that not all PCO will be enlarged and that there is an 
overlap with normal ovaries (Lakhani et al, 1998). The consensus view is that until 
more data are available and validated the definition of PCO includes an ovarian 
volume > 10 cm3.
Number and size of follicles.
Each ovary should be scanned in longitudinal cross-section from the inner to outer 
margins in order to count the total number of follicles. Follicle number should be 
estimated in two planes of the ovary in order to estimate their size and position and the 
diameter measured in three planes (Balen et al, 2003). Studies using TA and TV 
ultrasound have reported numerous prerequisite follicular size and number in defining 
PCO (Table 2.2).
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Table 2.2 Diversity results of some ultrasound studies in the literature
Keys: TA -  Transabdominal, TV -  Transvaginal, OS -  ovarian stroma, PCO -  asymptomatic women with polycystic ovaries, PCOS -  Polycystic ovarian syndrome, 
UER -  ultrasound examination route, *total o f both ovaries.
Authors UER Ultrasonic Variable Criteria 
Indicative of 
PCO
% of patients 
with clinical 
PCOS
% of controls 
having the 
criteria
No. of patients 
studied
No. of studied 
controls
Adams et al. 1985 TA Ovarian volume >15cmj 33 0 76 17
No o f follicles 4-10 mm >10 72 0
Yeh et al. 1987 TA Ovarian volume >10 cm3 70 0 108 25
No o f follicles 5-8mm >5 74 11 68 18
Uterine width/ovarian length >1 7 6 100 24
Pache et al. 1992 TV Ovarian volume >8 cm3 About 70 0 52 29
No o f follicles >6mm >11 About 50 0 52 29
Mean ovarian size >4mm About 70 7 52 29
Increased echogenicity o f OS Present 94 10 52 29
Robert et al. 1995 TV Increased stromal area *. 8 cm3 61 4 69 48
Increased maximal ovarian area *>10.8 cm3 55 2 69 48
Fox et al. 1999 TV Ovarian volume 17.6 cm3 60 0 29 35
No of follicles 2-5mm >15 46 0 25 0
Increased echogenicity o f OS Present 60 0 29 2
Atiomo et al. 2000 TV Ovarian volume > 9 cm3 Around 70
No o f follicles 2-8mm > 10 Around 80 Not mentioned 32 40
Increased echogenicity o f OS Present Around 60
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Sample et al (1977) described follicles being < 8 mm in size, whilst Swanson (1981) 
reported the follicular size to be 2-6 mm in diameter, although the number of follicles was 
not recorded or defined. In a study of 70 women, Yeh (1987) reported the follicular 
number as > 5 and the diameter as 5-8 mm for defining PCO. In contrast Adams (1985) 
described PCO as having, in one plane, at least 10 follicles (4-10 mm in diameter) usually 
arranged peripherally, although when scattered through the stroma the follicles were 
usually 2 - 4 mm in diameter. Others claimed that the TV definition of PCO should require 
the presence of at least 15 follicles (2-5 mm in diameter) in a single plane (Fox et al, 
1999), Atiomo (2000) suggests the presence of 10 follicles (2-8 mm diameter) and Jonard 
(2003) gave the threshold of 12 or more follicles of 2-9 mm in diameter.
Until recently there was no agreement with regards to the number and size of follicles in 
defining PCO. In clinical practice the ultrasonographer forms an impression of the ovary 
from the images obtained in three planes. There is therefore still a degree of subjectivity in 
this assessment. The recent consensus definition, agreed in 2003, suggests that the ovary 
should contain 12 or more follicles of 2 - 9 mm diameter (Balen et al, 2003).
Stromal volume and echogenicity
Increased ovarian volume and stromal echogenicity in PCOS is not only a key histological
characteristic (Hughesdon, 1982) but also an ultrasound feature. However, the later is a
subjective assessment, which depends on the setting of the ultrasound machine and
patient’s body habitus (Pache et al, 1991). In a study by Ardaens et al (1991), subjective
assessment of increased stromal echogenicity assessed transvaginally appeared to be
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associated with PCOS; normal stromal echogenicity is said to be less than that of the 
myometrium. Pache (1991) described a semi-quantitative ovarian stromal echogenicity 
score -  normal (1), moderately increased (2) or frankly increased (3) in which the total 
number of follicles in both ovaries combined correlated with stromal echogenicity, and the 
follicle number correlated with FAI. In a computer-assisted method used to assess stromal 
echogenecity in 57 women with hyperandrogenism, 65% had PCO visualised on 
ultrasound and elevated serum T and LH were found in 50% and 45% respectively. There 
was a significant correlation between ovarian stromal volume and A, but not T, LH or 
insulin. Nor were associations present between follicular area and any endocrine 
parameters (Dewailly et al, 1997), suggesting ovarian stromal volume is a better 
quantification of PCO than follicles.
Three-dimensional ultrasound has been reported to be more precise technique than 2-D 
ultrasound for assessing ovarian volume (Kyei-Mensah et al, 1996a, b). The ovarian and 
stromal values were similar in both PCO and PCOS women compared to those with 
normal ovaries and the total follicular volume was similar in all three groups of women, 
indicating that increased stromal volume is the main cause of ovarian enlargement in PCO 
(Kyei-Mensah et al, 1998). Furthermore, there was a positive correlation between stromal 
volume and serum A concentration in women with PCOS. In summary, ovarian volume 
correlates well with ovarian function and is both easily and reliably measured in routine 
clinical practice than ovarian stroma. The consensus definition for PCO does not require 
either quantitative or qualitative assessment of the ovarian stroma.
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Thus, the international consensus for the diagnosis of PCOS now requires two out of three 
of the following criteria (The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus 
Workshop Group; 2004):
1. Clinical — menstrual irregularity -  oligo-/amenorrhoea, anovulation, infertility
2. Biochemical -  free T or FAI
3. Ovarian morphology -  increased ovarian volume > 10 cm or 12 or more 
follicles measuring 2-9 mm in diameter.
Unfortunately, during the time of patient recruitment for this thesis, the international 
diagnostic criteria were not available. For the purpose of this thesis, the selection criteria 
for PCOS was that used in the UK and most of Europe, which included clinical (menstrual 
irregularity -  oligo/amenorrhoea, infertility, hirsutism/acne) and/or biochemical (raised 
LH, T, FAI and reduced SHBG concentration) criteria together with PCO morphology on 
TVS (Balen, 1999).
2.3 Cardiovascular risk factors, morbidity and mortality in women with 
PCOS
As described in Chapter 1, women with PCOS not only have a cluster of risk factors for 
cardiovascular disease but are also at an increased risk of developing type II diabetes, 
dyslipidaemia, hypertension and an abnormal vascular function in later life. This section 
summarises cardiovascular risk factors and the associated morbidity and mortality in 
women with PCOS.
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2.4 Vascular risk factors in women with PCOS
2.4.1 Fat distribution
In general, women with PCOS are more obese than their counterparts (Talbott et al, 1995) 
and, in the original report of PCOS, it was the obese women who tended to have what is 
now known as PCOS (Stein and Leventhal, 1935). Obesity is seen in 35-50% of women 
with PCOS (Balen et al, 1995) and is typically ‘centripetal’ -  related to fat accumulation in 
the centre of the body (truncal abdominal fat) -  resulting in an increased waist to hip ratio 
(Evans et al, 1983; 1988; Pasquali et al, 1993), as opposed to the fat accumulation in the 
thighs and hips (gluteo femoral fat).
There have been few studies comparing body fat distribution in women with PCOS and in 
controls. In a small Swedish study comparing 14 women with PCOS, mean age 29.0 ±3.0 
years and 13 normally menstruating control women, mean age 36.7 ± 0.9 years, the mean 
W/H ratio was significantly higher (W/H = 0.82; a W/H ratio > 0.8 is associated with 
increased risk of stroke -  Bray, 1981) in both obese and non-obese women with PCOS 
compared to controls. Furthermore, larger abdominal fat cells were observed in women 
with PCOS (fat cell size measured microscopically from needle biopsies taken from the 
femoral region -  lateral to the trocanter, and abdominal region -  lateral to the umbilicus) 
than controls, indicating preferential abdominal accumulation of lipid within adipose 
tissue (Rebuffe-Scrive et al, 1989).
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Dahlgren et al (1992a) studied a retrospective cohort of 33 women (mean age, 50 years) 
with ovarian histopathology typical of PCO at wedge resection (22 to 31 years previously), 
who answered a questionnaire and underwent a physical examination and blood test for 
biochemical assay (PCOS group). They were compared with 132 age-matched control 
women (mean age, 51.7 years, invited by questionnaire, and 120 underwent further 
physical and biochemical tests) recruited from a defined female population in Goteberg, 
Sweden. No significant difference in mean BMI was noted between women with PCOS 
and controls. However, the mean W/H was significantly higher in women with PCOS 
compared to controls (0.82 ± 0.1 vs. 0.79 ± 0.1; p = 0.01). This difference remained in 
obese subjects (BMI > 25 kg/m2), the mean W/H being 0.86 ±0.1 in women with PCOS 
and 0.81 ±0.1 in controls.
In a larger case control study (206 women with PCOS and 206 control women) from 
Pittsburgh, USA, the mean W/H was 0.82 in women with PCOS (clinical diagnosis -  
history of anovulation with either clinical evidence of androgen excess (hirsutism) or total 
serum T concentration > 2 nmol/L or LH/FSH > 2) and 0.76 in the controls (selected from 
voters register and directories of households followed by telephone questionnaire 
regarding demographic information and medical history; on acceptance a physical 
examination was performed and blood sample test for biochemical analysis). Although, 
the average BMI was higher in PCOS women (30.5 ± 8.3 kg/m2) than the controls (26.3 ± 
6.46 kg/m2), on multivariate analysis, the W/H was associated with PCOS independently 
of BMI (Talbott et al, 1995).
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In a recent population-based study, Korhonen et al (2001) looked at the relationship of 
metabolic syndrome (characterised by the presence of a cluster of cardiovascular risk 
factors) and obesity to PCOS, in 204 women (defined by a history of ovulatory disorders, 
hyperandrogenism, infertility and PCO morphology on TVS (>10 and <10 mm diameter 
subcapsular follicles), selected from a random sample of women in 5 age groups (range: 
35-54 years) who lived in a defined area. Metabolic syndrome was considered present if 
three of the eight criteria were present (Korhonen et al, 2001):
(1) First-degree relative with type II diabetes
(2) BMI > 30 kg/m2
(3) Waist to hip ratio > 0.88
(4) Blood pressure > 160/95 mm Hg or on drug treatment for hypertension
(5) Fasting serum triglyceride level > 1.70 mm/L
(6) High density lipoprotein cholesterol level < 1.20 mm/L
(7) Abnormal glucose metabolism
(8) Fasting insulin > 13.0 mU/L.
The control group consisted of 62 overweight women without central obesity or metabolic 
syndrome and 53 healthy lean women (BMI < 27 kg/m2). The group with the metabolic 
syndrome differed from the PCOS women according to the selection criteria and also had 
increased serum free T concentration. Oligomenorrhoea was more common in women 
with the metabolic syndrome, especially in PCOS women (46.2%), than in obese (25.4%) 
and lean (15.1%) controls.
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2.4.2 Glucose intolerance
The link between hyperandrogenaemia and abnormal carbohydrate metabolism was first 
suggested in the early 1920s by Archard and Thiers, who described the phenomenon as Te 
diabetic des femmes a barbe’ (the diabetes of the bearded women). Fifty years later, Kahn 
and co-workers (1976) described the syndrome of insulin resistance in six young women 
with acanthosis nigricans (a feathering pigmentation considered as a non-specific marker 
for moderate to severe insulin resistance) -  two of these women were found to have PCO 
morphology, diagnosed by gynaecography in one case and by laparoscopy in the other. 
These women also had hirsutism, primary amenorrhoea, elevated T levels and virilization 
in one case, though neither of them was obese. This presentation, is however rare and 
represents an extreme degree of insulin resistance in PCOS.
As previously described in the cross-sectional, retrospective, cohort follow-up study by 
Dahlgren et al (1992a, b), 15% of women with PCOS and 2.3% of the control women had 
diagnosed type II diabetes, a statistically significant difference. This study did not 
investigate any differences between women other than their PCOS and diabetes status. 
Therefore, it is unclear whether PCOS alone is the cause of the difference in the 
prevalence of diabetes between the two groups of women.
In particular, there was no analysis of the relationship between BMI or W/H and diabetes 
in the PCOS and non-PCOS groups (although these measures of obesity were mentioned 
elsewhere in the paper).
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Ehrmann et al (1999) characterised the prevalence and incidence of glucose intolerance in 
122 women with clinical and hormonal evidence of PCOS, recruited from medical, 
endocrinology, gynaecology and paediatrics clinics. Glucose tolerance (measured by oral 
glucose tolerance test) was abnormal in 55 of 122 women; 43 had impaired glucose 
tolerance and 12 had type II diabetes at the time of the study. Women with type II diabetes 
had a 2.6-fold higher prevalence of first-degree relatives with diabetes and were 
significantly more obese than those with normal glucose tolerance. The prevalence of 
impaired glucose tolerance and type II diabetes in PCOS women was significantly higher 
than expected, when compared with data from studies of age- and weight- matched 
populations of women without PCOS. The authors suggested that the conversion of 
impaired glucose intolerance to type II diabetes is accelerated in women with PCOS. This 
study however is incomplete because it lacked a follow-up of all patients (only 25 from 
122 Were re-evaluated) and there was no control group within the study. At baseline 45% 
of women with PCOS had an abnormal glucose tolerance test. While no causality can be 
inferred, it suggests that the prevalence of abnormal glucose tolerance is higher in women 
with PCOS than in the general population.
Legro et al (1999) studied 254 women with PCOS (ages 1 4 - 4 4  years; unexplained
hyperandrogenic chronic anovulation with a history of irregular menses and elevated
serum T levels) prospectively at two centres; one urban and ethnically diverse (n = 110),
and one rural and ethnically homogenous (n = 144). The control group comprised 80
weight, ethnicity, and age-matched women from the same areas. The prevalence of
glucose intolerance (31.1%) and type II diabetes (7.5%) was significantly higher in women
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with PCOS. In non-obese PCOS women (BMI < 27 kg/m2) the prevalence of glucose 
intolerance and diabetes was 10.3% and 1.5% respectively. Variables that were most 
associated with post-challenge serum glucose levels were fasting serum glucose (p = 
0.0001), PCOS status (p = 0.002), W/H (p = 0.001) and BMI (p = 0.021). The authors 
suggest that PCOS women are at increased risk of impaired glucose tolerance and type II 
diabetes at a young age, and that PCOS may be a more important risk factor than ethnicity 
or race for glucose intolerance in young women.
Cibula et al (2000) selected 28 women with PCOS from a large group who had undergone 
ovarian wedge resection between 1960 -  1981 (PCOS group -  typical appearance of PCO 
on histology followed by a questionnaire study: menstrual history -  oligomenorrhoea > 45 
days or amenorrhoea; hirsutism -  Ferriman and Gallwey score > 8; anovulatory infertility; 
biochemical assay) and compared them to 752 control women selected by age (45 -  59 
years) from a random female population sample. There was no difference in BMI, waist 
circumference, or W/H between the two groups. Both groups had comparable family 
histories with respect to type II diabetes, hypertension, coronary artery disease, and 
smoking habits. Overall the prevalence of type II diabetes was higher in women with 
PCOS and was four-fold higher in women with PCOS aged 45 to 54 years (p < 0.05).
In the only study of mortality in relation to PCOS status, Pierpoint et al (1998) studied 786 
women with PCOS (histological evidence of PCO -  two of the following, thickened 
capsule, subcapsular follicular cysts, luteinization of theca interna, increase in ovarian 
stroma; macroscopic evidence of PCO -  enlarged ovaries, and fibrotic or pearly white
when examined during culdoscopy, laparoscopy or laparotomy; clinical evidence of 
ovarian dysfunction -  hirsutism, secondary amenorrhoea, oligomenorrhoea) diagnosed 
between 1930 and 1979 in the UK, who were followed up for an average of 30 years. 
Though the mortality from all causes in women diagnosed with PCOS was no higher than 
the national rates for women of the same age group, diabetes mellitus was mentioned as an 
underlying or contributing cause of death for six of the women with PCOS, when only 1.7 
deaths would be expected.
The evaluation of Ehrmann’s (1999) study lacks follow-up of all women. At baseline 
nearly half (45%) of PCOS women had an abnormal glucose tolerance. Although one 
cannot determine causality, this suggests that the prevalence of abnormal glucose tolerance 
is high in PCOS women.
Legro (1999) found similar prevalence in two different populations and women with and 
without PCOS were followed to determine the incidence of carbohydrate deterioration. 
Whether the risk is equivalent in non-obese PCOS women cannot be determined.
The study by Cibula (2000) included 28 women from a large group who had undergone 
wedge resection. It is not known whether the 28 women were representative of the main 
group.
In Pierpoint’s study (1998) there were only six diabetes-related deaths recorded and it is 
not possible to consider factors such as BMI or other measures of obesity, which may
contribute to or cause diabetes mellitus. Furthermore, selection bias could be a problem 
because women who underwent wedge resection may have had more severe symptoms 
and for many of the patients potentially available, many records were not retrieved.
2.4.3 Dyslipidaemia
In addition to hirsutism, anovulation, infertility, and gonadotrophin secretion 
abnormalities, PCOS is also associated with metabolic disturbances. Wild et al (1985) 
evaluated lipid concentrations in 29 Caucasian women (mean age 29 years, range 1 8 - 3 7  
years) with PCOS (clinical history of menstrual irregularity -  oligomenorrhoea or 
hyperandrogenaemia -  hirsutism/acne and biochemical abnormality determined by raised 
serum levels of free T and/or dihydroepiandrosterone sulphate) and 30 regularly 
menstruating, healthy Caucasian control women (mean age 32 years, range 1 9 - 4 0  years) 
with no acne or hirsutism. They reported that women with PCOS had higher mean serum 
triglycerides (122 ±11 mg/dl vs. 63 ± 3 mg/dl; p < 0.05) and higher very low-density 
lipoprotein cholesterol levels (24 ± 2 mg/dl vs. 13 ± 1 mg/dl; p < 0.05) but lower high- 
density lipoprotein cholesterol (HDL) levels (43 ± 2 mg/dl vs. 58 ± 2 mg/dl; p < 0.05), 
compared to control women.
Although women with PCOS were heavier and had higher BP, were more sedentary, and 
had diets higher in saturated fat and lower in fibre, the differences in lipid concentrations 
were not solely due to differences in body weight/BMI.
The largest study of dyslipidaemia investigated in 206 PCOS women (clinical diagnosis -  
history of chronic anovulation in association with either clinical evidence of androgen 
excess (hirsutism) or increased total T level or LH/FSH > 2) were recruited using records 
from a large reproductive endocrine clinic, and compared them with the same number of
age and race-matched control women (no history of menstrual irregularity or 
hyperandrogenemia) recruited from a combination of voter’s registration tapes and 
directories of households (Talbott et al, 1995). PCOS women had increased concentrations 
of triglycerides, total cholesterol and LDL, and decreased concentrations of HDL 
compared to control women. After controlling for age, BMI and BP these differences were 
still significant between case and control subjects. This study was extended with repeat 
lipid concentration measurements to assess changes over time (Talbott et al, 1998). The 
results of this subsequent analysis showed that pre- and perimenopausal PCOS women (> 
40 years) had similar LDL cholesterol and total cholesterol levels as their age-matched 
controls, reflecting the LDL cholesterol increases with age among controls.
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Conway et al (1992) defined two groups, one lean (lean BMI < 25 kg/m » n = 48) and one
2
obese (obese BMI > 25 kg/m n = 54), of women with PCO confirmed on ultrasound and 
with clinical features of PCOS. Nineteen lean women with normal ovaries on ultrasound 
and with regular menstrual cycles were recruited from hospital staff as controls; however, 
obese women with normal ovaries were not included. A significant decrease in serum 
HDL cholesterol, but no change in total cholesterol and triglyceride concentrations, was 
noted in lean women with PCOS compared with lean controls. Comparison of obese 
PCOS women and lean controls indicated decreased serum HDL and increased 
triglyceride concentrations in the former but no significant difference in total cholesterol.
Norman et al (1995) compared 97 women with PCOS (clinical and/or biochemical), 21
women with ultrasonically detected PCO but no clinical or endocrine characteristics of
PCOS, and 26 women with neither PCOS nor PCO, who acted as controls. The authors
further subdivided the PCO and PCOS groups into those with regular (PCO, n = 15;
PCOS, n = 43) and those with irregular cycles (PCO, n = 6; PCOS, n = 54). Their control
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group contained 19 lean women without PCO/PCOS. In their initial results, Norman et al 
(1995) reported decreased serum HDL cholesterol concentrations but no significant 
differences in triglyceride, LDL and total cholesterol in serum from women with PCO or 
PCOS compared to control women. When subdivided on the basis of menstrual cycle, 
Norman et al (1995) found triglyceride levels to be higher in the group of women with 
PCO and irregular menstrual cycles than in any other group. However, as this group only 
consisted of six women, the clinical significance of this finding remains open to question.
Most studies have shown a degree of dyslipidaemia in PCOS women. There is however 
less agreement as to which lipid subtractions are affected. Most studies report higher 
levels of triglycerides and LDL cholesterol, and reduced HDL cholesterols, in PCOS 
women compared with controls. However, the dyslipidaemic pattern associated with 
insulin resistance includes intermediate lipoproteins, which play a role in the development 
of lipid disturbances (McKeigue, 1996). Dyslipidaemia is present in different populations 
of women with PCOS throughout the world, though no lipid parameters were distributed 
to an extreme extent. Cases and controls were age-matched only in Talbott’s study (1995) 
and weight-matched in Conway’s study (1992). It is not clear whether the differences in 
lipids between PCOS women and controls persists upto the peri-menopausal age and 
beyond the menopause.
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2.4.4 Hypertension
Studies examining blood pressure in women with PCOS have produced discrepant results. 
In the previously described study of Conway et al (1992) of 102 PCOS women and 19 lean 
women with normal ovaries, obese PCOS women had a higher mean systolic blood 
pressure (SBP) compared to lean women with normal ovaries (122.3 vs. 108.2 mmHg, 
respectively) This study did not include controls matched for BMI.
As previously described by Dahlgren et al (1992b) in a study of 33 PCOS women and 132 
age-matched controls, there was a higher prevalence of hypertension in both age groups in 
PCOS women compared to controls (27.8 % in 40 — 49 years and 53.3 % in 50 — 61 years 
vs. 3.5% and 17.3 %, respectively).
The aim of Holte’s (1996) study was to evaluate office and 24-hour blood pressure in 36 
women with PCOS (mean age 28.2 years [26.6 — 29.8 years]) and 55 control women
(mean age 25.3 years [23.9 — 26.7 years]) matched for BMI (26.3 kg/m2 [24.6 — 28.2 
kg/m2] vs. 25.1 kg/m2 [24.0 — 26.9 kg/m2]). The diagnosis of PCOS was based on 
menstrual irregularity, hyperandrogenism and PCO morphology on ultrasound. Control 
women were volunteers, hospital staff or students with regular menstruation, no hirsutism 
and normal ovaries on ultrasound. Compared with the controls, women with PCOS had 
higher mean daytime systolic blood pressure (126 ± 11 vs. 119 ± 12 mmHg, p < 0.05) and 
higher mean ambulatory arterial blood pressures (92 ± 7 vs. 86 ± 7 mmHg; p < 0.05); the 
groups did not differ significantly in daytime diastolic blood pressure or in night time
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recordings. The increased daytime blood pressure in women with PCOS persisted after 
adjusting for BMI, body fat distribution and insulin resistance, which may indicate a 
prehypertensive state in these women.
Elting et al (2001), evaluated 346 women registered as having PCOS (menstrual 
irregularity and/or hirsutism and/or infertility), who were traced and interviewed by 
telephone. The mean age was 38.7 years (range 30.3 -  55.7 years) and the mean BMI was
24.4 kg/m2 (range 17.5 -  55.8 kg/m2). In women aged 45 54 years, the prevalence of 
hypertension (assessed by a series of questions and if on relevant medication) was 2.5 
times higher (p < 0.01) than in the corresponding age group of the Dutch female 
population. This difference in prevalence was even greater in the younger women (3 5 -4 4  
years).
Zimmermann et al (1992) measured 24-hour ambulatory systolic and diastolic blood 
pressure in 14 women with PCOS (defined hyperandrogenaemia in conjunction with 
oligomenorrhoea, day 21 progesterone < 6.2 nmol/L; mean age 30 ± 1 years) and 18 
normal control women (no menstrual and/or fertility history and day 21 progesterone > 16 
nmol/L; mean age 31 ± 1) of comparable BMI (31 ± 2  vs. 30 ± 2 kg/m2) and race. In 
contrast to the results of many studies, they reported that the ambulatory systolic (121 ± 2  
vs. 118 ± 2 mmHg) and diastolic (76 ± 2 vs. 73 ± 2 mmHg) blood pressures were similar 
in women with PCOS and control subjects.
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Sampson et al (1996) performed a cross-sectional study of 24 non-obese PCOS women 
with irregular menses and classic PCO morphology on ultrasound examination (mean age 
31.7 ± 6.6 years, BMI 23.4 ± 2.8 kg/m2), matched with 26 women with normal menses and 
PCO morphology on ultrasound (mean age 30.3 ± 6.9 years, BMI 22.0 ± 2.7 kg/m2) and 
10 controls with normal menstrual cycles and ovarian morphology on ultrasound scan 
(mean age 31.4 ± 7.2 years, BMI 22.9 ± 2.1 kg/m2). Again no differences in 24-hour, 
daytime, or night time ambulatory blood pressure were noted between groups.
The results of the studies described are conflicting and several potential causes are 
apparent. In Dahlgren’s study, patients were evaluated by wedge-resection, but the 
histological diagnosis of PCOS was controversial, unstandardised, and not uniformly 
recognised among pathologists 22 to 31 years ago. Questionnaire data can be unreliable 
unless the questions are well designed. Blood pressure is commonly not measured with 
strict attention to detail and accuracy, including calibration of the instruments used. 
Numerous factors including genetic causes, inactivity, stress and salt loading affect blood 
pressure, yet none of these factors were controlled for in any of the studies that evaluated 
the small number of PCOS women. Thus further evidence is required to clarify whether 
PCOS is independently associated with hypertension or the increased blood pressures 
found in some studies are related to other contributing factors such as BMI.
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2.5 Polycystic ovary syndrome and the Metabolic Syndrome
Reduced sensitivity to insulin and compensatory hyperinsulinaemia noted in women with 
PCOS was first reported over 25 years ago (Burghen et al, 1980; Dunaif et al, 1987). As 
discussed previously, the metabolic abnormality in women with PCOS are similar to that 
in Metabolic Syndrome, a clustering within an individual of hyperinsulinaemia, glucose 
intolerance, dyslipidaemia, and hypertension (Reaven, 1988) all of which have been 
associated with an increased risk of cardiovascular disease.
When women with Metabolic Syndrome were studied for characteristic reproductive 
features of PCOS, they were no more likely to have PCO than other segments of the 
population; while only about half of them had a history of oligomenorrhoea (Korhonen et 
al, 2001). Nor do all women with PCOS have the Metabolic Syndrome.
In some countries obesity appears to be less common in women with PCOS. For instance, 
in the United Kingdom, a large study of 1700 women reported a high percentage of non- 
obese women with PCOS (Balen et al, 1995). Similarly, in the Netherlands, a follow-up 
study of over 300 women with PCOS showed that over half of these women were not over 
weight (Elting et al, 2001). Although these studies are not a representative population 
sample, they suggest a less obese PCOS phenotype is found in the UK and the Netherlands 
than is encountered in the United States (Legro et al, 1999; Ehrmann et al, 1999).
In a recent retrospective study of 106 women with PCOS, the prevalence of PCOS and
Metabolic Syndrome (n = 46) was 43%, nearly 2-fold higher than reported for age
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matched women in the general population; these women also presented with increased 
hyperandrogenism (increased free serum T levels and decreased levels of serum SHBG) 
and acanthosis nigricans, all features which reflect increased insulin resistance 
(Apridonidze et al, 2004). Therefore, it is probable that the existence of women with 
PCOS but without symptoms of the Metabolic Syndrome suggest it is more likely that the 
two syndromes are closely interwoven pathophysiologically to a variable degree, such that 
PCOS and Metabolic Syndrome often co-segregate, but can also be seen in isolation.
2.6 Polycystic ovary syndrome and the link to coronary vascular 
disease
2.6.1 Coronary artery
Wild et al (1990) surveyed 102 women undergoing cardiac catheterisation for evaluation 
of chest pain, 52 with coronary artery disease (mean age 63.6 years) and 50 with normal 
coronary arteries (mean age 60.5 years). In women with an abnormal angiogram, the 
incidence of hirsutism, diabetes mellitus and hypertension was significantly increased; 
these women also had a higher W/H than women with normal coronary arteries, despite 
similar BMI. The strongest associations were in women > 60 years.
Dahlgren et al (1992b) compared the distribution of risk factors for vascular disease in 33 
women with PCOS (based on histopathological evidence in ovarian biopsies) with 132 
age-matched controls. They estimated that myocardial infarction would be seven times 
more common in women with PCOS than in the general population. This estimate was 
based on applying a logistic regression model, derived in an earlier follow-up study
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(Dahlgren et al, 1992a), in which myocardial infarction was correlated with earlier results 
for serum triglycerides, W/H ratio, diabetes and hypertension.
Birdsall et al (1997) reported the association between PCO on TAS or TVS and the extent 
of coronary artery disease in 143 women aged 60 years or younger, undergoing cardiac 
catheterisation for the assessment of chest pain. Women with bilateral oophrectomy were 
excluded. The quantitative extent of the disease assessed by blind evaluation of 
angiograms and compared with the presence or absence of PCO. PCO were present in 
42% of the 143 women. Women with PCO had more coronary arteries stenosed > 50%, 
and exhibited a greater prevalence of hirsutism, previous history of hysterectomy, lower 
HDL cholesterol concentrations, and higher free T, triglyceride and C-peptide levels, than 
women with normal ovaries.
The findings of the study of Wild et al, (1990) suggest that the results were significant in 
older women (> 60 years), probably because of the increased incidence of coronary artery 
disease in general. Asymptomatic women were not included for ethical reasons (radiation 
and invasive nature of the procedure). Although the data collected was based on recall 
ability and from a pre-selected population (i.e. chest pain), the result is evenly distributed 
in those with and without confirmed disease. Some post-menopausal women reported 
hirsutism, but it is not clear whether this was related to PCOS. Secondly, ultrasound was 
not performed to assess ovarian morphology and it is unknown if those without chest pain 
would have the same findings.
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The results of Dahlgren’s study (1992b) may be biased due to its retrospective design and 
the inclusion of both premenopausal (n = 18; mean age 45.9 years) and postmenopausal 
women (n = 12; mean age 55.6 years). A questionnaire was used with no mention on types 
of questions asked, in particular smoking, which is a known risk factor for heart disease, at 
least in the younger women (Rosenberg, 1991). Age constitutes an important risk factor 
for myocardial infarction. Despite age matching, the control subjects were somewhat older 
than the PCOS subjects (mean age 45.9 and 46.5 years between 40 -  49 years; mean age
55.1 and 55.6 years between 5 0 - 6 1  years, respectively), albeit the differences were not 
significant.
The study of Birdsall (1997) has the advantage of ultrasound scanning (albeit PCO 
morphology alone does not support diagnosis of PCOS). Oophrectomy is associated with 
premature heart disease in women with or without PCOS; this was a useful and valid 
exclusion criterion. All the three studies discussed above establish the prevalence of PCOS 
in women having angiography; however, the disadvantage of angiography is that it is a 
surrogate endpoint for events.
2.6.2 Carotid artery
Guzick et al (1996) studied carotid artery intimal media thickness by carotid
ultrasonography in 16 premenopausal women with PCOS (mean age 44.4 years; history of
chronic anovulation in association with clinical evidence of androgen excess -  hirsutism
or total T concentration > 2 nmol/L or LH/FSH ratio > 2) and 16 age-matched control
women (mean age 43.9 years) with normal menstrual cycle. Carotid artery IMT was
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increased in patients with PCOS compared with healthy control subjects, but there was no 
difference in the prevalence of atherosclerotic plaques. Although evidence for the 
progression of vascular disease from increased IMT through plaque formation to 
disturbance in blood flow is lacking, increased IMT is viewed as an early indication of 
subclinical atherosclerosis.
In a larger retrospective study Talbott et al (1998) recruited 46 women (age 42 ± 8 years) 
with PCOS (chronic anovulation in association with clinical evidence of androgen excess 
(hirsutism) or elevated total serum T > 2 nmol/1 or LH/FSH ratio greater than 2.0) and 59 
controls (age 43 ± 7 years) with normal menstrual cycle. Subjects underwent carotid artery 
scanning at eight carotid artery sites using B-mode ultrasound. The carotid atherosclerotic 
index was calculated as the overall mean of the IMT measurements at the eight sites. The 
atherosclerotic index was significantly greater in PCOS women than in controls, and this 
difference was associated with age, BMI, diastolic blood pressure, and serum LDL 
cholesterol concentration. Some of these correlation factors were however collected 5 - 7  
years before the IMT measurement, and total cholesterol was not controlled for in the 
analysis.
In 2000, Talbott et al extended their study having recruited 125 women (mean age 37.5 ±
6.2 years) with PCOS (chronic anovulation in association with clinical evidence of
androgen excess (hirsutism) or elevated total T > 2 nmol/1 or LH/FSH ratio > 2.0) and 142
control women (mean age 39.0 ± 6.2 years) with normal menstrual cycle. Baseline
sociodemographic data, reproductive endocrine hormone levels and cardiovascular risk
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factors were collected between 1992 and 1994. During follow-up, four years later, B-mode 
ultrasound of the carotid arteries was performed to evaluate IMT and the prevalence of 
plaque. IMT was assessed as an average measure at each location (across 1.0 cm segments 
of the near and far walls of the distal common carotid artery (CCA), the far wall of the 
carotid bulb, and the internal carotid artery (ICA) on the left and right sides) to produce an 
overall measure of the IMT. The prevalence of plaque was defined as a distinct area 
protruding into the vessel lumen with at least 50% greater thickness than the surrounding 
areas and for each segment the degree of plaque was graded (0 = no plaque; 1 = one small 
plaque < 30% of vessel diameter; 2 = one medium plaque between 30 -  50% of vessel 
diameter or multiple small plaque; 3 = one large plaque > 50% of vessel diameter or 
multiple plaques with at least 1 medium plaque). The grades were summed across the right 
and left carotid arteries for an overall focal plaque index. The IMT and the overall plaque 
index were significantly greater in the PCOS women compared with controls and the 
difference remained significant after adjusting for age and BMI. Although there was this 
significant difference between the two groups, plasma lipids were not analysed in the 
second study (data from the previous study were used).
The study by Guzick (1996) has several flaws. Although PCOS women and controls were
matched for age, race and neighbourhood, they were not matched for smoking, a known
risk factor for cardiovascular disease (Cheng et al, 2002). The authors used a new tool to
assess the extent of vascular damage in the carotid vessels but did not mention if they
included the presence of plaque(s) in the bulb or in the first centimetre of the internal
carotid artery. Were the ultrasonographers blinded? Although the sample size in this study
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is limited, the results do suggest that women with PCOS have an increased risk of 
subclinical atherosclerosis in their 40s.
In Talbott’s studies (1998, 2000) there was a 5 -  7 year lapse between the collection of 
biochemical and biometric data, and the IMT estimates, and in addition total cholesterol 
was not assessed. There is evidence, both clinical and experimental, to suggest that 
elevated total cholesterol is associated with abnormal endothelial function in patients with 
and without atherosclerotic disease detected both by angiography and ultrasound (Vogel, 
1999).
Increased IMT is a surrogate marker for coronary artery disease and stroke. Atherosclerotic 
changes do not necessarily translate into more events and progression of disease can be 
halted with preventative efforts. The significance in both the Guzick and Talbott studies lies 
in the fact that increased IMT is associated with increase risk of heart disease and stroke. As 
summarised in Table 2.3, studies have shown increased morbidity in women with PCOS, 
suggesting these women may be at an increased risk of developing cardiovascular disease 
and may be ‘older’ from the circulatory point of view.
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Table 2.3 Summary of studies looking at morbidity in women with Polycystic Ovary Syndrome
Researcher Study design Subjects
(no)
Method Outcome
Wild et al, 
1990
Cross-sectional;
questionnaire
102 Questionnaire Hirsutism was common in PCOS women with positive 
coronary angiography.-Android fat distribution was 
associated with androgen excess and may be an indicator 
for greater risk for ischaemic heart disease.
Dahlgren 
et al, 1992a
Retrospective study 33 PCOS 
132 Controls
Questionnaire, 
interview and 
blood samples
Infertility, hirsutism, and oligomenorrhoea were common 
among women diagnosed clinically and histologically with 
PCOS. These women had increased central obesity and 
basal serum insulin concentrations and a higher (15%) 
prevalence of diabetes and hypertension (39%).
Dahlgren 
et al, 1992b
Retrospective follow- 
up
33 PCOS 
132 Controls
Statistical By risk-model analysis, PCOS women had a 7.4-fold 
greater risk of myocardial infarction than in age-matched 
controls.
Guzick 
et al, 1996
Prospective cross- 
sectional 16 PCOS 
16 Controls
Ultrasound Increased intima-media thickness of the common carotid 
bulb and internal carotid arteries in PCOS women may be 
associated with sub-clinical atherosclerosis.
Birdsall 
et al, 1997
Cross-sectional study
143 Questionnaire
PCOS women had greater than 50% coronary artery 
stenosis during cardiac catheterisation than women with 
normal ovaries.
Cibula 
et al, 2000
Retrospective follow- 
up study
28 PCOS 
752 Controls
Evaluation of 
histological, 
clinical and 
biochemical 
data
The prevalence of non-insulin dependent diabetes mellitus 
(32%) and coronary artery disease (21%) was higher in 
PCOS women compared with controls.
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2.7 Cardiovascular mortality in PCOS
In 1998, Pierpoint and colleagues published the first finding which has addressed this 
important issue. In this study, with a mean follow-up of 30 years, Pierpoint reported that 
mortality from all causes in a group of women with PCOS was no higher than the 
national mortality rates for women of the same age. Of the total of 59 deaths, 15 were 
from circulatory diseases (standardised mortality ratio 0.83; 95% Cl 0.46 -  1.36); 13 
from ischemic heart disease (standardised mortality ratio 1.40; 95% Cl 0.75 -  2.40) and 
two from other circulatory diseases. Deaths from type II diabetes were higher than 
expected in PCOS women (odds ratio 3.6, range 1.5 — 8.4). The authors concluded that 
women with PCOS do not have increased mortality rates from circulatory disease, 
although the condition is associated with type II diabetes, lipid abnormalities, 
hypertension and obesity.
The results of this study have been widely discussed because they appear to conflict with 
the anticipated results. Diagnosis of PCO was based primarily on ovarian wedge 
resection. Clinical indices, androgen excess and abnormal menses were not assessed. 
Polycystic ovary is a marker of PCOS, and is seen in 5 -  10% of women and the 
indication for wedge resection is not mentioned. The authors suggest that because these 
women underwent wedge resection, metabolic risk factors should be more severe; 
however, the main indication for wedge resection historically was for fertility, not for 
severity. Of all women who were potentially available and traceable, many records were 
not complete or retrieved. Selection bias was an issue and one cannot be sure if the 
excluded data were similar to the retrieved data. Regional differences for cardiovascular
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disease rates are known. Standardised mortality rates came from a national database, not 
taking into account regional variations. The hazards of using death certificate data and the 
problems with their accuracy are well known. In spite of these limitations, there was no 
increase in cardiovascular deaths.
In light of this scenario, the global problems associated with PCO transcend the younger 
women’s problems of amenorrhoea, irregular menses, infertility, and hirsutism; and may 
include potential long-term, metabolic and cardiovascular problems. Paediatricians, 
endocrinologists, dermatologists, gynaecologists and cardiologists may see these women 
from puberty through reproductive age to menopausal years. It is clear that PCOS is a 
multifaceted clinical entity with both short-and long-term consequences. Resistance to 
insulin is a key element of the syndrome, including upper body obesity, glucose 
intolerance, hypertension and dyslipidaemia; all factors leading to increased risk for 
cardiovascular diseases.
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CHAPTER3
MECHANICAL AND PHYSICAL PROPERTIES OF
BLOOD VESSELS
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3.1 Introduction
Atherosclerosis is a primary cause of heart disease and stroke (Lusis, 2000), characterised 
by progressive accumulation of lipids and fibrous elements in the large arteries. 
Cardiovascular disease represents the leading cause of morbidity and mortality in 
Western society (Peterson et al, 1999). The underlying pathological process of 
atherosclerosis progresses with age and is accelerated by the presence of cardiovascular 
risk factors such as hypertension, smoking, diabetes mellitus and hypercholesterolaemia.
A number of expert panels have published classification schemes and guidelines 
designed to aid diagnosis, assess severity and determine prognosis in patients with risk 
factors for cardiovascular disease (Anonymous - British Cardiac Society, 1998). The 
recommendations emphasize the role of high BP, cholesterol and glucose as examples of 
major risk factors that exhibit strong, positive, and continuous relationships with the risk 
of cardiovascular disease, even within defined normal ranges.
There are currently no progressive criteria in the UK for the detection of cardiovascular 
risk factors. There is however good evidence that treatment of hypertension and 
hypercholesterolaemia, as well as cessation of cigarette smoking and increasing exercise 
reduces the risk of cardiovascular incidents (CAPRIE Steering Committee, 1996; 
Zanchetti et al, 1998; Peterson et al, 1999; Robeer et al, 1998; Frishman, 2000).
Atherosclerosis is a geometrically focused disease affecting well-defined areas of the 
cardiovascular tree. The importance of the biophysical properties of blood vessels and
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flow on the development and localisation of cardiovascular disease is now being 
appreciated. Arterial dysfunction is reflected by changes in vascular elastic properties i.e. 
increased IMT and stiffness index and decreased vascular compliance, to the extent that 
these parameters are now recognised risk markers, as well as potentially modifiable risk 
factors in cardiovascular disease.
Changes in the structure (intrinsic properties) of the arterial wall occur to alter the 
physical characteristics of blood vessel walls and impair the pulsatile nature of arteries 
before the clinical manifestations of cardiovascular disease (Hickler, 1990; Geroulakos et 
al, 1994; Glasser et al, 1997; Bots et al, 1997; Aminbaksh and Mancini, 1999; Simons et 
al, 1999; Balbarini et al, 2000). Physical properties which are modified include arterial 
elastic properties and increased IMT, both of which are regarded as markers of early 
atherosclerosis (Burke et al, 1995; Glasser et al, 1997; Reneman and Hoeks, 2000; Van 
Popel et al, 2000).
3.2 Structure of normal artery
Blood vessels are responsible for the circulation of blood throughout the body. Whilst 
arteries carry blood at high pressure away from the heart, veins predominantly carry 
blood at low pressure back into the heart. Structurally the two vessels vary in order to 
carry out their functional roles efficiently.
In order to understand arterial biomechanical parameters, the structure and function of the 
arterial wall must be defined. The arterial wall is composed of three main layers, these
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being, from within outward; the tunica intima, the tunica media and the tunica adventitia 
(Figure 3.1). The tunica intima consists of a layer of endothelial cells resting on a basal 
lamina closely abutting upon the internal elastic lamina. This layer has an important role 
in the maintenance of the integrity of the intravascular function. The tunica media 
consists of non-striated myocytes with varying amounts of collagen and elastin fibres. 
The larger elastic arteries are distributed predominantly near the heart and organs, e.g. the 
aorta and its major branches including the common carotid artery, and their key 
functional role involves the pulsatile movement of large volumes of blood. Structurally, 
these vessels are composed of a high density of layered, elastic membrane in the tunica 
media. The smaller muscular arteries, such as the femoral artery, have the same basic 
structures as the elastic arteries, except that the elastin fibres within the tunica media are 
reduced to two well defined sheets, the internal and external laminae. Also in these 
arteries, the tunica media contains an increased abundance of smooth muscle cells 
relative to the elastic fibres. The tunica adventitia, the outermost layer of the blood vessel 
is entirely composed of collagen, the branches of blood vessels, together with lymphatics 
and nerve plexi terminate. Functionally these arteries are responsible for the rapid and 
complete distribution of blood to all organs and tissues within the body.
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Figure 3.1 Composition of the arterial wall (Reproduced with permission from 
The Basis of Medicine by Pocock and Richards, 1999)
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The vascular smooth muscle cells within the tunica media have an important role in 
maintaining the active tension of the vessel wall (Burton, 1954; Roach and Burton 1957; 
Petersen et al, 1960). Passive tension is attributed to the elastin and collagen fibres, and 
the vessel tension-strain relationship at low levels resembles that for elastin fibres 
(Burton AC, 1954; Roach and Burton 1957; Petersen et al, 1960). In other words, elastin 
fibres provide vessel wall elasticity at low blood pressures. At higher pressures, the 
tension-strain relationship resembles more closely to that of the collagen fibres, 
indicating collagen fibres are stretched at normal to high temperatures.
3.2.1 Rationale for assessing the mechanical properties o f arteries
The development and progression of arterial vascular disease is a multifactor process and 
abnormalities in individual risk factors, viewed in isolation, are poor predictors of 
increased risk (Kannel, 1996; Van den Hoogen, 2000). The relative risk of cardiovascular 
events increases with the magnitude of disturbance in each of the risk factors, the 
population risk (function of relative risk and the percentage of the at-risk population) and 
also increases for a majority of individuals who exhibit relatively minor alterations in 
traditional risk factors (Kuller et al, 1999; Lloyd-Jones et al, 2000). Thus the majority of 
at-risk population have normal or minor alterations in risk factors that are below the 
present threshold for intervention, but have a detrimental effect on arterial wall 
properties, which increases the risk of developing arterial disease. The risk factors for 
cardiovascular disease mediate their effects by altering the vascular structure, properties 
and function of the vessel wall and endothelial components of the arterial blood vessels 
(Ross, 1993). The ability to detect sub-clinical vascular damage, representing the
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cumulative and integrated influence of risk factors in impairing arterial wall integrity, 
holds the potential to monitor disease progression and assess the impact of 
pharmacological intervention in this process (St. John, 2000).
The importance of assessing arterial wall integrity is demonstrated by the observation that 
a reduction in the pulsatile function of large arteries represents an independent risk factor 
for cardiovascular events (Franklin et al, 1999; Chae et al, 1999; de Simone et al, 1999; 
Vaccarino et al, 2000). There is increasing evidence that the pulsatile characteristics of 
arteries are modified early in the disease process (Yamashita et al; 1998; Arnett et al,
1999; Leeson et al, 2000) and impaired arterial function is recognised as an independent 
predictor for risk for vascular events including coronary heart disease (Benetos et al, 
1993; Franklin et al; 1999) and hypertension (Benetos et al; 1998) as well as for diabetes 
mellitus (Emoto et al, 1998; Van Popel et al, 2000).
Changes in the mechanical behaviour of the blood vessels provides direct information on 
the arterial wall integrity and progression of arterial wall disease, and holds predictive 
potential for therapeutic intervention (Cohn; 1999). The consequences of impaired 
pulsatile characteristics of the arterial circulation are outlined in Figure 3.2.
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Figure 3.2 Reduced compliance promotes blood vessel damage and predisposes 
to premature clinical events (Reproduced with permission from McVeigh et al, 
2002)
Intima
(Endothelial dysfunction)
Cardiovascular
Events
Ischaemic Impedance load
Blood Vessel Damage
Reduced Arterial Compliance
► Media
(Impaired pulsatile function)
Left ventricular hypertrophy 
Congestive cardiac failure
Impaired Ventricular -  Vascular Interaction
• Accelerates atherogenesis
• Promotes plaque rupture
• Enhances vasoconstrictor
• Decreases dilator reserve
• Promotes thrombogenesis
T Pulse pressure 
4 Diastolic blood pressure
Systolic blood pressure
79
3.3 Arterial haemodynamics
There is no universally established standard for the characterisation of arterial wall 
mechanics. This is largely due to the complex physical and mechanical nature of the 
arterial tree. At any point the mechanical properties of arteries are different depending on 
the arterial wall structure (elastin and collagen) and the pressure of the blood flow. The 
arterial system is composed of a branching network of elastic conduits and large 
distributing arteries, which offer little resistance to blood flow. For maximal efficiency, 
blood flow should be achieved with the least possible energy expenditure (McVeigh et al, 
2002).
The fibrous proteins, elastin and collagen largely determine the mechanical behaviour of 
blood vessels. As discussed previously, the distribution of elastin, collagen and smooth 
muscle fibres differs between central and peripheral arteries. Looking at each component 
separately, elastin fibres are up to 10 times more distensible compared with rubber and 
determine the mechanical strength of blood vessels at low pressures. The collagen fibres 
on the other hand are less extensible and function to protect the blood vessel against 
structural damage at normal to high blood pressures. Characteristically, the vascular 
smooth muscle, whether relaxed or contracted, contributes very little to the overall 
elasticity of the blood vessel wall. Rather, it produces active tension; on extension 
vascular smooth muscle exhibits deformation and maintains its length for a period of 
time, but then has the ability to contract when activated and return to its original length.
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When blood vessels are subjected to pressure, they distend in the circumferential and 
longitudinal directions and undergo radial thinning of the vessel wall. These changes 
occur in three directions at 90° to each other. Movement of blood through the vessels is 
governed by Newtonian fluid mechanics which, in turn, is influenced by the physical 
properties of the vessel wall and how the vessel wall responds when subjected to 
pressure.
Blood pressure can be divided into two main components: the mean arterial pressure and 
the pulse pressure. The mean arterial pressure reflects the steady state component of the 
blood pressure and is dependent on the cardiac output and total peripheral resistance. The 
local pulse pressure (systolic minus end-diastolic blood pressure) is dependent on a 
combination of the forward pressure wave produced by blood being ejected from the left 
ventricle into the vascular system, and the reflected waves (wave reflections) returning 
from the periphery. Hence, a simple circuit cannot be used to describe the complexity of 
the vascular network.
Due to the complexity of the vascular system, there are no universally established 
methods for the characterisation of vascular mechanical properties. The concepts related 
to the direct assessment of mechanical wall properties are however gaining recognition in 
the research community but barriers remain to be overcome before acceptance is gained 
in the clinical arena. The lack of a ‘gold standard’ method has fostered the growth of a 
variety of techniques and methodologies for the estimation of mechanical wall properties. 
The relationship between the different descriptive terms, representative of the mechanical
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properties of the arteries and the circulation is therefore difficult to grasp. For example, 
arterial stiffness has been employed as an all encompassing term to include arterial 
compliance, arterial distensibility (change in diameter or area for a given change in 
pressure), elastic modulus (the change in stress for a given change in strain of the wall 
material) and stiffness index, a measure representative of the mechanical properties of 
arteries (O’Rouke and Mancia, 1999; Table 3.1).
In attempting to understand the complex biophysics of blood vessels in vivo, a variety of 
indices have evolved. Different methods have also been developed to measure these 
indices (Table 3.1) (Bramwell and Hill, 1922; Petersen et al, 1960; O’Rouke, 1982; 
Hickler, 1990; Lehman et al, 1996, Glasser et al, 1997). This had led to debate over the 
best indices for measuring these arterial properties, as well as to confusion in the 
comparison of results between studies. Techniques that can provide quantitative estimates 
of arterial wall properties are outlined in Table 3.2.
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Table 3.1 Indices defining the arterial wall elastic properties.
Arterial Index Definition
Petersen’s {P. ~ Pa )
elastic modulus (D , - Dd)l Dd
(Ep) (mmHg) Modified changes in the volume to changes in diameter as an artery 
is usually circular in cross-section and the change in diameter (Ds) 
is small with respect to the initial end-diastolic diameter (Dd)
Stiffness index ((3) 
(Dimensionless)
Pulse wave velocity 
(PWV) (cm/sec)
Compliance 
(cm x mmHg"1)
Diametrical compliance 
or Distensibility 
(C) (%mmHg1)
P =
D T
Thought to be less dependent on blood pressure as it is expressed in 
the natural logarithm of the ratio of the systolic to diastolic blood 
pressure_____________________________________________
= d_ = 1  / JpxD C
t
The distance travelled by the pulse wave for a given period of time. 
Relies on high fidelity equipment and problematic if the pulse wave 
travels over segments with opposite wave directions. PWV is related 
to the elastic modulus or the inverse of the distensibility__________
_ [A(D) s -  A(D) d  )
(ps - pd )
Defined as the change in volume for a given change in pressure. 
Assuming a linear volume pressure relationship, the change in 
volume could be replaced by the difference between the systolic and 
diastolic volume and the change in pressure by the pulse pressure.
For a circular arterial segment in cross-section, the volume change 
could be replaced by area change or diameter change.____________
_ \A (D ) s  -  A(D) d  Jx 100 
( P s -  P d  )x  A ( D ) a
Defines the relative change in the dimension of an artery for a given 
change in pressure. Allows vessels of different diameters to be 
compared.____________________________________________
V ? ""s  ~  A d ~)
-  P
Compliance coefficient 
(CC) (m2x Pa'1) tf y
Claimed to be less pressure dependent
— FDistensability coefficient 
(DC) (Pa1)
d y \d
p d )
Claimed to be less pressure dependent
Abbreviations: s -  systolic pressure; d -  diastolic pressure; P -  pressure; D -  diameter; 
A -  cross-sectional area; V -  volume; and h -  height; t -  time
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Table 3.2 Methods used to estimate the mechanical properties of arteries 
(Reproduced from McVeigh et al, 2002)
Methods Advantages Limitations Information
Direct
Angiography Evaluation of different aortic 
segments
Expensive, invasive Regional wall properties
Magnetic resonance imaging Non-invasive, not limited by 
acoustic window, can examine 
multiple arterial segments
Claustrophobia, 
expensive, limited 
availability
Regional wall properties
TTE / TOE TTE non-invasive, reasonable 
availability
Expensive, TTE limited 
by acoustic window, 
operator-dependent 
techniques, TOE invasive, 
remote site o f BP 
measurement
Regional wall properties
Transcutaneous Et / IVUS 
techniques
Transcutaneous technique is 
non-invasive; both techniques 
reproducible
Operator-dependent, 
IVUS invasive, remote 
site o f BP measurement 
with ET, clinical research 
application
Local wall properties
Indirect
Fourier analysis o f pressure 
and flow waveforms
Reference technique, pulsatile 
and steady-state information
Expensive, invasive, 
limited to research arena
Total arterial impedance
Stroke - volume to pulse - 
pressure ratio
'Ion-invasive, reasonable 
availability
Non-invasive estimate of  
stroke volume required, 
brachial BP measurement
Total arterial compliance
Pulse - wave velocity 'Ion-invasive, reproducible, 
jotential for wider clinical 
application
Limited to aorta, errors 
estimating path length and 
waveform distortion with 
pulse propagation
Segmental arterial 
stiffness
Pulse - contour analysis Non-invasive, reproducible, 
potential for wider clinical 
application
Non-invasive 
measurement o f stroke 
volume, assumed model 
of the arterial system
Compliance estimates 
derived from Windkessel 
modelling
Abbreviations: BP -  blood pressure; TTE -  trans-thoracic echocardiography; TOE -trans- 
oesophageal echocardiography; ET -  echo tracking; IVUS -  intravascular ultrasound.
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3.4 Assessment of vascular haemodynamics and mechanical 
properties of blood vessels
Methods developed for measurement of peripheral blood flow can be quantitative or 
qualitative, or inferred from other parameters such as tissue temperature. They differ as to 
whether they measure blood flow in a single vessel or organ. The various techniques 
differ in their degree of invasiveness, accuracy and reproducibility.
3.4.1 Doppler Ultrasound
Christian Johann Doppler, an Austrian physicist, first observed the Doppler effect in 
1842, noting that the frequency of a wave decreases if the observer is moving away from 
the source. This observation referred to light emitted from stars, but the implications 
extend beyond astronomy and form the basis of an important technique for circulatory 
assessment. For over 40 years, ultrasound scanners have exploited the Doppler effect 
where analysis of echoes scattered by moving blood provides estimate of blood flow 
velocity. The clinical use of blood flow imaging systems has expanded immensely since 
Satumura performed the first measurement of flow in the heart in 1956. Many disease 
processes in the body result from alterations in the circulatory system (Hoskins, 1999). 
There may be gross tissue changes such as proliferation of new vessels, deposition of 
atheroma, arterial plaque development and regions of infarction. Many of these changes 
alter the overall blood flow and also local blood flow patterns in the vessels.
When an ultrasound beam from a stationary source is transmitted to the blood vessel, it 
becomes scattered by the moving blood cells. The change in frequency (f^) of the
reflected beam is related to the transmitted frequency (f), the velocity of the moving 
blood, (v), and the angle the beam subtends to the vessel {(p), as well as the speed of
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propagation of ultrasound through the medium, (c). The Doppler shift frequency is given 
by the equation;
f J 2fv cos (p
a =  ------------------------------- ' —
Over the past 20 years, successive generations of equipment have evolved rapidly to 
assess vascular dynamics. In brief:
1. Spectral Doppler. Referring to the display of Doppler shift frequency in the form 
of a time-frequency plot. Spectral analysis yields various parameters such as peak 
systolic and end diastolic velocities, pulsatility index (PI) and resistance index (RI) 
that aid in the recognition and quantification of disease (Hoskins, 1999).
2. Continuous wave (CW) system. Device in which ultrasound is transmitted and 
received continuously. Continuous wave transducers are light and easy to 
manipulate, and the signals can be obtained quickly. Signals from the vessel are 
recognised by the shape of the flow-velocity waveform. A disadvantage of this 
method is that signals from several vessels in the path of the beam are superimposed 
on one another (Forsberg, 1997).
3. Pulsed Doppler (PW) system. With pulsed-wave Doppler, ultrasound is 
transmitted in short bursts and the reflected signals are detected at timed intervals 
after the signal is sent out. This ensures that the detected scattered echoes received 
originate from a fixed depth, which is determined by time delay between the 
transmission and detection. The advantage of pulsed Doppler is that it is depth 
selective, and if this is combined with ultrasound imaging the precise area of 
insonation can be visualised (Forsberg, 1997).
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4. Duplex system. Device consisting of a real-time B-scanner and a pulsed wave or 
continuous waves Doppler. The advantage of the duplex system is that the angle of 
incidence can be estimated from the B-scan allowing Doppler frequency shifts to be 
transformed to flow velocities. Assessment of the angle of incidence rests on a 
number of assumptions, such as the flow is parallel to the vessel walls and there is 
no curvature of the vessel in the scan plane. The velocity estimate error is 
dependent on the angle of incidence, and in modem machines the angle cursor 
increments every 1 or 2° ensuring smaller velocity estimate errors and thus greater 
accuracy (Hoskins, 1999).
5. Colour flow imaging. Detection of blood flow within the scan plane of an 
ultrasound scanner and the colour display of haemodynamic parameters, such as 
flow velocity (magnitude and direction), turbulence or simply the presence of flow, 
is known as colour Doppler imaging (Fish, 1999). Colour Doppler flow mapping 
provides information on the direction of flow, towards or away from the probe 
being represented by different colours. Colour Doppler machines incorporate a 
computer, which enables the system to provide a real-time image of an area and 
also to sample simultaneously multiple, tiny volumes within that area for Doppler 
information. Colour Doppler imaging extracts and displays two parameters of the 
Doppler signal: mean velocity and variance (width) of the spectrum. This 
information is processed, and the mean frequency shift in each sample is colour 
coded on a real-time image. Colour flow mapping affords the possibility of repeated 
measurements on the same vessel over a period of time (Allan, 1992).
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Quantitation of Doppler waveforms
Analysis of the waveform can provide information on disease (Hoskins, 1999). The 
simplest quantitative approach is to use indices, which are related to the degree of 
waveform pulsatility i.e. the degree of diastolic flow. The two common indices used are 
the PI and RI (Hoskins, 1999). PI and RI are calculated from the ratios of systolic and 
diastolic Doppler shift frequencies rather than from absolute velocimetry of blood flow. 
PI expresses the difference between peak systolic Doppler shift frequency (A) and the 
diastolic Doppler shift frequency (B) relative to the mean Doppler shift frequency 
(mean), and this is defined as:
PI = (A-B^/mean
The RI is defined as the ratio of the difference between peak systole and end diastole 
Doppler shift frequencies, relative to the peak systolic Doppler shift frequency (Pourcelot 
1974) and this is defined as (Figure 3.3):
RI = (A -  B) / A
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Figure 3.3 Parameters of the maximum velocity waveform used to calculate PI
and RI.
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PI and RI provide a semi-quantitative assessment of vascular resistance in the vessels 
interrogated. For smaller vessels, both PI and RI are independent of the angle of 
insonation and do not require the vessel diameter. The advantages of PI are that 
abnormal waveforms can be identified with a high sensitivity and that small and tortuous 
vessels can be evaluated. Unlike RI, PI requires collection of the complete spectral 
waveform because it requires an estimate of the Mean Doppler shift frequency i.e. the 
averaging of all frequency shifts throughout the cardiac cycle. This is an advantage of 
the PI measurement, but it requires a computerised spectrum analyser to calculate the 
mean; modem systems have this facility incorporated in the equipment. It is important to 
use the same machine if repeated measurements are to be used for comparison and this 
requirement was met in the studies described in this thesis.
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The movements of the Doppler shift frequency-time waveform correspond directly to 
measures of flow velocities that are of physiologic interest. In particular, the time 
averaged mean velocity, peak systolic velocity and the end diastolic velocity can be 
extracted from the velocity waveform (Fish, 1999). The peak systolic velocity ( V max) or 
the end diastolic velocity ( V min) are both useful for the diagnosis of carotid artery stenosis 
(Taylor et al, 1990). The ratio of velocities in different vessels provides a quantitative 
measure which allows for the wide differences in arterial velocities between individuals, 
which depends on factors such as ventricular contraction and arterial compliance, and can 
be used to compare flow between individuals (Taylor et al, 1990).
Limitations and sources of errors with conventional Doppler ultrasound
Although Duplex (spectral and colour) instrumentation is widely accepted as valid for
most vascular applications, this method has disadvantages (Gill, 1985):
1) Causes of errors in estimating blood vessel resistance/velocity: 
o Imaging not perpendicular to the longitudinal axis of the vessel.
o Pulsatility of blood flow, causing variation in vessel diameter with time,
o Only short length of vessel being available for imaging.
Thus high bifurcations and anatomic variations may result in sub-optimal results.
2) Sampling problems: All pulse mode Doppler machines provide centre-line
measurements of peak velocity (Langlois et al, 1984). Abnormalities may not be 
detected due to failure to sample nearer the vessel wall where flow disturbances
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are most likely to occur (Rittgers et al, 1983).
3) Operator errors:
o Excessive pressure of the transducer against the skin results in deformation of the 
vessel wall; superficial vessels are more prone than deeper vessels.
o Angle of insonation -  referring to the equation in Section 3.4.1, it is evident that 
the angle of insonation affects the Doppler shift. When the ultrasound beam is at 
right angle to the vessel (cos 90° = 0), the Doppler shift frequency is theoretically 
zero and no signal is obtained. When the transducer is aligned with the vessel (cos 
0° = 1), the largest Doppler shift is obtained. However, there is difficulty in 
obtaining signals at such low angles because of total reflection of sound waves at 
the vessel walls. For these reasons, angles between 30° and 60° are recommended 
(Stacey-Clear and Fish, 1984).
4) Patient-related factors:
o Any patient movement during measurement results in a blurred image, yielding 
inaccurate results.
o Carotid artery blood flow is influenced by noise (Gangar et al, 1991).
Doppler ultrasound has gained wide acceptance as a method of circulatory measurement 
in clinical practice and research. Ultrasound examinations, both grey scale and colour 
Doppler, can adequately detect the internal morphology and circulatory changes within 
the organ or vessel can be assessed. Although Doppler ultrasound is not a measure of
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blood flow, it provides a measure of downstream vascular resistance, and is of great 
importance, both in the display of normal haemodynamics and in the recognition of 
vascular disease.
3.4.2 Assessment o f mechanical properties o f blood vessels
Knowledge of the elastic properties of the arterial wall is essential when investigating 
cardiovascular dysfunction since the function of the arterial wall is influenced by a 
combination of elastic and viscous components inherent to arterial tissue. All biological 
material exhibits a level of elasticity and in the case of blood vessels, the distension is not 
only influenced by the force applied by the blood flowing through the vessel but also by 
the elasticity of the constituents of the wall. Similarly, this elasticity also influences the 
rate at which the vessel regains its original shape. During systole, the increase in blood 
pressure causes the arterial wall circumference to increase and returns to its previous 
dimension during diastole. When intraluminal pressure changes are plotted against the 
changes in vessel diameter, the resultant curve forms a hysteresis loop.
Having identified the dynamic properties of blood vessels, it is important to identify 
potential indices which define the essential mechanical properties of blood vessels which 
influence their dynamic performance. Many indices have been derived to describe and 
quantify the physical behaviour of blood vessels in response to an intra-luminal force. 
This has lead to discussion as to the best indices for measuring arterial vascular properties 
leading to discrepancies in comparing results between studies. (Lehmann et al, 1996). 
The functional behaviour of the arterial system can be described in terms of compliance 
and distensibility, representative of the dynamic artery wall properties.
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In 1960, Petersen and colleagues defined the elastic modulus Ep as an index of arterial 
stiffness, which describes the relationship of strain to intra-luminal pressure in an open- 
ended vessel. The original description referred to the change in vessel volume, but as the 
arterial lumen is generally circular in cross-section, the equation can be simplified to:
E p  (mmHg ) =  ^ S ^ y  Strain
where strain is defined as the fractional pulsatile diameter change that occurs in an artery 
exposed to a given change in intra-luminal pressure:
K  - D dStrain = /  D ^
Where D and P are vessel diameter and blood pressure and s and d denote systole and 
diastole respectively.
The inverse of Petersen’s elastic modulus is known as cross-sectional or diametrical 
compliance (C) which is a fundamental property of the vessel wall, defined as the change 
in blood vessel diameter in response to change in pressure, and given by:
1 _ o  (-^c  — - ^ 7 )  A
C(%mmHg jcIO Z) = - ^ r  ^ r jd ( T
Dd \ps - pd)
Both Ep and C are useful indices of vascular distensibility and describe the response of 
vessel wall diameter to changes in blood pressure.
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Kawasaki and co-workers (1987), recommended the stiffness index (P) as a useful 
parameter when comparing physiological changes in vessel wall between individuals. 
This is because it is less dependent on quantitative pressure change when describing the 
elasticity of an artery within physiological pressure ranges (Sonesson et al, 1993). Thus p 
may be the same for two individuals even though their respective blood pressures may be 
different. Conversely, their measured compliance values would not be similar, as 
compliance is a pressure dependent variable, p can be calculated as:
Whilst mathematical definitions have been derived to describe the arterial physical 
properties, no consensus has been reached with regards to the definition and terminology 
best describing the mechanical vessel wall property (Lehmann et al, 1996). The 
diametrical compliance and stiffness index have been used to assess the vascular 
properties in this thesis, as diametrical compliance measures the percentage change rather 
than the absolute change in the viscoelastic properties of the artery and also provides a 
means by which arteries of varying diameters can be compared. The stiffness index is a 
calculation of distensibilty whose formula minimizes the influence of the systolic- 
diastolic pressure differential by logarithmic treatment of pressure factors and provides a 
more reliable measurement of stiffness of the arterial wall (Hirai et al, 1989).
Assessment of compliance using ultrasound
Over the past two decades, ultrasound has been the favoured method for assessing 
vascular diametrical compliance. This method requires assessment of the diameter of the
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artery under investigation at the onset of the cardiac cycle, and the distension induced 
during the cardiac cycle by the local pulse pressure. In short, during vascular examination 
the artery of interest is imaged in B-mode in longitudinal section and the M-line 
positioned perpendicular to the vessel wall. The ultrasound system is then switched to M- 
mode. A radio frequency (RF) data acquisition system is linked to a computer onto which 
the M-mode echo images of the artery under investigation are displayed. The anterior and 
posterior walls of the vessel are identified either manually or automatically. The RF 
signals from the ultrasound M-mode output over a cardiac cycle are digitised and relayed 
to a wall tracking system (Hoeks et al, 1990; Figure 3.4). From these signals end-diastolic 
and end-systolic intraluminal diameters can be easily determined, and the maximum 
changes in diameter or distension for each beat. Blood pressure is measured non- 
invasively and the vascular compliance can be calculated according to the formula 
described previously.
Ultrasound has inherent inaccuracies related mainly to the recognition of the precise 
positions of the inner or outer walls of the blood vessel (Beach et al, 1989), producing an 
inter- and intraobserver variability error of 5% in measuring static diameter, and 10-15% 
when measuring pulsatile diameter changes (Hansen et al, 1993). Increased angle of 
insonation by the ultrasound transducer in the longitudinal axis also falsely increases 
vessel diameter and its changes. Due to the tortuous nature of some vessels, it is difficult 
to insonate exactly perpendicular to the vessel axis, which is a further source of error 
when measuring diameter and compliance in small calibre vessels. This uncertainty is
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partially overcome by the use of intravascular ultrasound; however this technique has the
major drawback of being invasive (Hansen et al, 1993).
Figure 3.4 B-mode and M-mode image of the common carotid artery (A); typical 
radiofrequency signal acquired from the artery is analysed to locate and mark 
anterior (A) and posterior (P) luminal surfaces (B). Vessel distension over 4 cardiac 
cycles is displayed (C).
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3.4.3 Principles o f inlima-media thickness measurement
Arterial wall structural changes are seen on ultrasound either as atherosclerotic plaques, 
found predominately at arterial bifurcations, or as diffuse thickening of the arterial wall. 
Both are measurable as increases in intima-media thickness (IMT) i.e. the distance 
between the lumen-intima interface and the media-adventitia interface. Ultrasound allows 
precise measurement of the IMT in large and medium sized peripheral arteries such as the 
femoral, carotid or radial arteries (Salonen et al, 1991). Due to the principles of 
diagnostic ultrasound, the measurement of the IMT thickness is most reliable at the far 
arterial wall, since the near field is often poorly resolved.
With improved resolution of ultrasound systems, assessment of the dimensions of small 
structures such as arterial wall thickness has become possible (Pignoli et al, 1986). 
Unfortunately however, the software which is essential to the running of commercial 
ultrasound equipment is poorly suited to the detection of small distances with high 
accuracy. To circumvent this problem, the B-mode image is digitised, transferred onto a 
personal computer and IMT assessed off-line using high quality image analysis software. 
Assessment of arterial wall thickness by B-mode ultrasound perpendicular to the vessel 
wall is possible since the lumen-intimal induces a relatively weak signal, while the media 
adventitia transition induces a relatively strong signal. Thus the media is seen as a dark, 
relatively hypoechoic layer between the intima and the adventitia. The transition between 
the adventitia and the surrounding tissue is unclear, as the connective tissues in which 
arteries are embedded are hyperechoic and exhibit high ultrasound signals. Therefore, not 
wall thickness, but only IMT can be obtained.
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IMT is normally obtained only on the posterior wall, because the trailing end of the 
adventitia signal from the anterior wall partly obscures the media, preventing accurate 
measurement of the anterior wall IMT. The lumen-intima boundary has low reflectivity, 
but higher reflectivity than red blood cells. The media itself has a very low echogenicity, 
bounded by weak reflections from the intima and strong reflections from the media- 
adventitia transition, correlating to the double-line pattern seen on ultrasound. This 
appearance and IMT determined by B-mode imaging has been correlated with 
histological and pathologic measurements in the far wall of the artery (Pignoli et al, 1986; 
Linhart et al, 2000).
Intima-media measurement technique
The most common method for measuring IMT is based on high-resolution B-mode 
imaging. Repeated and averaged manual measurements are easy to perform (Tardy et al, 
1992; Ferrara et al, 1994) but are operator dependent and have poor reproducibility. 
Modem analysis software assists automatic detection of wall thickness based on RF 
signals received along the M-line, analysing the grey scale of digitised images to allow 
accurate measurements with excellent reproducibility (Hoeks et al, 1997). This system 
requires horizontal visualization of the artery in longitudinal view, producing a well- 
defined double line pattern corresponding to the IMT (Figures 3.5 and 3.6). The operator 
defines the region of interest by placing the M-line accordingly, and IMT detection and 
measurement. Greyscale analysis is performed for each column of pixels along the M-line 
perpendicular to the vessel wall.
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Figure 3.5 Longitudinal ultrasound image of the common carotid artery with the 
double-line pattern of the far wall corresponding to IMT
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Figure 3.6 Anatomy of the carotid intima-media thickness (IMT). (Reproduced 
with permission from Linhart et al, 2000).
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Near wall: The thickness of anatomical adventitia [1] is less than its ultrasound correlate 
[A]. In contrast, anatomical media [2] is thicker than its ultrasound image [B]. Ultrasound 
interface between media [B] and intima [C] corresponds to the anatomic boundary 
between [2 and 3]. Anatomic intima [3] is thinner than its ultrasound correlate [C] which 
is gain dependent.
Far wall: Ultrasound interface between the lumen and the intima [D on sonogram] 
corresponds to its anatomic correlate. The intima appears thicker on ultrasound [D] than 
anatomically. In contrast, the media appears thinner on ultrasound image [E]. The 
interface between the media [5] and adventitia [6] corresponds to [E and F] on sonogram. 
Because the interfaces between the lumen and the intima and between the media and the 
adventitia on the sonogram correspond to anatomy, ultrasound is accurate in measuring 
IMT.
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By interpolation, a continuous curve is obtained from the histogram of greyscale density 
values. The curve is then analysed using a dedicated mathematical algorithm, which 
defines the exact position of lumen-intima and media-adventitia interfaces. As there are 
systolic-diastolic differences in the IMT, the M-mode is started synchronously with a 
trigger derived from the R-peak of the electrocardiograph followed by RF data 
acquisition; RF data is collected over a period of 4 seconds and stored on the hard disk 
for off-line analysis.
Off-line analysis of the IMT requires automated digitisation of the B-mode image, after 
capturing it in a pre-selected phase of the cardiac cycle. To delineate the different 
boundaries of the intima and media, markers had to be placed manually on the video 
image. This was time-consuming and introduced some subjectivity, dependent on the 
reflectivity of the structures, the gain setting and signal processing characteristics of the 
ultrasound system. The process is improved and speeded up by automated interpolation 
of the IMT (Figure 3.7). This improved the reproducibility of the procedure and was 
more user-independent.
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Figure 3.7 Typical IMT measurement of the CCA IMT using Wall Tracking 
System
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Ultrasound IMT assessment is a non-invasive, reproducible method for the detection of 
early arterial structural changes associated with various risk factors for atherosclerosis. 
Arterial wall thickening reflects the influence of multiple risk factors (age, blood 
pressure, blood lipids, diabetes, and gender) (Linhart et al, 2000) over time and has strong 
prognostic value for cardiovascular events such as myocardial infarction or stroke 
(Chambless et al, 1997; Bots et al, 1997; O’Leary et al, 1999). The ease and accuracy of
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computer assisted IMT measurement make it a useful and practical marker for 
cardiovascular dysfunction related to early atherosclerotic disease processes.
3.4.4 Basics o f Laser Doppler flowmetry and iontophoresis
Laser Doppler flowmetry
The laser Doppler technique measures blood flow in the very small blood vessels of the 
skin; tissue thickness of approximately 1 mm and the arteriole diameter of 10 microns 
(Figure 3.8). Cutaneous iontophoresis of pharmalogically active substances, with 
simultaneous laser Doppler measurement of dermal blood flux at the site of 
administration, is a promising non-invasive method for studying the physiology and 
pathophysiology of the skin microcirculation (Grossmann et al, 1995).
The technique of laser Doppler imaging is based on the frequency shift of low-powered 
red-laser light caused by moving red blood cells in the arterioles. Due to the minimal 
penetration of the laser it is used as an index of blood flow specific, uninfluenced by 
underlying muscle blood flow (Saumet et al, 1988). In this thesis, a 2.0 mW helium-neon 
laser was used to scan the surface of the skin and the back-scattered light from moving 
erythrocytes was recorded. The relative measure of volume flow is called laser Doppler 
flux, and is expressed in arbitrary perfusion units. Perfusion responses were stored on a 
personal computer and analysed off-line using dedicated software. The advantage of this 
method is that it provides a non-invasive, instantaneous and continuous measurement of 
microcirculatory flow offering advantages over the use of transdermal injections. The 
disadvantage is that it gives information about tissue perfusion only at a focal point.
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Furthermore skin blood flow may artefactually be modified by the placement of laser 
probe on the skin surface.
Figure 3.8 Schematic representation of skin depth penetration with laser Doppler 
flowmetry (Reproduced with permission from the manufacturer’s manual).
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Iontophoresis
Iontophoresis is a non-invasive method of introducing charged substances across the 
surface of the skin by means of electric charge, allowing a known concentration of drug 
to be delivered to a local site on the skin (Harris, 1967). The extent of drug delivery is 
proportional to the magnitude and duration of current applied (Sanderson et al, 1987; 
Phipps et al, 1989), i.e. current x time is an index of drug dose. This technique has 
advantages over the use of intradermal injections, since injection trauma to the skin is 
avoided and subject fear of injection is eliminated (Sloan and Soltani, 1986). This 
technique provides direct assessment of skin microvascular function, is simple to use, and 
most importantly for clinical application is non-invasive. However, there are factors 
which may influence iontophoretic drug responses, and iontophoretic data has to be 
cautiously interpreted. It is assumed that drug delivery is solely influenced by the 
magnitude of current applied and its duration. This ignores the fact that the electrical 
properties of the skin differ between subjects and could impact on effective drug delivery. 
Secondly, the absolute concentration of drug at the site of action is unknown (Pikal and 
Shah, 1990). Even if the amount of residual drug in the delivery reservoir can be assayed, 
degradation within the reservoir, the extent of dermal penetration, and the rate of removal 
of drug by metabolism and by washout in the microcirculation are unknown (Morris and 
Shore, 1996).
It has been demonstrated that current alone may affect tissue perfusion and vasodilatation 
to vehicle has been observed at both anode and cathode, although the increase in 
erythrocyte flux at cathode has been reported at low current levels than that at the anode
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(Morris et al, 1995). The major pathway of iontophoretically applied current across the 
skin is through areas of low electrical resistance such as sweat ducts, hair follicles and 
broken skin (Harris, 1967). Sweat glands also contain vasoactive substances such as 
kinins (Renolds et al, 1991), which may possibly be iontophoresed along with the 
substances being tested. Transcutaneous nerve stimulation has also been reported to 
stimulate the skin (Wallengren et al, 1987). The combination of the above effects of 
iontophoresis could account for the observed response to vehicle alone (Berghoff et al, 
2002). However, the use of saline virtually eliminated electrically induced artefact in 
most subjects (Ferrell et al, 2002). Furthermore, skin blood flow may easily alter by the 
placement of laser probe on the surface of the skin if any pressure is exerted.
3.4.5 Animal model for PCOS
Considerable species differences exist between human and experimental animals and thus 
the results from studies in animal models and human disease must be cautiously 
interpreted. Ideally, an animal model for investigating the vascular changes should have 
all or as many as possible of the features seen in a woman with PCOS. Such features 
include distinct ovarian histological appearance together with biochemical features. A 
number of studies have therefore been attempted to induce a PCOS-like state in rat 
model, as shown in Table 3.3. As seen in Table 3.3, a fully convincing animal model of 
PCOS, as a whole, has not been established perfectly.
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Table 3.3 Characteristics of rat models for Polycystic Ovary Syndrome
Method Ovarian Morphology LH FSH Testosterone Insulin
Exposure of constant 
light (Singh, 1969; 
Daane & Parlow, 
1971; Campbell & 
Schwarts, 1980
Polyfollicular ? ? Not done
Neonatal 
androgenization 
(Barraclough &
Gorski, 1961; 
Goldzieher & Axelrod, 
1963; Lookingland et 
al, 1982; Jones et al, 
1987
Polyfollicular Not done
HCG treatment to 
hypothyroid rats 
(Adams & Sensemann, 
1976)
Polycystic X = n t Not done
Chronic oestrogen 
exposure (Brawer et 
al, 1986; McCarthy & 
Brawer, 1990)
Polycystic/macrocysts i t Not done Not done
DHEA treatment 
(Knudsen et al, 1975; 
Mahesh et al, 1987)
Polyfollicular
polycystic?
■i = /t X Not done
Mifepristone (Van den 
Schoot et al, 1987; 
Sanchez-Criado et al, 
1992; Ruiz etal, 1997)
Polycystic t = n t t
hCG and Insulin 
treatment (Poretsky et 
al, 1992)
Polycystic X =!i t t
(Abbreviations: DHEA -  dihydroepiandrosterone, HCG -  human chorionic
gonadotrophin, LH — luteinising hormone, FSH — follicle stimulating hormone, T- 
increased, 'I — decreased, = no change, X — exogenous administration)
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With exposure to constant light and neonatal androgenisation, follicles grow to 
preovulatory size and become atretic, hence the term polyfollicular. With single injection 
of oestrogen or insertion of oestradiol implants induces PCO, the LH levels were 
relatively low. Similarly, daily injections of DHEA produce PCO, but the LH levels were 
suppressed with increased FSH levels. On the contrary, in the presence of elevated basal 
levels of LH (hCG treatment and with mifepristone), preovulatory follicles become 
luteinised, but ovulation does not occur. For the purpose of this thesis administration of 
mifepristone to cyclic rats has been used to ‘create’ an animal model because of its 
similarities with PCOS women (endocrine and ovarian morphology)
Action of mifepristone
It has been reported that mifepristone (also known as RU 486) binds to the progesterone 
receptor, but does not activate the receptor and therefore acts as a progesterone antagonist 
(Baulieu, 1991). However, in the rat daily injections of mifepristone induce (Figure 3.9):
1. Ovulatory failure, persistent vaginal comification, and enlarged ovaries 
containing follicular cysts (Baulieu, 1991, Sachez-Criado et al, 1993a).
2. Increased serum concentrations of LH, testosterone, oestrogen and prolactin and 
decreased levels of FSH (Sachez-Criado et al, 1992b, Sachez-Criado et al, 1993b).
3. Increased levels of insulin-like growth factor 1 (Ruiz et al, 1997).
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Figure 3.9 The effects and interrelation of mifepristone on serum hormone levels 
and ovarian follicular development in the rat
Anovulation -► Cysts
Mifepristone (RU486) LH ^ ^  Androgens^
Inhibin^ f s h J,
Atresia
t
ProlactinT -► Progesterone t
In comparison with the ovaries of control rats, ovaries of rats treated with mifepristone 
show (1) arrest of follicular growth and increased rate of follicular atresia, (2) increased 
number of follicular cysts with differing degrees of luteinisation and increased size of 
corpus luteum, and (3) abundant interstitial glands in the ovary (Sanchez-Criado et al,
1990).
3.5 Endothelium, nitric oxide and vascular disease
Endothelium is a continuous, thin single layer of polygonal flat endothelial cells » 0.2 -
0.3 pm thick (except over the bulging nucleus), totaling several hundred grams in an 
adult, lines the lumen throughout the circulatory system. The enormous area of inner, 
luminal surface enables endothelium to interact effectively with plasma, white cell and
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platelets. Similarly, the enormous area of the outer, abluminal surface enables 
endothelium to interact effectively with the tissues of the body (Levick, 2000).
The functional importance of the endothelium was suggested by Furchgott and Zawadski 
(1980), who showed that it is not only the inner lining of the blood vessels, but it also 
releases humeral factors, which control vessel wall contraction and relaxation, 
fibrinolysis and platelet activation. Thus the endothelium contributes not only to blood 
flow but also to vessel patency. Impaired endothelial function is likely therefore to 
contribute substantially to cardiovascular disorders such as atherosclerosis.
3.5.1 Physiology of the endothelium
Stimulation of intact endothelial cells by neurotransmitters, hormones and shear forces 
generated by the circulating blood, causes the release of a substance that induces 
relaxation of the underlying vascular smooth muscle. This substance, the endothelial- 
derived relaxing factor (EDRF), was found to be highly unstable with a half-life of 
seconds. In the late 1980s, two different research groups suggested that EDRF was nitric 
oxide (NO) because the two compounds had similar biological properties (Palmer et al, 
1987; Ignarro; 1989).
NO has an intravascular half-life of about 2 ms and an extra-vascular half-life of less than 
2 s. It must therefore be generated continuously to be effective. NO is produced from the 
amino acid L-arginine, which enters the cell via an amino-acid transporter in the cell 
membrane. NO is cleaved from L-arginine by the enzyme nitric oxide synthase (NOS).
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Three isoforms of NOS have been described, endothelial NOS (eNOS), neural NOS 
(nNOS) and inducible NOS (iNOS); two (eNOS and nNOS) are calcium dependent. The 
rate of production of NO in blood vessels is determined by the activity of eNOS, which is 
regulated by humoral factors and shear stress on the vessel wall, via their effects on 
changes in intracellular calcium (Ca2+) concentration (Channon et al, 2000).
1. Humoral factors: eNOS is bound to the inner cell membrane and activated by
• 2+  •calcium-calmodulin, a complex that is formed when cytosolic Ca increases and 
binds to protein calmodulin. Substances such as acetylcholine, bradykinin, 
thrombin, insulin, testosterone and histamine raise endothelial cytosolic Ca2+ 
concentration and enhance eNOS activity, and ultimately NO production and 
vasodilation. The rise in cytosolic Ca2+ and NO production is by a dual process: 
(a) humerol factors activate the receptor-operated cation-channels, which allows 
influx of extracellular Ca2+ ions into the cell; (b) in addition humerol factors 
liberate intracellular Ca2+ store. In the latter case, the agonist-receptor complex 
activates a membrane-bound enzyme called phospholipase C, which catalyses the 
breakdown of phosphatidyl inositol biphosphate (PIP2) to form an intracellular 
‘second messenger’, inositol triphosphate (IP3) and IP3 activates calcium release 
channels in the membranes of intracellular Ca2+ reservoirs, inducing release of 
stored Ca2+ and an elevation of intracytoplasmic Ca2+ concentration.
2. Shear stress: Shear stress, the mechanical force tangential to the endothelial 
luminal surface, is considered to be the most important stimulus, normally, of 
eNOS activity increase intracellular Ca2+ and thus a continuous production of NO.
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3.5.2 How does NO cause vasodilation
NO diffuses from the endothelium into the vascular smooth muscle, where it has two 
actions, (1) NO combines with the haem group in the enzyme guanylate cyclase, 
activating the enzyme, which catalyses the production of cyclic guanosine 
monophosphate (cGMP) from guanosine triphosphate (GTP). The precise mechanism by 
which cGMP relaxes vascular smooth muscle is unclear. It is suggested that cGMP 
activates protein kinase G, which increases calcium entry due to the stimulation of Ca2+- 
ATPase pump. (2) An alternative proposal suggests that hyperpolarization, increases the 
probability of the open state for voltage-gated Ca2+ channels, leading to an increase in 
Ca2+ concentration, and the sensitivity of the contractile process to Ca2+ is reduced 
because protein kinase A phosphorylates myosin light chain kinase (MLCK), inhibiting 
its action on the vascular smooth muscle (Levick, 2000; Figure 3.10).
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Figure 3.10 Generation and action of nitric oxide (Reproduced with permission 
from Levick J.R, 2000).
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Endothelial cells also release prostacyclin (PGI2) in response to shear stress, hypoxia and 
in the presence of substances such as acetylcholine (ACh) and serotonin, which also 
stimulate the release of NO. Prostacyclin is produced from arachidonic acid by the 
enzyme cyclo-oxygenase. PGI2 causes vascular smooth muscle relaxation by activating 
adenylate cyclate and increasing the production of cyclic 3’, 5’-adenosinemonophosphate
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(cAMP) from adenotriphosphate and causing a decrease in intracellular Ca ion 
concentration which leads to vascular smooth muscle relaxation. In most blood vessels, 
the contribution of PGI2 to vascular tone is limited, and its effect is essentially additive to 
generally more substantial influence of NO (Levick, 2000).
Even when endothelial NO and PGI2 production have been pharmacologically blocked, 
there is still relaxation in small arteries. This occurs in response to a relaxing factor 
known as endothelium-derived hyperpolarizing factor (EDHF), which causes 
hyperpolarization of vascular smooth muscle cells possibly by increased calcium 
dependent-potassium ions. The effect of EDHF on vascular tone relative to NO varies 
with vessel size. In large arteries, NO is the dominant endothelial-derived vasodilator, but 
in small vessels EDHF may dominate (Shimokawa et al, 1996).
3.5.3 Endothelium-derived-contracting factors
Soon after the discovery of NO, it became clear that endothelial cells could also mediate 
vascular contraction (Luscher and Vanhoutte, 1990). These contracting factors include 
endothelin and prostaglandin.
Endothelin (ET) is a 21 amino acid peptide which is found in three isoforms of 
endothelin, ET-1, ET-2 and ET-3. ET-2 and ET-3 differ from ET-1 in amino acid 
residues two and six respectively. Only ET-1 is synthesised by human endothelial cells 
(Masaki, 2000) and it is released soon after synthesis rather than being stored 
intracellulary. ET-1 is liberated from the basal surface of the endothelial cell and binds to
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receptors, ETA and ETb on the vascular smooth muscle cells. Although structurally 
highly similar, ETA has a higher affinity to ET-1 and ET-2 than ET-3; whilst ETB binds
all three peptides with equal affinity and is also located on the surface of the endothelium.
2+
These receptors trigger the opening of receptor-operated Ca channels, allowing the 
influx of calcium ions. ET-1 binding also activates phospholipase C, stimulating IP3 
synthesis, and causes the release of intracellular Ca2+ stores. The rise in intracellular Ca2+ 
ion concentrations stimulates smooth muscle contraction resulting in vasoconstriction 
(Masaki, 2000).
Prostaglandin (PG-H2) is produced by the endothelium and synthesized from arachidonic 
acid via the enzyme cyclo-oxygenase. Prostaglandin activates the thromboxane receptors 
in vascular smooth muscle and counteracts the effects of NO and prostacyclin. In 
addition, the cyclooxygenase pathway produces superoxide anions (formed by the 
reduction oxygen molecule-0 2 "), which counteracts the effects of NO and PGI2 causing 
vasoconstriction (Rubanyi and Vanhoutte, 1986; Luscher and Vanhoutte, 1990).
3.5.4 Cardiovascular risk factors and endothelial dysfunction
Endothelial dysfunction has been defined as impairment in the ability of vascular 
endothelium to stimulate vasodilatation, causing changes in endothelial cell morphology, 
which are associated with functional alterations and intimal thickening (Li and 
Forstermann, 2000). Endothelial dysfunction precedes structural vascular alterations, 
indicating a protective role for the functionally intact endothelium. It is therefore possible 
that a deficiency in local endothelial NO production and availability could be a pathway
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that accelerates atherogenesis in humans. There are two general mechanisms by which 
endothelial NO deficiency might occur in endothelial dysfunction (John and Schmieder, 
2000). Firstly, the synthesis of endothelial NO may be diminished due to reduced 
expression or activity of eNOS (Luscher and Barton, 1997). Secondly, the breakdown of 
endothelium eNOS-derived NO may be increased by production of superoxide, reducing 
NO bioactivity and producing peroxynitrite, which readily oxidises lipids and damages 
the cell membrane (Channon et al, 2000).
Dyslipidaemia
Hypercholesterolaemia and atherosclerosis are associated with impaired endothelium- 
mediated vasodilatation (Tanner et al, 1991). Clinical studies have shown that patients 
with dyslipidaemia may have endothelial dysfunction, even in the absence of 
angiographically detectable disease. In coronary arteries, there is evidence of a direct 
relationship between serum cholesterol levels and the response to ACh infusions, with 
greater vasodilatation at lower cholesterol levels (Vita et al, 1990). Small LDL particles 
are particularly atherogenic since they accumulate in the subendothelial space and impair 
endothelium-dependent vasodilatation (Dyce et al, 1993), possibly due to increased levels 
of superoxide radicals (Drexler and Homig, 1999) and the resultant quenching of 
endothelium-derived NO signaling.
Endothelial dysfunction is more extensive in advanced stages of atherosclerosis due to 
impaired bioavailibility of endothelial NO, resulting from reduced synthesis, increased 
breakdown (Shimokowa et al, 1989) and enhanced production of superoxide (Shimokowa
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and Vanhoutte, 1989; Minor et al, 1990). There is some evidence from studies in the 
aorta of hypercholesterolaemic rabbits that the overall production of NO is not reduced 
but rather augmented; however, increased production of NO is inactivated by superoxide 
radicals produced within the endothelium (Minor et al, 1990). Similar observations have 
also been reported in rabbits with fully developed atherosclerosis (Minor et al, 1990). 
Thus, conditions of hypercholesterolaemia and atherosclerosis, biologically active NO 
concentrations are markedly reduced, as suggested by bioassay experiments with 
coronary arteries from hypercholesterolaemic pigs (Shimikova and Vanhoutte 1989).
Endothelin production is also increased in atherosclerotic vascular disease (Lerman et al,
1991), though the expression of endothelin receptors is down regulated (Winkles et al, 
1993). A likely stimulus for the increased endothelin production is LDL, which increases 
endothelin gene expression and endothelin release from porcine and human aortic 
endothelial cells in vitro (Boulanger et al, 1992); vascular smooth muscle cells that 
migrate into the intima during the atherosclerotic process also produce endothelin, 
causing vasoconstriction (Hahn et al, 1990).
Hypertension
Endothelial dysfunction in hypertension may contribute to an increased vascular 
resistance or to other vascular complications (Luscher and Barton, 1997); high BP is 
associated with reduced endothelium-dependent relaxation (Luscher and Vanhoutte, 
1990). This increase in resistance is due to increased media thickness:lumen diameter, 
thereby narrowing blood vessels that control vascular resistance (Agabiti et al, 1995). The
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mechanism of endothelial dysfunction however differs in various models of hypertension. 
In the spontaneously hypertensive rat model of genetic hypertension, the activity of the 
eNOS is increased but is ineffective, probably due to increased inactivation of NO by 
superoxide (Nava et al, 1995). In contrast, salt-induced hypertension is associated with a 
marked impairment of eNOS (Hayakawa and Raiji, 1997). Furthermore, studies of the 
human vasculature in hypertensive patients have demonstrated increased changes in the 
arterial wall architecture
Diabetes
Diabetes is a risk factor for coronary artery disease, and although patients with diabetes 
are free of angiographic evidence of atherosclerosis, these patients have abnormal 
responses to ACh compared with controls (Nitenberg et al, 1996). Other studies have 
reported endothelial dysfunction in the skin microcirculation in response to endothelium- 
dependent and-independent vasodilator stimuli in patients with non-insulin-dependent 
diabetes mellitus (NIDDM) and insulin-dependent diabetes mellitus (IDDM) (Williams et 
al, 1996; Timimi et al, 1998). The underlying mechanism is not clear, but may involve 
increased synthesis of endothelin and/or impairment of the L-arginine-NO pathway 
(Yamaguchi et al, 1990), and an increased in-vitro expression of NO synthase and the 
production of superoxide ions (Cosentino et al, 1995).
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CHAPTER 4
MATERIALS AND METHODS
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4.1 Introduction
A variety of techniques are currently employed to evaluate arterial mechanical properties, 
however, all have theoretical, technical and practical limitations that impact on their 
widespread application in the clinical setting. This chapter summaries patient 
selection/exclusion criteria, physical data, endocrine/biochemical parameters measured and 
techniques used in this thesis to assess the arterial wall mechanics in women with PCOS.
4.2 Subject selection
Three groups of women aged 18-35 years were recruited from the North Middlesex and 
the Royal Free Hospitals:
1. Women attending the Reproductive Endocrinology & Gynaecology clinics, with 
PCOS confirmed by the presence of bilateral polycystic ovaries on TVS (fulfilling 
the criteria of Fox et al, 1991) and clinical features of menstrual irregularity, 
infertility, oligomenorrhoea (intermenstrual interval > 35 days) and / or hirsutism 
(Ferriman and Gallwey (1961) score of >7).
2. The PCO group was recruited from over 250 asymptomatic (regular menstrual 
cycles and no hirsutism or acne) women, attending the family planning clinics at 
the North Middlesex and a neighbouring hospital (St Ann’s), between 1998 and 
2002. These women attended for localisation of intrauterine contraceptive devices 
by ultrasound examination and the presence of PCO morphology was also 
ascertained All those with PCO morphology, defined according to the criteria 
described by Fox et al, 1999, were asked to participate in the studies; no exclusion 
criteria were applied other than those stated in Section 4.2.
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3. Control group were staff members -  radiographers, student midwives and nurses 
and medical students, with normal ovaries on TVS, no clinical features of 
hyperandrogenemia (hirsutism or acne), regular menstrual cycles (cycle length of 
21-35 days). None of the controls had sought treatment for menstrual 
disturbance, infertility or hirsutism at any time. No controls who agreed to 
participate were rejected except on the basis of the exclusion criteria.
One member of staff who agreed to participate in the control group had PCO morphology 
on TVS with no other clinical or biochemical features of the syndrome. She agreed to be 
part of the PCO group but had to withdraw due to job relocation.
The same women from the first clinical study were not included in the subsequent studies 
as many were not traceable due to their relocation. However, the selection criteria 
described above was followed throughout. Although the controls were not matched with 
PCOS women for BMI, there is a correlation with respect to BMI and PCOS and control 
women in all the clinical studies.
Women who smoked, had diagnosed respiratory or cardiovascular disease, or were taking 
prescribed medication such as oral contraceptives or aspirin, which could influence 
vascular resistance, were excluded. All measurements were recorded 6 hours post- 
prandially, between days 4 and 7 in oligomenorrhoeic and control women; there was no 
special timing for amenorrhoeic women. Ethical committee approval was obtained for the 
studies and informed consent was obtained in writing from each subject.
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Height (m) and weight (kg) measurements were used to calculate the BMI. The minimum 
waist measurement between the costal margin and the pelvic brim, and the maximum hip 
measurement at the level of the greater trocanters, were used to calculate the W/H.
The degree of hirsutism was assessed according to the Ferriman and Gallwey score 
(1961). The Ferriman and Gallwey model quantitates the extent of hair growth in nine 
anatomic sites (upper lip, chin, chest, higher back, lower back, higher abdomen, lower 
abdomen, arms, thighs/legs) and graded from scale 0 (no terminal hair) to 4 (maximal 
growth) for a maximum score of 36. A score of > 7 or more indicates the presence of 
androgen excess.
Pulse and blood pressure were measured on the left arm in each women, in all clinical 
experiments, using an automatic Dinamap device (Critikon Inc, Tampa, FL, USA), at 2 
minute intervals until the pulse rate varied by less than 5 beats/min and systolic and 
diastolic blood pressures by less than 5 mmHg over two readings.
Since carotid artery blood flow is influenced by auditory stimulation-noise (Gangar et al, 
1991), subjects were exposed to white noise, 50dB above the hearing threshold, via 
occlusive headphones (Kamplex Diagnostic Audiometer; P.C. Werth Ltd, London UK), 
worn throughout the procedure.
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4.3 Pilot study
A preliminary pilot study was performed for all experiments, prior to main data collection 
to test the proposed methods and research tools. The results from this pilot study were not 
included in the main study. The pilot studies served as a means of familiarising with the 
equipment and analysis package on the ultrasound machines, the audiometer and the 
continuous pulse and blood pressure machine. Furthermore, the results of these initial 
studies indicated that the method was appropriate. In addition, the patient information 
sheet was discussed with the subjects and revised to include a statement of confidentiality 
and details about the length of time in the hospital.
A justifiable criticism of the study protocol is that it was not possible to assess intra­
observer variability especially for the first clinical study as a second trained observer was 
not available at the time of the study i.e. not trained in vascular studies.
In the assessment of diametrical compliance, stiffness index and IMT, the prime source of 
measurement error would result from the different abilities of the observers in accurately 
visualising the correct arterial segment, properly aligning the linear array at right angles 
to the axis of flow, and minimizing probe movement during vessel wall motion capture. 
During the initial trials of the wall tracking system, the degree of agreement between 
observers measuring diametrical compliance, stiffness index and IMT in the same sitting 
was less than that for consecutive measurements made by a single observer on the same 
individual (personal communication Tai, N.R. and Cheng, K.S.). It was therefore decided
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to concentrate on inter-observer variation as it would be the main contributor to observer 
error in the technique used.
The protocol for laser Doppler and iontophoresis was agreed between myself together 
with another researcher and was validated to account for intra-observer variation. There 
was no difference with respect to erythrocyte flux between left and right arm and 
therefore one side was assessed.
Due to ethical issues, it was not possible to validate the organ bath technique using 
thoracic aorta from mifepristone treated animals. Organ bath equipment was validated 
using human uterine artery and rat aorta obtained from an ongoing research project in the 
department.
4.4 Ethical implications
This research project involved examination on human subjects, resulting in no immediate 
direct benefit to women in the study. Although the investigation was relatively non- 
invasive with no known side effects, approval of the Local Ethics Committee was 
obtained.
A patient information sheet was provided. Participation was voluntary and informed 
consent was obtained in writing, after the study had been fully explained. Subjects were 
informed that they could withdraw at any stage without prejudice.
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4.5 Biochemical assays
Biochemical analyses were performed by the Departments of Biochemistry at the North 
Middlesex and Royal Free Hospitals. Venous blood samples were drawn from an 
antecubital vein after ultrasound examination (before 10.00 hours in all subjects). 
Samples were collected in plastic sterile tubes, coded to ensure anonymity, centrifuged 
and serum stored at -20°C until assay.
North Middlesex Hospital:
Serum levels of LH, FSH, testosterone, oestradiol and prolactin were determined by ACS 
180 Chemiluminesce based kits (Ciba-Coring Diagnostics Ltd, Essex, UK) with intra­
batch COV of 5.0-8.0% and inter-batch COV of 2.1-7.0%. Serum SHBG was 
determined using the Chemiluminescent Immulite kit (Diagnostic Products Corporation, 
LA) with an intra-batch COV of 4.0-6.6% and inter-batch COV of 2.3-5.3%.
Serum concentrations of total cholesterol, HDL and triglyceride were measured using 
Enzymatic Calorimetric tests (Boehringer Mannheim Immunodiagnostics Systems, UK) 
with intra-batch COV of 4.0-7.0% and inter-batch COV of 1.1-2.8%. Serum glucose and 
fasting serum insulin were measured using an automated ELISA ES700 technique 
(Boehringer Mannheim Immunodiagnostics Systems, UK) with intra-batch COV of 1.1— 
2.5% and inter-batch COV of 1.3-1.6%.
Royal Free Hospital
Serum levels of LH, FSH, testosterone, oestradiol, prolactin and SHBG were determined 
by electrochemiluminescence immunoassay (ECLIA) using an E l70 analyser (Roche
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Diagnostics Corporation, Indianapolis, USA) with intra-batch COV of 3.0-5.0% and 
inter-batch COV of 1.1- 4.5% .
Serum concentrations of total cholesterol, HDL and triglyceride were measured using an 
Enzymatic Calorimetric test on a Roche 704 analyser (Roche Diagnostics Corporation, 
Indianapolis, USA) with intra-batch COV of 2.0-3.0% and inter-batch COV of 1.7— 
2.4%. Serum insulin was measured using a Microparticle Enzyme Immunoassay (Abbott, 
Diagnostics, AxSYM System, Japan) with intra-batch COV of 2.0-2.9% and inter-batch 
COV of 2.9-4.1%; serum glucose was determined using an enzymatic test on a Roche 
704 analyser (Roche Diagnostics Corporation, Indianapolis, USA) with intra-batch COV 
of 1.8 -  2.1 % and inter-batch COV of 0.7 -  1.0%.
The free androgen index (FAI) was calculated as (testosterone/SHBG) x 100, which 
provides an estimate of the active free testosterone in serum. Ratio between fasting 
plasma insulin (mU/1) and fasting plasma glucose (mmol/1) was used to assess insulin 
resistance. Serum LDL concentration is calculated according to the formula:
LDL concentration = Total Cholesterol (HDL + Triglyceride / 2.2)
4.6 Scanning protocol
Scans were performed by myself in all the experiments. All subjects rested for 15 min in 
supine position to allow pulse and blood pressure to stabilise before any measurements 
were taken. To avoid unnecessary patient movements, a clear and concise explanation of 
the procedure was given beforehand.
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o Vascular resistance and vascular reactivity were assessed using a Toshiba 
Eccocee SSA 340 ultrasound machine with a 7.5 MHz linear probe and colour 
Doppler facility. For this experiment the PI, Vmax and back pressure were recorded 
and calculated as these parameters are good indicators of a measure of 
downstream vascular resistance especially in low resistance vascular beds 
(Taylor, 1990; Gosling et al, 1991; Fish, 1999).
In order to minimise measurement errors care was taken with the placement of the 
transducer, avoiding excessive pressure against the skin which may result in the 
deformation of the vessel; more important of the superficial CCA. To further reduce this 
error, the CCA was scanned using the stemomastoid muscle as a stand-off. As the 
Doppler shift frequency is proportional to the angle of insonation, an angle of 60° was 
used in all subjects.
o The viscoelastic properties and IMT were assessed using a Pie 35 machine (Pie 
Medical Systems, Maastricht, Netherlands) with 7.5 MHz linear probe and colour 
Doppler facility with signal output to a high resolution wall tracking system (Wall 
Track, Pie Medical Systems, Maastricht, Netherlands).
As previously described in Section 3.4.2, the diametrical compliance (C) and stiffness 
index (P) were used to assess the vessel wall properties in the three groups since these 
two parameters are less pressure dependent. Due to reduced ultrasound resolution of the
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anterior vessel wall, the IMT was determined in the far wall and an average of three 
readings taken within 2 cm from the carotid bulb in all subjects.
o Iontophoretic drug delivery 
After the 15 min acclimatisation period, two perspex iontophoresis chambers (ION1, 
Moor Instrument Ltd, Axminster, UK) were attached 5.0 cms from the medial condyle 
with at least 10.0 cm between them on the right forearm (Figure 4.1) by means of double­
sided adhesive rings avoiding hair, broken skin, and superficial veins for the reasons 
given before (Section 3.4.4). 0.25 ml of 1% acetylcholine chloride (ACh) (Sigma 
Chemicals Ltd, UK) was placed in the anodal chamber and 0.25 ml of 1% sodium 
nitroprusside (SNP) (Sigma Chemicals Ltd, UK) in the cathodal chamber. A laser 
Doppler probe was positioned through the centre of each chamber. The vehicle for both 
drugs was normal saline and mixed prior to administration; sodium nitroprusside was 
kept in the dark. Skin blood perfusion was measured using a double chamber laser 
Doppler perfusion monitor (Laser Doppler DRT4 system, Moor Instrument Ltd, 
Axminster, UK).
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Figure 4.1 Laser Doppler Iontophoresis set-up
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Drug delivery was performed using a battery-powered constant current iontophoresis 
controller (MIC-le, Moor Instrument Ltd, Axminster, UK). Low currents were used to 
limit the iontophoresis dose and to prevent galvanic effects which may cause non-specific 
vasodilatation (Berghoff et al, 2002) and a cumulative dose-response protocol was used 
(Morris et al, 1995). Baseline erythrocyte flux was measured for 100 s without current i.e. 
no drug was iontophoresed. This was followed by drug delivery at 10 pA, 15 pA and 20 
pA, sequentially, each for 100 s, followed by 800 s at zero current. Microvascular
129
perfusion was continually assessed graphically by laser Doppler as shown in Figure 4.2; 
recording of erythrocyte flux in women with PCOS and controls with iontophoretic 
application of ACh at predetermined points. In the present study the mean erythrocyte 
flux estimates are reported at the end of baseline period, at 50 s intervals during 
iontophoresis, and at 100 s intervals thereafter.
Figure 4.2 Example of laser Doppler trace
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Animal work
All animals were kept in the Comparative Biology Unit and injection protocol was 
performed by the unit staff. At the end of the injection regimen, general anaesthesia and the 
in-vivo work was performed with the help of Dr W. Yang. In-vivo measurements of the 
thoracic aorta were taken using Pie 35 machine (Pie Medical Systems, Maastricht, 
Netherlands) with 7.5 MHz linear probe and colour Doppler facility with signal output to a 
high resolution wall tracking system (Wall Track, Pie Medical Systems, Maastricht, 
Netherlands).
Ms S. McLellan performed all the immunoassays using dedicated kits. Serum 
concentrations of LH, FSH and insulin were measured in duplicate in 50 pL samples using 
an enzyme-linked immunoassay (EIA) supplied by using Biotrak kits and methods 
(APBiotech, Amersham, UK). Serum testosterone was also assessed in duplicate in 50 pL 
samples using an ELISA kit (Roche Diagnostics, Welwyn Garden City, Herts, UK).
Organ bath experiments were performed with the help of Ms A. Dooley. The thoracic 
aorta was placed in a container with oxygenated Krebs buffer solution and tested within 6 
hours. The aortic segment was cleaned of fat and adhering connective tissue and cut into 
2 mm wide rings. The rings were mounted on hooks in 7 ml organ baths, containing 
Krebs buffer, maintained at 37° C and oxygenated with 95% O2 , 5% CO2 (Figure 4.3). 
The isometric tension was measured with a transducer (Grass Instruments, Quincy, Mass, 
USA) and digitized using a multi-channel computerised continuous recording system 
(Linton Instrumentation, Diss, Norfolk, UK) with AcqAcknowledge ACK100W software
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(Biopac Systems Inc., Goleta, CA, USA), which allowed simultaneous testing of six 
rings.
Figure 4.3 Schematic diagram of aortic ring organ bath
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Rings were adjusted to a resting tension of 1 g and equilibrated for 60 min in oxygenated 
Kreb’s buffer. Tissues were then pre-contracted with phenylephrine (PE) 3 pM to give 
75% of the maximal contraction. Their dilatory response to cumulative doses of 
acetylcholine (Ach; InM-OOpM) was then measured. This PE-ACh treatment cycle was 
repeated once, then again after addition of lOOpM N -nitro-L-arginine methyl ester (L-
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NAME) to three of the six aortic rings. A final treatment cycle used the cumulative doses 
of sodium nitroprusside (SNP -  a NO donor, 1 nM -100 pM) instead of ACh after PE- 
mediated contraction and L-NAME addition to the same three samples as before (Liu et 
al, 2000; Figure 4.4). Aortic tension was expressed graphically, as percentage relaxation, 
such that the tension induced by 3 pM PE was defined as 0% relaxation, and the tension 
prior to PE treatment was defined as 100% relaxation.
Figure 4.4 Graphical representation of ACK 100W
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CHAPTER 5
INTERNAL CAROTID ARTERY VASCULAR 
RESISTANCE AND VASCULAR REACTIVITY TO 5% 
CARBON DIOXIDE IN WOMEN WITH POLYCYSTIC
OVARIES
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5.1 Introduction
Haemodynamic changes have been reported in women with PCOS. In a study of 30 
oligomenorrhoeic (cycle length > 35 days) and 12 amenorrhoeic, hirsute women (no 
vaginal bleeding for > 3 months and Ferriman and Gallwey score > 8), all with PCO 
morphology on TVS, and 18 control women (normal menstrual cycle), increased uterine 
artery PI and decreased ovarian stromal RI was observed by Doppler ultrasound in 
women with PCOS compared with controls (Battaglia et al, 1995). Similarly in 1996, 
Aleem and Predanic (1996) in a study of 40 women with PCOS (menstrual irregularity, 
infertility and hyperandrogenism and PCO morphology on TVS) and 50 control women 
(menstrual cycle 26 -  32 days and normal ovarian morphology on TVS) reported 
increased uterine artery PI and both decreased PI and RI ovarian parameters in women 
with PCOS. Since insulin resistance is the central feature in PCOS women, it is of interest 
that the mean blood flow velocity in the middle cerebral artery measured using 
transcranial Doppler ultrasound was increased in diabetic subjects (Kawata et al, 1998). 
However, this study did not mention the type of diabetes and insulin levels, therefore it 
was very poor. Similar changes have also been reported in cerebral circulation, assessed 
with radiolabelled microspheres in pancreatomised dogs (Sieber et al, 1993b). As 
described in Chapter 1, Prelevic (1995) reported decreased flow velocity over the aortic 
arch assessed by Doppler ultrasound and an increase in resting forearm flow (1996).
The aim of this study was to use Doppler ultrasound to assess vascular resistance at 
baseline and vascular reactivity following inhalation of 5% carbon dioxide, a known 
vasodilator (Widder et al, 1986), in the left and right common and internal carotid arteries 
(CCA and ICA; respectively) in women with PCOS, PCO and healthy controls.
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5.2 Methods
The sample size required was calculated using data from a study of the effect of a nitric 
oxide donor on uterine artery Doppler velocimetry in women with PCOS, where the 
difference in Doppler parameters in cases and controls was +2.77 ± 0.4 and -0.13 ± 0.06 
respectively. Power calculation indicated a sample of 16 subjects in each group was 
necessary to provide 80% power detecting differences of similar magnitude in the present 
study and a significance of 5%.
5.2.1 Subjects and study design
A total of 68 women were recruited in this cross sectional study from the North 
Middlesex Hospital:
> 35 women with PCOS (defined according to the criteria in Section 4.2)
> 15 asymptomatic women with polycystic ovarian morphology on TVS (PCO).
> 18 control women (staff members) with normal ovaries on TVS (controls).
The inclusion and exclusion criteria were followed as described in Section 4.2. Height 
and weight measurements were used to calculate BMI and the waist and hip 
measurements to calculate the W/H (Section 4.2). Fasting peripheral blood was obtained 
from all women for serum endocrine and metabolic parameter measurements (Section 
4.5).
136
5.2.2 Protocol
All women were scanned in the supine position with the head hyperextended and turned 
away from the side being examined. All scans were performed using a Toshiba Eccocee 
SSA 340 machine with a 7.5 MHz linear probe. The pulse Doppler range gate (2 mm) 
was placed midway across the CCA and 2.0 cm distal to the carotid bulb for the ICA. The 
colour pulsed repetition frequency of 20 Hz with a wall filter of 100 Hz was used to 
achieve an enhanced blood flow image of the vessel. The Doppler exposure time was 
kept to a minimum.
Once Doppler parameters (PI and Vmax) were obtained at baseline while the subject 
breathed room air, the procedure was repeated following inhalation of 5% C 02 through a 
tight fitting face mask for 5 minutes at a flow rate of 3 L/min. A mixture of 5% C 0 2 and
95% O2 was chosen as this has been shown to increase the total cerebral blood flow by 
approximately 75% (Kety and Schmidt, 1948; Sokoloff, 1960 and Breslau et al, 1982). 
5% C 02 was inhaled for 2 minutes; a 2 minute interval was chosen as the response to 5% 
C 02 is maximal after 20 seconds and remained stable after 2 minutes (Kety and Schmidt, 
1948).
The Doppler spectral waveform was simplified by displaying the time dependence of a 
single parameter, the maximum velocity. At least three consecutive waveforms 
(representing three cardiac cycles) were displayed, the peak systolic velocity (Vmax cm/s) 
and PI were estimated for each vessel on both the left and the right sides. In view of the 
difficulty in interpreting PI in low impedance vascular beds such as the cerebral
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circulation, downstream backpressure was calculated using the model proposed by 
Gosling et al (1991). According to this model, the back pressure is the sum of arteriolar 
vasomotor tone and intracranial pressure, and can be estimated using PI, systolic blood 
pressure (SBP) and diastolic blood pressure (DBP):
Back pressure = DBP + (SBP -  DBP) x (1/3 -  [1/PI])
Pulse and blood pressure were measured (at baseline and after the inhalation of 5% CO2) 
on the left arm in each woman using an automatic Dinamap device (Critikon Inc, Tampa, 
FL, USA) as described in Section 4.2. Since carotid artery blood flow is influenced by 
auditory stimulation-noise (Gangar et al, 1991), occlusive headphones were worn 
throughout the procedure (Section 4.2). Ambient light and temperature (18-20°) were 
controlled throughout the procedure.
5.2.3 Statistical analysis
Data are mean ± standard deviation (SD). Analysis of variance was used to identify any 
linear trends in clinical / biochemical parameters and PI, Vmax and back pressure from 
controls through PCO to PCOS women where appropriate. The main outcome measures 
were comparisons of haemodynamic characteristics (PI, Vmax, back pressure) at baseline 
and the mean changes in these parameters after inhalation of 5% CO2 , calculated for the 
PCOS, the PCO and the control groups.
Departure from the normal distribution for PI, Vmax and back pressure was assessed in
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each group with the Kolmogorov Smimov test. Few data sets were non-normal and a 
non-parametric test -  the Mann-Whitney U test was used to assess the significance of 
differences with other sets, as was appropriate. Differences between normally distributed 
data sets were assessed by analysis of variance (ANOVA), with Benferroni’s test being 
used for group-to-group post hoc comparisons.
The following confounding variables were known a priori to differ between PCOS and 
healthy women, and to be associated with haemodynamic disturbances: SBP and DBP, 
FAI, oestradiol and insulin resistance index. All confounding variables were controlled 
for within multiple linear regression models. Estimated marginal means (adjusted means) 
and differences in Vmax, PI and back pressure between controls and the PCO or the PCOS 
groups were obtained from general linear models (GLM procedure). This was performed 
to include in the GLM command the mean value of confounding factors calculated for the 
control group; 95% confidence interval (Cl) and p values for adjusted differences 
indicated the magnitude and statistical significance of haemodynamic changes, explained 
only by the presence of polycystic ovaries. Statistical test considered significant for p 
values < 0.05. All analysis was performed using the statistical package SPSS for 
Windows (version 9.0).
5.3 Results
The Vmax and PI for each artery on the left and the right sides were highly correlated and 
the means were therefore combined for analysis (r = 0.81; p < 0.001). The coefficients of 
variation for ultrasound measurements were between 2% and 8% indicating high 
reproducibility. Haemodynamic parameters -  PI, Vmax and back pressure were normally
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distributed and there was minimal difference between the median and mean values; mean 
values were therefore compared by ANOVA. Median and mean value for each parameter 
respectively were: PI PCOS -  1.59 vs 1.63, PCO 1.61 vs 1.69, Control 1.83 vs 1.87; Vmax 
PCOS - 71.8 vs 71.5 cm/sec, PCO 69.0 vs 68.1 cm/sec, Control 70.2 vs 74.0 cm/sec; 
back pressure - PCOS 53.1 vs 52.1 mmHg, PCO 56.5 vs 56.1 mmHg; Control 54.7 vs
54.1 mmg/Hg.
Table 5.1 shows the expected upward trend from control through PCO to PCOS women 
for BMI, waist/hip ratio, BP, FAI, oestradiol, LH, and insulin resistance index, while the 
PI decreased significantly in the ICA (p = 0.003) and just failed to do so in the CCA. 
There were no significant differences in V max or backpressure in the ICA or in any of the 
ultrasound parameters in the CCA before adjustment for confounding factors.
On multiple regression analysis (Table 5.2), significant adjusted differences between 
control and PCO or PCOS women were observed in ICA PI (p = 0.019 and p = 0.016 
respectively), while the differences in Vmax in the ICA were non-significant (p = 0.51 and 
p = 0.32, respectively). The adjusted means of back pressure in the ICA were much lower 
in both the PCO and PCOS groups than in the controls, especially after removing the 
confounding effect of blood pressure. Although the differences were of similar 
magnitude, that between the control and PCO group was statistically significant (p = 
0.038), whereas that between the control and PCOS women failed to reach significance (p 
= 0.070). No significant adjusted differences were observed in the CCA between control
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and PCO or PCOS women, except in Vmax, which was considerably decreased in PCOS 
women relative to controls.
Within groups, there was a significant decrease in the ICA Vmax (p = 0.024) and an 
increase in back pressure (p = 0.016) in women with PCOS, after inhalation of 5% CO2 
relative to baseline estimates. Changes in ICA PI in response to 5% CO2 inhalation were 
not significant, as were changes in ICA PI, Vmax and back pressure in normal women and 
asymptomatic women with PCO in response to this treatment (Figure 5.1). Within 
groups, a significant change was also observed in the CCA Vmax in PCOS and PCO 
women (p = 0.001 and p = 0.029, respectively) in response to 5% CO2 treatment, but 
there was no significant change in PI or back pressure.
Between the control, PCO and PCOS groups, a significant linear trend was found only in 
the ICA back pressure changes in response to 5% CO2 , after adjusting for confounding 
factors (p = 0.044). There was no evidence of any linear trend in PI or Vmax in any 
parameters in the CCA.
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Table 5.1 Physical, endocrine, biochemical and haemodynamic characteristics 
in controls, PCO and PCOS women
Values are mean ± SD. Analysis of variance was used to test for a significant 
increase/decrease from control through PCO to PCOS women and p values are given.
Variable Control
(n=18)
PCO
(n=15)
PCOS
(n=35)
Test for trend* 
p value
Age, (years) 27.2 ± 2.9 25.8 ±3.8 26.1± 4.0 0.36
Body Mass Index, (kg/m2) 22.9 ± 3.2 23.3 ± 3.6 25.7 ± 4.9 0.019*
Waist to hip ratio 0.74 ± 0.05 0.77 ± 0.05 0.80 ± 0.06 0.002*
Systolic Blood Pressure, (mmHg) 107± 10 112 ± 9 123 ± 10 0.001*
Diastolic Blood Pressure, (mmHg) 63.2 ±4.9 68.1± 6.8 68.2 ± 5.9 0.007*
Free Androgen Index, (%) 2.6 ±1.2 3.8 ±1.5 7.3 ± 4.6 0.001*
Oestradiol (pmol/L) 209 ± 67 181 ± 9 9 2 7 0 ± 122 0.024*
Luteinsing Hormone, (IU/L) 5.6 ±2.3 5.9 ±3.5 9.0 ±6 .5 0.022*
Follicle Stimulatin Hormone, (IU/L) 6.0 ± 1.6 5.9 ±1 .6 5.4 ± 1.8 0.20
Prolactin (mU/L) 394 ± 234 3 5 2 ± 177 351 ±379 0.68
Insulin resistance index (mU/mmol) 2.5 ± 0.9 2.6 ± 0.9 3.2 ± 1 .3 0.031*
Total Cholesterol (mmol/L) 4.9 ± 1.8 4.4 ±0 .7 5.0 ± 1.0 0.53
Triglycerides (mmol/L) 0.77 ± 0.27 0.83 ± 0.29 1.07 ± 0.74 0.057
High-density lipoprotein, (mmol/L) 1.4 ±0.2 1.3 ±0 .2 1.2 ± 0 .4 0.17
Low-density lipoprotein, (mmol/L) 3.2 ± 1.8 2.6 ±0 .7 3.3 ±0 .8 0.50
ICA, Vmax (cm/s) 74.0 ± 17.1 68.1± 8.3 71.8 ± 15.4 0.74
ICA, (PI) 1.87 ±0.38 1.69± 0.23 1.63 ±0.21 0.003*
ICA Back pressure, (mmHg) 54.1± 7.3 56.1± 8.3 52.1 ± 8 .7 0.29
CCA Vmax, (cm/s) 102.6 ± 12.3 101.3 ±8 .5 101.3 ±  14.6 0.73
CCA, (PI) 2.51± 0.37 2.42± 0.25 2.35 ± 0.27 0.069
CCA Back pressure, (mmHg) 59.9 ± 6.9 64.4 ± 6.7 62.7 ± 7.3 0.25
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Table 5.2 Adjusted comparisons of V max, PI and back pressure between control 
and PCO/PCOS women.
Estimated marginal means were calculated using mean values for the control group: BMI = 22.9 
kg/m2, systolic blood pressure = 107 mmHg, diastolic blood pressure 63.2 mmHg, FAI 2.6%, 
oestradiol = 209 pmol/1, insulin resistance index = 2.5 mU/mmol. Adjusted differences are given 
with 95% Cl. Significant differences indicated by *p < 0.05.
Group Adjusted Difference 
(95% C.I)
Variable
Control
(n=18)
PCO
(n=15)
PCOS
(n=35) Control -  PCO Control -  PCOS
ICA PI 1.87 1.55 1.58 0.32 (0.06 to 0.58)* 0.29 (0.06 to 0.52)*
ICA Vmax (cm/sec) 74.0 69.7 68.1 4.2 (-8.9 to 17.3) 5.9 (-6.0 to 17.7)
ICA Back pressure (mmHg) 54.1 50.6 50.8 3.5 (0.2 to 6.8)* 3.3 (-0.3 to 6.9)
CCA PI 2.51 2.25 2.39 0.26 (0 to 0.52) 0.12 (-0.12 to 0.36)
CCA V max (cm/sec) 102.6 100.4 92.5 2.3 (-7.6 to 12.2) 10.1 (0.2 to 20.2)*
CCA Back Pressure (mmHg) 59.5 58.5 59.4 1.3 (-0.4 to 3.1) 0.4 (-1.7 to 2.6)
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Figure 5.1 Changes in Doppler parameters in the internal carotid artery after 
inhalation of 5% CO2 (mean change, 95% confidence interval)
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5.4 Discussion
This is the first demonstration of lower PI in the ICA in women with polycystic ovaries 
and with overt PCOS. Conventionally, a lower PI with similar Vmax in the internal carotid 
artery would be considered to be indicative of reduced downstream resistance and 
increased blood flow.
Gosling and colleagues (1991) have highlighted the difficulties in interpreting PI in low 
resistance vascular bed such as the ICA. They suggested that small changes in PI do not 
alter the spectral waveform shape (affected by pressure drop across the vascular bed and 
not resistance, per se), and proposed a model characterised by two parameters: back 
pressure (estimated from systemic blood pressure and PI) and ‘pure’ resistance to flow. 
According to Gosling et al (1991), the back pressure in the cerebral circulation is the sum 
of arteriolar vasomotor tone and intracranial pressure, a better indicator of resistance in 
low impedance vascular beds.
Unadjusted analysis at baseline showed non-significant differences in back pressure 
between the three groups. However, after adjusting for confounding variables, 
significantly lower values were seen in women with PCO and a difference of similar 
magnitude between control and PCOS women, although this was only marginally 
significant. The finding of lower back pressure in women with polycystic ovaries is 
consistent with a decrease in vascular tone with lower PI seen in these women. There
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were no significant differences in the Doppler parameters and back pressure in the 
common carotid artery in PCO/PCOS women.
The mechanism responsible for decreased internal carotid artery PI and back pressure in 
these women is unknown. There is some evidence that hyperglycaemia which is 
associated with PCOS may influence haemodynamic changes. Griffith and colleagues 
(1987) reported increased cerebral flow in short duration Type I diabetics with no 
diabetic complications, and similar findings were reported by Grill et al (1990) in long- 
duration well-controlled Type I diabetics. PCOS is, however, more closely related to 
Type II diabetes, in which the regional blood flow may be reduced. Wakisaka et al (1990) 
reported decreased cerebral blood flow suggestive of increased resistance in Type II 
diabetic subjects. However, 30% of the subjects studied had retinopathy, neuropathy or 
nephropathy and since these complications are not seen in PCOS women, this result may 
not be relevant to this syndrome.
The results of animal studies are also contradictory. Sieber et al (1993a) reported 
increased cerebral blood flow in chronically hyperglycaemic dogs (after 
pancreactectomy), but these results were not confirmed when the study was repeated in 
unanaesthetised dogs or in those anaesthetised with pentobarbital or fentanyl (Sieber et al, 
1993b). The authors concluded that the increased cerebral blood flow observed in the first 
study may have resulted in surgical stimulation during insertion of vascular catheters, and 
that hyperglycaemia may not be associated with altered cerebral blood flow.
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The study also provides evidence of a significant effect of CO2 inhalation on ICA 
Doppler variables in women with PCOS but not in women with PCO alone or in controls. 
Increased back pressure after inhalation of CO2 is suggestive of an increased vascular 
tone, an increased intracranial blood pressure, or both. The absence of an effect of 5% 
CO2 inhalation in healthy controls cannot be explained by a failure to induce hypercapnia, 
since the technique was validated by an increase in end-tidal CO2 concentration, assessed 
by means of an infrared analyser. Lees and colleagues (1998), in a small study of 10 
women with PCOS and nine control women with regular menstrual cycles between 26- 
29 days and normal ovarian morphology on TVS, reported similar paradoxical response 
in PCOS women and no difference in control women in the uterine artery resistance 
assessed with colour Doppler ultrasound following the administration of glyceryl 
trinitrate.
The increased trend in back pressure, following inhalation of 5% CO2 , from control 
women through asymptomatic women with PCO to women with PCOS, suggests a 
progressive alteration in CO2 reactivity in women with PCO. Very few studies have used 
ICA Doppler ultrasound to investigate the effect of carbon dioxide. Breslau and 
colleagues (1982) reported a 96% higher internal carotid artery end-diastolic velocity 
after inhalation of 6.8% CO2 in five healthy volunteers. However, this study used male 
volunteers and the researchers have failed to report the mean change and its significance.
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The physiological mechanisms responsible for the vasodilatory response to CO2 are 
unclear. Whether CO2 , bicarbonate or hydrogen ions exert effects directly on cerebral 
vessels, or whether other intermediate processes and/or messenger systems are involved 
remains unknown. It is also possible that the dilatory effect of CO2 may be under 
neurological control involving stimulation of either the aortic or carotid chemoreceptor or 
both (Madden, 1993).
The results of the present study provide evidence of vascular abnormality but the clinical 
interpretation of altered vascular reactivity of the cerebral circulation during hypercapnia 
is still unclear. One possible explanation of these findings may be due to alteration in 
vascular mechanics in PCOS women, suggestive of reduced resistance in the cerebral 
vascular beds independent of blood pressure, insulin resistance or other endocrine and 
metabolic factors. Furthermore, the alteration in cerebrovascular PI could also reflect 
change in vascular compliance; increased vessel stiffness has been reported in women 
(but not in men) with diabetes (Ryden-Ahlgren et al, 1996), and this is addressed in the 
next chapter.
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CHAPTER 6
IMPAIRED CAROTID ARTERY ELASTIC 
PROPERTIES IN WOMEN WITH POLYCYSTIC OVARIES
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6.1 Introduction
As has been discussed previously, PCOS is associated with insulin resistance (Dunaif, 
1997), type II diabetes (Wild et al, 1985; Talbott et al, 1995) and gestational diabetes 
(Urman, 1997). These conditions are associated with decreased vascular compliance and 
thus increased arterial stiffness (Lehman et al, 1992). This increase has been suggested as 
an early marker of structural and/or functional changes in the arteries related to the 
pathogenesis of atherosclerosis. In this thesis (Chapter 5), a paradoxical constrictor 
response to 5% CO2 , a known vasodilator, was noted in the ICA of women with PCOS 
(Lakhani et al, 2000b). A similar constrictor response to the vasodilator glyceryl trinitrate 
reported in the uterine artery of women with PCOS (Lees et al, 1998). These findings 
suggest endothelial function may be impaired resulting in stiffer vessels in women with 
PCOS compared to controls. The present study was designed to assess elastic properties 
in the carotid arteries in women with PCOS, PCO and controls.
6.2 Methods
The sample size required was calculated using data from a study of testosterone 
suppression in men and controls, where the change in systemic arterial compliance from 
baseline for controls and cases was +0.06 ± 0.37 and -0.26 ± 0.33 respectively. Power 
calculation indicated a sample of 18 subjects was necessary to provide 80% power of 
detecting differences of a similar magnitude in the present study at a significance of 5%.
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6.2.1 Subjects and study design
In this cross-sectional study a total of 60 women were recruited from the North 
Middlesex and Royal Free Hospitals:
> 20 women clinics with PCOS (defined according to the criteria in Section 4.2)
> 20 asymptomatic women with polycystic ovarian morphology on TVS (PCO).
> 20 control women (staff members) with normal ovaries on TVS (controls).
The inclusion and exclusion criteria were followed as described in Section 4.2. Height 
and weight measurements were used to calculate the BMI, and the waist and hip 
measurements to calculate the W/H (section 4.2). Fasting peripheral blood was obtained 
from all women for serum endocrine and metabolic parameter measurement (Section
4.5). In this study the arterial compliance (C) and stiffness index ((3) were used to assess 
the vessel wall properties in the three subject groups (Section 4.6).
6.2.2 Protocol
All women were examined in the supine position, with the head hyperextended and 
turned away from the side being scanned. Scans were performed by the same operator 
(KL) using a colour Doppler Pie 350 machine (Pie Medical Systems, Maastricht, 
Netherlands) with a 7.5 MHz linear probe, the signal output being connected to a high 
resolution wall tracking system (Wall track, Pie Medical Systems, Maastricht, 
Netherlands). This system allowed the measurement of vessel wall (CCA and ICA) 
movement over time by automatically tracking assigned points of the induced radio 
frequency signal deemed to be representative of the anterior and posterior vessel wall (as 
described in Section 3.4.2). In brief, the M-mode cursor positioned perpendicularly and
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midway to the long axis of the CCA and 2 cm distal to the carotid bulb for the ICA, the 
change in induced radio frequency signal from the vessel was sampled. The data was 
transferred to a personal computer for off-line analysis of the anterior and posterior 
arterial walls.
Pulse and blood pressure were measured on the left arm in all women, using an automatic 
Dinamap device (Critikon Inc, Tampa, FL, USA), as described in Section 4.2. Since 
carotid blood flow is influenced by auditory stimulation (Gangar et al, 1991), occlusive 
headphones were worn throughout the procedure (Section 4.2). Ambient light and 
temperature (18 -  20°) were controlled throughout the procedure.
6.2.3 Statistical analysis
The CCA and ICA wall movement was obtained over three cardiac cycles, and the 
average diametrical compliance and stiffness index were calculated according to 
equations described in Section 3.4.2, and blood pressure estimated measured at the 
corresponding time and site. The average of three measures of C and p data at a given site 
was used to calculate to obtain mean values for each site along the vessel in each subject. 
Intra-observer variability was determined separately for each site, by determining the 
coefficient of variation of repeated measurements. Coefficients of variations below 10% 
were considered to indicate good reproducibility.
Normality of data was assessed using the Kolmogorov-Smimov test. Differences between 
normally distributed data sets were assessed by ANOVA, with Bonferroni’s test being
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used for group-to-group post hoc comparisons. Non-normally distributed data were 
assessed using a non-parametric test -  the Mann-Whitney U test to assess the significance 
with other sets, as appropriate. The following confounding variables were known a priori 
to differ between PCOS and healthy women and are known to be associated with 
haemodynamic disturbances: age, BMI, SBP and DBP. Inter-group differences in C and p 
were compared by one-way ANOVA and if significant differences were detected multiple 
regression analysis were performed, including all known confounders controlled for 
within regression models. Inter-group comparisons of adjusted means were performed 
between PCOS versus controls and PCO versus controls. Adjusted means were calculated 
using general linear models (GLM) procedure. This was achieved by including in the 
GLM command the mean values of the confounding factors calculated for the control 
group. Statistical tests considered significant for p values < 0.05. All analyses were 
performed using the statistical package SPSS for Windows (version 9.0).
6.3 Results
Arterial compliance and stiffness index were correlated between the right and the left 
sides and therefore only the right side was assessed due to easy accessibility of this side. 
The coefficients of variations for compliance and stiffness index were between 3.5% and 
7.0% for the CCA and 7.6% and 10% for the ICA, indicating good reproducibility for the 
CCA and reasonable reproducibility for the ICA.
Table 6.1 summarises the physical characteristics in controls and in women with PCO 
and PCOS. There was no significant difference with respect to age between the three 
groups. There was a significant difference in BMI (p = 0.003) and systolic (p = 0.03) and
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diastolic blood pressures (p = 0.04) in women with PCOS compared with healthy 
controls.
Table 6.1 Physical characteristics for the three groups. Values are mean (SD), 
HDL high-density lipoprotein, LDL low-density lipoprotein, NS, Not significant
Variable Control
(n=20)
PCO
(n=20)
PCOS
(n=20)
p value between 
groups
Age, (years) 27.5 ± 4.00 27.7 ± 4.60 29.2 ± 4.00 NS
Height, (m) 1.68 ±0.06 1.64 ±0.08 1.65 ±0.07 NS
Weight, (kg) 61.0± 11.30 68.1 ±11.60 85.5 ±25.30 0.008
Body Mass Index, 
(kg/m2)
24.2 ± 3.40 22.5 ± 3.80 31.3 ±8.20 0.003
Systolic blood pressure, 
(mmHg)
108.2 ±9.60 103.1 ±9.7 118.7 ± 18.20 0.03
Diastolic blood pressure, 
(mmHg)
59.5 ± 8.40 56.3 ± 6.80 68.9 ±14.60 0.04
Fasting Insulin, (mU/L) 10.43 ±4.60 16.41 ± 7.12 23.83 ±10.31 0.02
Total cholesterol, 
(mmol/L)
4.42 ± 0.52 5.41 ±2.49 4.59 ±1.89 NS
High-density lipoprotein, 
(mmol/L)
1.38 ±0.20 1.36 ±0.21 1.33 ±0.43 NS
Low-density lipoprotein, 
(mmol/L)
2.72 ± 0.44 3.61 ±2.51 3.69 ± 1.43 NS
Triglycerides (mmol/L) 0.70 ±0.17 0.91 ±0.32 1.27 ±0.95 NS
There was minimal difference between the median and mean compliance values; mean 
values were therefore compared ANOVA. The median and mean value for each group 
respectively were: C c c a  - PCOS 14.73 vs 14.86 % mmHg’x 10'2, PCO 9.8 vs 10.1 % 
mmHg’x 10'2, Control 20.53 vs 18.86 % mmHg’x 10"2; Qca PCOS 9.9 vs 12.5 % 
mmHg’x 10"2, PCO 9.8 vs 10.15 % mmHg'x 10"2, Control 12.69 vs 13.195 % mmHg'x 
10' 2 .
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While no difference was noted in unadjusted mean compliance and stiffness index 
between controls, PCO and PCOS groups, on multiple regression analysis and correction 
for the influence of confounding variable, significant adjusted differences were observed 
in compliance and stiffness index between controls and PCO or PCOS women (Tables
6.2 and 6.3).
Table 6.2 Adjusted comparison of compliance (C) of the common carotid artery 
(CCA) and the internal carotid artery between control and PCO/PCOS women.
Estimated marginal means were calculated from the GLM model using mean values o f the confounding 
factors for the control group: Age = 27.5 years; BMI = 24.2 kg/m2; systolic blood pressure = 108.2 mmHg; 
diastolic blood pressure = 59.5mmHg and insulin 10.43 m-units/L. Adjusted differences are given with 
95% confidence intervals. Significant differences are indicated by:* p < 0.05.
Adjusted mean
Adjusted Difference 
(95% C.I)*
Variable
Control
(n=20)
PCO
(n=20)
PCOS
(n=20) Control -  PCO Control -  PCOS
C cca (% mmHg 1 x 10 2) 19.2 14.1 10.7 5.1 (8.1 to 2.6)* 8.5 (10.2 to 4.8)*
C ica (% mmHg 1 x 10 2) 16.9 11.0 10.1 5.9 (8.7 to 1.4)* 6.8 (9.2 to 0.4)*
Table 6.3 Adjusted comparison of stiffness index (|3) of the common carotid artery 
(CCA) and the internal carotid artery between control and PCO/PCOS women.
Estimated marginal means were calculated from the GLM model using mean values o f the confounding 
factors for the control group: Age = 27.5 years; BMI = 24.2 kg/m2; systolic blood pressure = 108.2 mmHg; 
diastolic blood pressure = 59.5 mmHg and insulin 10.43 m-units/L. Adjusted differences are given with 
95% confidence intervals. Significant differences are indicated by:* p < 0.05.
Adjusted mean
Adjusted Difference 
(95% C.I)*
Variable
Control
(n=20)
PCO
(n=20)
PCOS
(n=20) Control -  PCO Control -  PCOS
P CCA 6.7 10.2 12.3 -3.5 (-1.1 t o -4.7)* -5.6 (-2.8 t o -6.2)*
P ICA 8.7 16.2 14.8 -7.5 (-0.9 t o -15.2)* -6.1 (-4.5 t o -13.1)*
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6.4 Discussion
This is the first demonstration of decreased vascular compliance and increased arterial 
stiffness of the CCA and ICA in both PCOS and asymptomatic PCO women compared 
with control women. This is significant in view of the relationship between the functional 
properties of the arterial wall i.e. atherosclerosis appears to affect blood vessel stiffness 
by changing the intrinsic properties of arterial wall, and therefore an increase in 
cardiovascular mortality and morbidity (Lusis, 2000).
Arterial elasticity diminishes with age, hypertension and other risk factors, such as 
hyperlipidaemia and smoking (Benetos et al, 1993) as well as in patients with frank 
coronary artery disease (Dart et al, 1991). The results of this study are unlikely to be 
confounded by these factors, because all the subjects in this study were young (25 -  33 
years), non-smoking adults who had no symptoms of coronary artery disease. Similarly, 
BP, BMI and fasting serum insulin were higher in women with PCOS than in controls, 
and are all associated with decreased vascular compliance. It is possible therefore that 
some or all of these confounders could account for the decreased compliance and 
increases stiffness index in the ICA and CCA in women with PCOS relative to controls. 
After adjusting for the confounders in the general linear regression model, vascular 
parameters remained disturbed in the PCOS women. However, in asymptomatic women 
with PCO, the BP and BMI was non-significant relative to controls, whereas fasting 
serum insulin levels were just significant. It is possible that after adjusting for 
confounders in the general linear regression model, insulin could account for the 
observed disturbed vascular parameters in the PCO women.
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The decreased vascular compliance in women with PCOS is compatible with earlier onset 
of atherosclerosis in these women, arterial elasticity being reduced by fatty streak 
formation before other pathological changes occur (Hironaka et al, 1997). Such a 
conclusion is supported by other evidence for subclinical atheromatous change in PCOS, 
before plaque formation or disturbance in blood flow (O’Leary et al, 1991) -  for 
example, the observation that intima-media thickness in the carotid artery is increased in 
women with PCOS (Talbott et al, 1995; Guzick et al, 1996). This observation is of 
significance in view of the correlation between carotid atherosclerosis and the incidence 
of coronary artery disease and stroke (Hertzner et al, 1985; Urbinati et al, 1992).
The mechanism responsible for the decreased arterial compliance and increased stiffness 
index in women with PCOS and asymptomatic women with PCO is not known, although 
similar findings in type II diabetes have been attributed to non-enzymatic glycation of 
elastin and collagen in the tunica media (Ilegbusi et al, 1999) and the accumulation of 
advanced end products of glycation which inhibit the appropriate muscular tone in the 
arterial wall (Irace et al, 1999). It is reasonable to suggest that this mechanism may be 
relevant in PCOS, given that the association with hyperglycemia and hyperinsulinaemia 
was seen in women with PCOS. The parallel with diabetes may also extend to endothelial 
dysfunction, as seen in the brachial artery in women with NIDDM (Goodfellow et al, 
1996). The abnormal response to glyceryl trinitrate (Lees et al, 1998) and paradoxical 
vasoconstrictor response to 5% carbon dioxide supports the concept of endothelial 
dysfunction in women with PCOS.
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The unexpected finding of decreased compliance and increased stiffness index in 
asymptomatic women with PCO may suggest ovarian morphology be the cause, but this 
seems unlikely. Some other ‘causative factor/s’ i.e. genetic may be responsible. The 
hypothesis that obesity leads to hyperinsulinaemia promoting increased ovarian androgen 
production and the expression of PCOS in asymptomatic women with PCO may be one 
of the reasons. But this seems unlikely because there was no difference in BMI of PCO 
women relative to controls. An alternative explanation is that it seems likely that a ‘PCO’ 
gene or combination of genes related to insulin secretion and action may be responsible.
The results of this study provide additional evidence of significant vascular dysfunction 
in women with polycystic ovaries and highlight the need to confirm or refute the present 
discrepancy between cardiovascular risk and mortality in these women.
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CHAPTER 7
INTIMA-MEDIA THICKNESS OF ELASTIC AND 
MUSCULAR ARTERIES OF YOUNG WOMEN WITH 
POLYCYSTIC OVARIES
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7.1 Introduction
As discussed previously (Chapter 6) the finding of decreased vascular compliance and 
increased vascular stiffness (Lakhani et al, 2002) in women with PCOS may reflect early 
atherosclerotic disease. Increased IMT is considered an early morphological marker of 
atherosclerosis appearing before the formation of plaque and disturbance in blood flow 
(Cheng et al, 2002). Furthermore, there is evidence of increased IMT in women with 
PCOS (Guzick et al, 1996; Talbott et al, 2000), though the women investigated were all 
aged over 40 years.
The present study was designed to test the hypothesis that women with PCOS suffer from 
precocious arterial disease, by measuring IMT using a reproducible automated technique 
capable of measuring to within 0.01 mm (Allan et al, 1997; Liang et al, 1998; Willekes et 
al, 1999; Cheng et al, 2000; Wilson et al, 2000). IMT was assessed in the CCA, the 
carotid bulb and the common femoral artery (CFA) in three groups of women aged less 
than 35 years -  women with PCOS, asymptomatic women with PCO and healthy 
controls.
7.2 Methods
The sample size required was calculated using data obtained from a study in which IMT 
was measured using B-mode ultrasound in women with PCOS and in controls, IMT 
estimates being 0.68 ± 0.019 and 0.63 ± 0.012, respectively. A power calculation 
indicated that a minimum sample of 12 subjects in each group was necessary to provide
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80% power in detecting differences of a similar magnitude in the present study at a 
significance of 5%.
1.2.1 Subjects and study design
Cross-sectional study of 43 women recruited from the North Middlesex and Royal Free 
Hospitals:
> 19 women with PCOS (defined according to the criteria in Section 4.2)
> 12 asymptomatic women with polycystic ovarian morphology on TVS (PCO).
> 12 control women (staff members) with normal ovaries on TVS (Controls).
The inclusion and exclusion criteria were followed as described in Section 4.2. Height 
and weight measurements were used to calculate the BMI and the waist and hip 
measurements to calculate W/H ratio (Section 4.2). Fasting peripheral blood was obtained 
from all women for serum endocrine and metabolic parameter measurement (section 4.5).
7.2.2 Protocol
The principles for the assessment of IMT are described in Section 3.4.3. In brief, the 
subjects rested for 15 min in supine position to allow pulse and blood pressure to stabilise 
before any form of measurements was performed. Pulse and blood pressure were 
measured on the left arm in all women using an automatic Dinamap device (Critikon Inc, 
Tampa, FL, USA) as described in Section 4.2. Since carotid blood flow is influenced by 
noise (Gangar et al, 1991), occlusive headphones were worn throughout the procedure
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(Section 4.2). Ambient light and temperature (18 -  20°) were controlled throughout the 
procedure.
Electrocardiographic (ECG) leads were placed appropriately on the chest wall for ECG 
R-wave triggered measurements. Real-time B-mode and M-mode images of the arterial 
wall motion and IMT were recorded using a 7.5 MHz linear probe in the sagittal plane at 
90° to the long axis of the CCA or CFA using a specially adapted duplex scanning system 
(Pie 350, Pie Medical Systems, Maastricht, Netherlands). Data was collected for 4 
seconds, i.e. 3-5 heart beats, with the signal output to a high resolution wall tracking 
system (Wall track, Pie Medical Systems, Maastricht, Netherlands) at a sample frequency 
of 20 MHz and an M-line update frequency of 400 Hz. This system allowed measurement 
of the intraluminal diameter and IMT over time, by automatically tracking the assigned 
points representing the anterior and posterior vessels walls. The automatic system records 
the IMT defined by two parallel echogenic lines (double line pattern) corresponding to 
the lumino-intima and media-adventitia interfaces, detected automatically from the RF 
signal (Section 3.4.3).
For the right CCA, the women were examined in the supine position, with the head 
hyperextended and tilted to the left at an angle of 45°. The IMT was assessed with the 
jugular vein in front of the carotid artery, thereby enhancing the ultrasound signal from 
the underlying CCA. For the CFA, ultrasound examination was performed with an empty 
bladder as a full bladder affects CFA artery wall properties (Willekes et al, 1998). The 
IMT was measured midway to the long axis of the CCA and CFA. At the end of the
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measurement protocol all recorded files were processed using the wall thickness program. 
The data were transferred to a personal computer for analysis.
7.2.3 Statistical analysis
The intra-observer errors were estimated, separately for each site, by determining the 
coefficient of variation of repeated measurements. Analysis of variance was used to 
identify any differences in biochemical and IMT parameters from controls through PCO 
to PCOS. The following confounding variables were known a priori to differ between 
PCOS and healthy women and are also associated with haemodynamic disturbances: age, 
BMI, SBP and DBP, cholesterol and insulin. Inter-group differences in parameters were 
compared by one-way ANOVA and, if significant by, multiple regression analysis. All 
confounders were controlled for within regression models. Adjusted means were 
calculated from general linear models (GLM) procedure. This was achieved by including 
in the GLM command the mean values of the confounding factors calculated for the 
control group. Inter-group comparisons were performed between PCOS versus controls 
and PCO versus controls. Statistical tests considered significant for p values < 0.05. All 
analyses were performed using the statistical package SPSS for Windows (Version
10.05).
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7.3 Results
The coefficient of variation for IMT measurements were 7% in the CFA, 8% in the CCA 
and 23% in the carotid bulb, respectively. Table 7.1 summarises the characteristics of the 
three groups. There was no significant difference with respect to age, systolic/diastolic 
blood pressures and the mean vessel wall luminal diameters between the three groups. As 
expected there were significant differences in BMI (p = 0.02), LH (p = 0.005) and FAI (p 
= 0.005) between women with PCOS and controls. The heart rate was also increased in 
women with PCOS compared with controls (p = 0.001).
There were minimal differences between the median and the mean IMT values. Mean 
values were therefore compared by ANOVA. Median and mean values for each 
parameter respectively were: IMTCCA - PCOS 0.56 vs 0.54 mm, PCO 0.49 vs 0.51, 
Control 0.37 vs 0.40 mm; IMTBUlb - PCOS 0.54 vs 0.56 mm, PCO 0.55 VS 0.54 mm, 
Control 0.46 vs 0.44 mm; IMTCfa-  PCOS 0.71mm vs 0.74 mm, PCO 0.53 mm vs 0.52 
mm, Control 0.41 mm vs 0.42 mm.
The IMT was significantly increased in the CFA and CCA in young women with PCOS 
compared to controls (Table 7.2). On multiple regression analysis, when controlling for 
known confounders (age, SBP and DBP, cholesterol and insulin), the differences in IMT 
still remained significant (Table 7.2).
In asymptomatic women with PCO, the CCA IMT was increased relative to controls but 
this difference failed to reach statistical significance after adjusting the means for
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confounding factors. Although there was a downward trend from PCOS though PCO to 
control women with respect carotid bulb IMT, this failed to reach the predetermined 
statistical significance.
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Table 7.1 Physical, endocrine, biochemical and mean luminal diameter for 
controls, PCO and PCOS women.
Variable Control PCO PCOS p-value
between
groups
No. of subjects 12 12 19
Age, (years) 27.7+4.8 28.2 ±5.4 29.0 ± 5.0 0.77
Height, (m) 1.67 + 0.06 1.64 ±0.06 1.63 ±0.07 0.25
Weight, (kg) 67.4 + 9.4 64.2 ± 10.3 74.8 ±16.1 0.06
Body Mass Index, (kg/m)2 24.2 ±3.2 24.0 ±3.5 28.3 ±6.5 0.02*
Systolic Blood Pressure, (mm Hg) 110 + 11 112 ± 15 119 ± 18 0.26
Diastolic Blood Pressure, (mm Hg) 63 + 80 59 ± 80 65± 13 0.28
Heart rate, (beats/minute) 65 + 80 63± 80 75± 90 0.001*
Luteinising hormone, (IU/L) 3.21 ± 1.32 5.78 ±4.33 9.81 ±6.66 0.005*
Follicle stimulating hormone, (IU/L) 6.53 ±3.20 6.02 ±1.68 5.91± 1.98 0.77
Testosterone, (nmol/L) 1.84 ±0.78 1.96 ±0.78 2.21 ±0.79 0.53
Sex-hormone binding globulin, (nmol/L) 79.60 ±41.9 58.90 ± 29.9 31.90 ± 15.7 0.002*
Free Androgen Index (%) 2.31 ± 1.5 3.33 ± 1.8 6 .92+ 1 .6 0.005*
Prolactin, (mU/L) 244.5 ± 90.2 245.0 ± 138.0 223.0 ± 186.0 0.91
Oestradiol, (pmol/L) 123.6 ±54.3 175.0 ±89.7 227.0 ± 175.0 0.13
Fasting Glucose, (mmol/L) 5.16 ±0.62 5.07± 0.48 4.81 ±0.79 0.37
Fasting Insulin, (mU/L) 8.10 ±3.95 12.80 ±18.28 20.44 ± 20.01 0.31
Total cholesterol, (mmol/L) 4.88 ±0.56 4.70 ±0.91 4.87 ± 0.79 0.80
High-density lipoprotein, (mmol/L) 1.73 ±0.41 1.58 ±0.32 1.49 ±0.41 0.30
Low-density lipoprotein, (mmol/L) 2.73 ± 0.78 2.79 ± 0.87 2.79 ± 0.92 0.98
Triglycerides, (mmol/L) 1.01 ±0.52 0.94 ± .49 1.47 ± 1.15 0.19
CFA diameter, (mm) 6.95 ± 1.14 6.97 ± 0.98 7.18 ±1.60 0.30
CCA diameter, (mm) 6.39 ±0.53 6.49 ± 0.63 6.45 ± 0.60 0.43
♦significant
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Table 7.2 Unadjusted and adjusted IMT measurements in the common carotid artery, carotid bulb and common femoral 
artery
Variable PCOS PCO Control PCOS-Control 
(95% Cl)
p-value PCO-Control 
(95% Cl)
p-value
Number of women 19 12 12
Unadjusted
IMTccA(mm) 0.54±0.11 0.51±0.18 0.4010.09 0.14(0.04 to 0.23) 0.006* 0.11 (0.006 to 0.22) 0.038*
IMTbulb (mm) 0.56±0.19 0.5410.18 0.4410.11 0.12 (-0.008 to 0.24) 0.066 0.10 (-0.04 to 0.24) 0.17
IMTcFA(mm) 0.74 ±0.30 0.5210.16 0.4210.07 0.32 (0.16 to 0.49) 0.001* 0.10 (0.09 to 0.28) 0.28
Adjusted
IMTcca (mm) 0.53±0.09 0.5010.15 0.4410.09 0.09 (047 to 0.98) 0.034* 0.06 (0.81 to 0.70) 0.84
IMTbulb (mm) 0.62±0.25 0.5810.14 0.4710.12 0.15 (-0.19 to 0.46) 0.46 0.11 (-0.55 to 0.19) 0.25
IMTcFA(mm) 0.71±0.29 0.5310.18 0.4210.04 0.3 (0.02 to 0.53) 0.032* 0.11 (0.09 to 0.42) 0.20
Adjusted for age, systolic and diastolic BP, BMI, cholesterol and insulin; * p < 0.05
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7.4 Discussion
The results of this study address the critical question in relation to PCOS and the 
cardiovascular system as to whether the clustering of risk factors in these women 
translates into disease. An increase in IMT in the CCA and CFA in such women is 
indicative of atherosclerotic pathology at relatively young age. This is an important issue 
to address in view of the conflicting nature of the available evidence and the high 
prevalence of the syndrome. This conflict in evidence may be attributed to the differing 
criteria used to define PCOS and hence the physical, metabolic and endocrine 
characteristics of PCOS women varying between different studies. It is noteworthy 
therefore that the degree of endocrine dysfunction in the subjects in this study was 
modest, such that the serum concentrations of insulin levels were not significantly 
increased in PCOS women compared with controls because of high variability. This may 
reflect to the BMI of these subjects; most of whom were overweight (BMI 25-30 kg/m2) 
rather than obese (> 30 kg/m2). Nevertheless, adjusted differences were still significant.
The results of this study suggests that the risk factors in women with PCOS do translate 
to disease in both elastic (common carotid) and muscular (common femoral) arteries. The 
increase in IMT in the PCOS women was however not significant in the carotid bulb. At 
first sight this is surprising in view of the vascular turbulence at this site, which is thought 
to be a factor in the development of arterial disease. The lack of statistical significance 
may however be explained by the increased intra-group variation, which in turn probably 
resulted from the decreased reproducibility inherently associated with IMT measurement 
at the carotid bulb (coefficient of variation 23%). The failure to detect any significant
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differences in the mean vessel wall luminal diameter in either artery may reflect the mean 
age of our women and being asymptomatic with normal lipids; luminal narrowing and an 
increased IMT have been reported in older subjects with peripheral vascular disease 
(Benetos et al, 1993).
Although evidence demonstrating the progression of atherosclerotic disease from 
increased IMT through plaque formation to alteration in blood flow is lacking, increased 
IMT is considered to be an early marker of atherosclerosis (Gariepy et al, 1995; Poredos 
et al, 1999; Aminbaksh et al, 1999), before any effect on blood flow occurs. Increased 
IMT is also associated with thinning and fracturing of elastin fibres together with the 
deposition of collagen, perhaps due to non-enzymatic glycation of elastin and collagen in 
the tunica (Ilegbusi et al, 1999). These changes lead to thickening of the arterial wall, and 
result in a reduction in the buffering capacity, decreasing arterial elasticity and 
compliance (Pupita et al, 1991).
In addition to providing evidence of early atherosclerosis in women with PCOS, the 
finding of increased carotid and femoral IMT also suggests that they are at increased risk 
of developing coronary heart, cerebrovascular and peripheral vascular disease. In this 
study, 7 of the 19 PCOS women (37%) had CCA IMT > 0.56, which in the study by 
Hodis (1998) is associated with an odds ratio for coronary heart disease of 5.5. According 
to Bots (1997) the relative risk of cerebrovascular disease is increased by 1.4 for each 
standard deviation above the mean CCA IMT. It was found that the mean in the PCOS 
women was 1.6 SD above that for the controls, which would suggest these women have
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an odds ratio of 2.2 for cerbrovascular disease (Bots et al, 1997). Similarly from other 
studies, admittedly in older age groups, the increased CFA IMT in women with PCOS in 
this study would suggest an association with an increased risk of peripheral vascular 
disease (Bots et al, 1994; Simons et al, 1999). It has been suggested that any increased 
cardiovascular morbidity in PCO& women is wholly attributable to their higher BP, BMI, 
cholesterol and insulin. The findings for younger women in this study, and the study by 
Talbott and co-workers for older women (2000) show that the increased IMT remains 
after adjusting for these risk factors. This supports the hypothesis that PCOS is an 
independent risk factor for arterial disease and refutes the suggestion that the 
cardiovascular risk related to PCOS is due entirely to BP, cholesterol, insulin and BMI 
changes.
As previously discussed only one study has investigated mortality in women with PCOS 
and the results showed no increase in deaths from coronary heart disease. Several reasons 
have been proposed to explain this. Firstly, the diagnosis of PCOS was based solely on 
ovarian morphology. However, the main indication for wedge resection was for 
infertility, not severity of clinical features. Secondly, many patients’ records were not 
followed up or retrieved, raising the possibility of selection bias. Thirdly, standardised 
mortality rates were derived from UK national database and took no account of regional 
variations in mortality rates. Finally, the problems of using death certificate data and their 
accuracy are well known. It is however possible that mortality is not increased in PCOS 
women, and increased serum oestrogen is protective in these women.
170
Confirmation of increased cardiovascular mortality in PCOS would provide evidence to 
support the establishment of a screening programme, and ultimately pharmacological 
intervention. Many clinicians suggest opportunistic screening for type II diabetes in 
women presenting with symptoms of PCOS, and this is certainly justified in some PCOS 
populations in which the prevalence of type II diabetes is as high as 15% (Legro, 2003). 
A similar argument could be used in favour of screening for dyslipidaemia, but the cost 
effectiveness of either test has not been evaluated in women with PCOS. As regards 
intervention, it would seem prudent to recommend lifestyle modification, particularly for 
obese women with PCOS. There is also some logic in the suggestion that long-term 
treatment with an insulin sensitiser such as metformin may be appropriate in patients with 
PCOS. Although the initial results of the use of insulin senstisers in women with PCOS 
has been promising, there have been no large-scale, randomised, placebo-controlled trial 
to support its use as frontline agent and its long-term cardiovascular (? beneficial) effects 
in women with PCOS.
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CHAPTER 8
CUTANEOUS MICRO VASCULAR FUNCTION IN YOUNG 
WOMEN WITH POLYCYSTIC OVARY SYNDROME
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8.1 Introduction
The evidence of increased IMT in the CFA and CCA (Lakhani et al, 2004; Talbott et al; 
2000, Guzick et al, 1996) and decreased compliance in the CCA and ICA (Lakhani et al, 
2002) suggest that women with PCOS have accelerated arterial disease. Furthermore, the 
response of femoral artery blood flow to intra-arterial methacholine chloride (MCh) 
administration in 12 obese women with PCOS (elevated T, together with hirsutism and 
amenorrhoea or oligomenorrhoea -  less than 6 periods per year) was 50% less than in 13 
weight-and age-matched control women (regular menses -  27 to 31 days and no hirsutism 
or abnormal T levels), suggesting compromised endothelial NO production or release 
(Paradisi et al, 2001). There is also evidence of impaired cutaneous vascular function in 
women with previous gestational diabetes (Hannemann et al, 2002) and in patients with 
type II diabetes mellitus (Morris et al, 1995). The present study was designed to assess 
endothelial and vascular smooth muscle function in the skin microcirculation, using laser 
Doppler perfusion with transcutaneous iontophoretic administration of vasoactive 
compounds, in young women with PCOS and control women with normal ovaries.
8.2 Methods
The sample size required was calculated using data from a study of the response of the 
skin microcirculation to ACh and SNP in patients with NIDDM, where the increase in 
skin perfusion with ACh was 0.86 ± 0.09 in the study group and 1.36 ± 0.14 in the 
control group. Skin perfusion with SNP in the study group was 0.12 ± 0.05 and 0.45 ± 
0.11 in the control group. Power calculation indicated minimum sample of 10 subjects in
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each group was necessary to provide 80% power detecting differences of a similar 
magnitude in the present study at a significance of 5%.
8.2.1 Subjects and study design
Cross-sectional study of 24 women recruited from the North Middlesex and Royal Free 
Hospitals:
> 12 women with PCOS (defined according to the criteria in Section 4.2)
> 12 control women (staff members) with normal ovaries on TVS (Controls).
8.2.2 Protocol
All measurements were performed with the subjects sitting comfortably on an armchair in 
a quiet room with an ambient temperature of 22 ± 1°C. During a 15 min acclimatization 
period, the volar aspect of the right forearm was gently cleaned with an alcohol wipe and 
swabbed with deionised water. Blood pressure and pulse were measured on the left arm 
in all women using an automatic Dinamap device (Critikon Inc, USA) at 2 min intervals 
as described in Section 4.2.
The drug delivery iontophoresis protocol is described in Section 4.6. In brief, the anodal 
chamber was filled with 0.25 ml 1% (w/v) ACh and the cathodal chamber with 0.25 ml 
(w/v) 1% SNP. Baseline erythrocyte flux was measured for 100 s without current, i.e. no 
drug iontophoresed followed by drug delivery at 10, 15 and 20 pA, sequentially, each for 
100 s, followed by 800 s at zero current. Microvascular perfusion was assessed 
continuously with laser Doppler and the mean erythrocyte flux was measured at baseline,
174
at 50 s intervals during iontophoresis at 10, 15 and 20 pA and at 100 s intervals 
thereafter.
8.2.3 Statistical analysis:
Intra-observer errors were determined, separately for each increment in current with ACh 
and SNP, by determining the coefficient of variation of repeated measurements. 
Normality of data was assessed using the Kolmogorov-Smimov test. Data sets which 
were not normally distributed were assessed using the Mann-Whitney U test. Differences 
between normally distributed data sets were assessed by ANOVA. A Levene test for 
homogeneity of variance was simultaneously applied, and when test groups failed, the 
ANOVA result was ignored, and the data sets were logio transformed, square root and/or 
reciprocal function, and re-tested for homogeneity of variance, and then by ANOVA. 
Differences were considered significant if p < 0.05. Data are expressed as mean ± SD. All 
analyses were performed using the statistical package SPSS for Windows (version 9.0)
8.3 Results
There was no significant difference between women with PCOS and controls with respect 
to age, SBP and DBP, and heart rate. These parameters were also comparable before and 
after iontophoresis (Table 8.1). Serum LH (p = 0.05), testosterone (p = 0.05) and BMI (p 
= 0.006), were elevated in women with PCOS compared to controls.
175
Table 8.1 Physical, endocrine and biochemical parameters between PCOS and 
controls
Variable PCOS Control p-value
between
groups
No. of subjects 12 12
Age, (years) 30.3 ± 4.4 27.7 ± 4.8 0.18
BMI, (kg/m2) 31.1 ±7.1 24.2 ±3.5 0.006*
W/H ratio 0.77 ± 0.06 0.76 ± 0.04 0.60
Pre systolic blood pressure, (mm Hg) 115± 16 110 ± 7 0.30
Pre diastolic blood pressure, (mm Hg) 67 ± 12 63 ±8 0.28
Pre heart rate, (beats/min) 73 ±8 66 ± 10 0.09
Post systolic blood pressure, (mm Hg) 117 ± 17 111 ± 12 0.30
Post diastolic blood pressure, (mm Hg) 68 ± 11 67 ±7 0.90
Post heart rate, (beats/min) 71 ± 10 65 ±9 0.15
Luteinising hormone, (IU/L) 10.8 ±6.6 4.8 ±3.4 0.05*
Follicle stimulating hormone, (IU/L) 6.3 ± 2.30 5.8 ±2.60 0.65
Testosterone, (nmol/L) 2.35 ±0.78 1.71 ±0.78 0.05*
Sex-hormone binding globulin, (nmol/L) 53.70 ±47.5 57.4 ± 26.4 0.80
Prolactin, (mlU/L) 250.0 ± 113.0 273.0 ± 103.0 0.60
Oestradiol, pmol/L 257.0 ± 152.0 198 ± 126.0 0.60
Fasting Glucose, (mmol/L) 5.05 ± 0.45 4.98 ±0.50 0.70
Fasting Insulin, (mU/L) 20.3 ± 11.3 11.4 ±7.8 0.06
Total cholesterol, mmol/L 4.71 ±0.97 4.50 ±0.90 0.60
High-density lipoprotein, (mmol/L) 1.42 ±0.41 1.53 ±0.41 0.40
Low-density lipoprotein, (mmol/L) 2.99 ±1.10 2.57 ±0.85 0.30
Triglycerides, (mmol/L) 1.01 ±0.39 0.88 ±0.36 0.99
*significant; pre -  before the start of iontophoresis; post -  end of iontophoresis protocol.
The COV of repeated flux measurements after iontophoresis of ACh at 10, 15 and 20 
were 9.5%, 10.8% and 12.6%, respectively. Corresponding figures for SNP were 5.1%, 
9.1% and 16.6%, respectively. Basal forearm skin perfusion was not significantly 
different in women with PCOS compared with controls (23.58 ± 3.4 vs 24.23 ± 4.2; 
respectively, erythrocyte flux is in arbitrary units). The peak ACh induced erythrocyte 
flux occurred at the end of 20 pA iontophoresis period and there was a minimal 
difference in the median and mean erythrocyte flux at this point. The mean values were
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compared by ANOVA. The median and mean values respectively were: Peak - PCOS
98.1 AU vs 125.1 AU, Controls 186.9 AU vs 200.8 AU; Baseline -  PCOS 22.9 AU vs 
20.8 AU.
The forearm skin blood flow increased in response of ACh (Figure 8.1) and SNP (Figure 
8.2) within both groups for all time points compared to baseline, the increase percentage 
flux in response to ACh iontophoresis was however decreased significantly in women 
with PCOS relative to controls (p = 0.018; Figure 8.1); there was no difference in 
response to SNP (p = 0.59; Figure 8.2) between women with PCOS relative to controls.
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Figure 8.1 The fold increase (Mean ± SEM) in forearm cutaneous microvascular 
erythrocyte flux in response to ACh iontophoresis, relative to the baseline flux at 
100 s, in PCOS (n = 12) and control (n = 12) women.
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Figure 8.2 The fold increase in forearm cutaneous microvascular erythrocyte 
flux in response to SNP iontophoresis, relative to the baseline flux at 100 s, in PCOS 
(n = 12) and control (n = 12) women.
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While no difference was noted in unadjusted mean peak erythrocyte flux between 
controls and PCOS group (p = 0.079), adjusted differences, sequentially adjusted for 
confounding variables, known a priori, to differ between PCOS and control women 
showed no effect in the mean peak erythrocyte flux in response to ACh between the two 
groups are shown in Table 8.2.
Table 8.2 Differences in mean peak erythrocyte flux ratio in PCOS and control 
women
Variable Unadjusted Adjusted
BMI
Adjusted
BMI,
testosterone
Adjusted BMI,
testosterone,
Insulin
Number of women 24 24 24 18
Difference 0.17 0.26 0.24 0.21
95% Cl (-0.02 to 0.36) (0.03 to 0.48) (0.01 to 0.48) (-0.10 to 0.52)
P value 0.079 0.026 0.041 0.016
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8.4 Discussion
The results of this study demonstrate blunted cutaneous microvascular flux response to 
the vasodilator ACh in women with PCOS relative to controls, indicating that endothelial 
dysfunction may occur in the cutaneous microcirculation in young women with PCOS. 
The response to SNP (a nitric oxide (NO) donor), which acts directly on smooth muscle 
was comparable in women with PCOS and controls, suggesting normal smooth muscle 
function.
This altered response could be related to the metabolic or endocrine abnormalities present 
in women with PCOS. Insulin resistance is an obvious candidate since a similarly 
impaired microvascular response to ACh has been found in NIDDM (Morris et al, 1995; 
Pitie et al, 1997; Cabellero et al, 1999), and insulin resistance and glucose intolerance are 
present in 30 -  60% (Dunaif et al, 1992) and 8 -  40% (Robinson et al, 1993) of PCOS 
women, respectively. Indeed, mean serum insulin was almost doubled in women with 
PCOS in the present study, though this result just failed to reach significance (p = 0.06), 
probably due to limited sample size.
The abnormal response to ACh in diabetic patients is thought to result from decreased 
NO production or release (Morris et al, 1995; Pitie et al, 1997; Cabellero et al, 1999). It 
has also been suggested, however, that it may also be due to accumulation of products 
formed by a nonenzymatic reaction between glucose and collagen in the diabetic 
microvascular basement membrane (Bucala et al, 1991), which impairs endothelium 
dependent relaxation through the reduction of NO due to reduce Ca2+ influx as described
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in Section 3.5.2 (Rodriguez-Manas et al, 1993). There is also evidence from animal 
studies of altered sensitivity of vascular smooth muscle to NO in diabetes (Okon et al, 
2003).
Of these potential mechanisms, the results of the present study would support the 
possibility that endothelial NO production or release is compromised in women with 
PCOS, but the other mechanisms are unlikely to occur. Vascular smooth muscle 
sensitivity to NO is unaltered -  there was no difference in the perfusion response to SNP, 
a direct NO donor. Furthermore, though insulin tended to be elevated in women with 
PCOS, no differences were seen in serum glucose, perhaps due to the young age of the 
women, suggesting basement membrane glycosylation would be similar in both groups.
The vasodilatory response to ACh is also impaired in hypercholesterolaemic (Khan et al, 
1999), obese (Steinberg et al, 1996) and hypertensive (Panza et al, 1994) patients, 
independent of insulin resistance. Since BMI is increased in 35 -  60% of PCOS women, 
and there is evidence of increased cholesterol and blood pressure (Wild et al, 1985; 
Conway et al, 1992; Talbott et al, 1995), these factors could influence endothelial 
function in these women with the syndrome. In the present study BMI was elevated in the 
PCOS group, however, there was no evidence of altered serum cholesterol or BP, perhaps 
due to relatively young age of the women. In the comparisons of adjusted differences, 
BMI showed no effect on the cutaneous circulation and the effect of insulin was also not 
significant, though this may have been due, in part, to the small sample size (n = 18).
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The characteristic endocrine feature of PCOS is hyperandrogenaemia. Testosterone is 
known to influence vasocontractile responses, and impairs endothelium dependent 
relaxation (Adams et al, 1995; Hutchinson et al, 1997) in hypercholesterolemic rabbits 
and monkeys. Furthermore, androgen deprivation in adult men enhances endothelium 
dependent relaxation (Herman et al, 1997). More recent studies suggest, however, that the 
vascular effects of testosterone may be more complex. For example, acute exposure to 
even low nanomolar doses of testosterone significantly potentiates endothelin-1 induced 
vasoconstriction in coronary artery rings (Teoh et al, 2000b). However, in the present 
study, testosterone showed no effect on the cutaneous circulation in women with PCOS 
compared with controls since the response differences were still apparent after 
testosterone had been adjusted for in the analysis.
Questions have been raised regarding the cause of vascular flux increases occurring 
during iontophoresis. The galvanic effect of current and voltage application causes 
vasodilation, even in the absence of drug in the iontophoresis chamber (Berghoff et al,
2002). The low current used in this study would have limited such effects (Berghoff et al,
2002). Furthermore, any limited galvanic vasodilatation would have been more apparent 
in the cathodal (SNP) chamber, where no differences were noted between the two groups 
(Morris and Shore, 1996). Iontophoresis of ACh can stimulate local C-nociceptive nerve 
fibres causing indirect nerve axon reflex (Walmsley et al, 1990). It has recently been 
shown, however, that local anaesthesia has no effect on the total ACh induced 
vasodilatation and that ACh iontophoresis is a reliable index of skin endothelium-
183
dependent vasodilation, and is unaffected by local nerve fibre function (Caselli et al,
2003).
In summary, this is the first report of microvascular endothelial dysfunction in women 
with PCOS. The ACh induced increase in microvascular perfusion due to vasodilation, 
which is dependent on endothelial NO release, was blunted in women with PCOS. This is 
perhaps a result of impaired endothelial NO release related to endocrinological or 
metabolic changes other than BMI, testosterone and insulin in women with the syndrome.
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CHAPTER 9
AORTIC FUNCTION IS COMPROMISED IN A RAT 
MODEL OF POLYCYSTIC OVARY SYNDROME
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9.1 Introduction
The finding of increased vascular stiffness (Lakhani et al, 2002) and IMT in the carotid 
and femoral arteries in women with PCOS (Lakhani et al, 2003), suggests they exhibit 
increased atherosclerosis and underlying endothelial dysfunction (Balletshofer et al,
2003). Indeed evidence of endothelial dysfunction in women with PCOS has been 
observed in-vivo in the femoral artery (Paradisi et al, 2003; Kelly et al, 2003) and in the 
microvasculature (Chapter 8), though not in the brachial artery (Mather et al, 2000).
An animal model would allow in-vivo analysis of arterial function followed by in-vitro 
investigation of endothelial function, albeit such data would require cautious 
interpretation due to species differences. In the rat, daily injections of mifepristone (an 
antiprogestin, also know as RU 486) for one week or more, induce many features 
characteristic of PCOS in humans, for example ovulatory failure, persistant vaginal 
comification, and enlarged ovaries containing atretic follicles and follicular cysts 
(Sanchez-Criado et al, 1993a; Ruiz et al, 1996) as well as increased serum concentrations 
of LH, T, oestradiol and serum insulin-like growth factor 1 levels and decreased prolactin 
(Sanchez-Criado et al, 1997; Ruiz et al, 1997). The mifepristone-treated rat is a 
‘fundamentally adequate PCO model’ with which to investigate the effect of PCOS-like 
endocrinological perturbations in the short term ( 1 - 2  weeks). It is not a suitable model 
with which to study long-term cumulative changes, likely to occur in older women with 
PCOS.
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This model was used to test the hypothesis that arterial mechanics and endothelial 
function are modified in PCOS, since it allowed in-vivo assessment of the mechanical 
properties of the aorta followed by precise in-vitro assessment of endothelial and vascular 
smooth muscle function.
9.2 Methods
9.2.1 Study design
The procedures and protocols of the study have been approved by the Home Office under 
the Animals (Scientific Procedures) Act 1986. It is part of the project licence number 
70/5735 and is entitled ‘Haemodynamic assessment of PCOS’. In order to do this work, 
the author had to satisfactorily complete an accredited course laid out by the Home Office 
to fulfil the Animals (Scientific Procedures) Act 1986 and successfully applied for a 
personal licence (PIL 70/18075).
Animals
Adult female (1 2 -1 4  weeks) Sprague-Dawley rats (body weight 242 ± 4.5 g) were bred 
and housed locally at 22°C under a 14 hour on /10 hour off light cycle, with free access to 
food and water. Vaginal smears were prepared from rats on up to three occasions to 
assess oestrus i.e. presence of comified cells only. Only those rats showing at least two 
consecutive 4 - 5  day oestrus cycles (Figure 9.1) were allocated to the treated group 
(Group 1) or control group (Group 2).
Group 1 -  treated group: Eight rats were subcutaneously injected daily with of 
mifepristone (1 ip-17p-hydroxy-17a-estra-4,9-diene-3-one; Sigma Aldrich Chemicals,
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Gillingham, Dorset, UK) suspended in olive oil at a dose of 2 mg/0.1 ml olive oil/100 g 
body weight for 6-10 consecutive days, beginning on the day of oestrus.
Group 2 -  control group: Six rats treated daily with subcutaneous injection of 0.1 ml 
olive oil/100 g body weight daily over 6-10 consecutive days beginning on the day of 
oestrus.
Figure 9.1 Histology slide demonstrating oestrus: Vaginal smear consisted of 
cornified cells only -  suggesting the female is on ‘heat’
V
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At the end of the injection regimen ( 6 - 1 0  days), anaesthesia was induced in each rat 
with intramuscular injections of Hypnorm (fentanyl citrate and fluanisone; Janssen 
Animal Health Ltd, Buckinghamshire, UK; 0.5 ml/kg) plus diazepam (Dumex Ltd, 
Hertfordshire, UK; 2.5 mg/kg). General anaesthesia was maintained using isoflurane 
(Baxter Health Ltd, Norfolk, UK), nitrous oxide and oxygen through a standard 
anaesthetic circuit (Yang et al, 2003). Body temperature was monitored with a rectal 
probe maintained at 37-38°C with an electric heating mat. Arterial oxygen saturation and 
heart rate were monitored non-invasively with a Biox 3740 pulse oximeter (Ohmeda Inc, 
Louisville, Colarado, USA), to ensure a consistent level of anaesthesia was maintained.
9.2.2 Measurements
Once stable anaesthesia was established, the abdomen was shaved to allow good contact 
between the ultrasound probe and the skin, thus facilitating accurate measurements of the 
aorta. The technique of duplex estimation of arterial compliance has been described 
previously (Section 3.4.2). In brief, real time B-mode and M-mode images of the arterial 
wall motion were recorded using a 7.5 MHz linear probe. Measurements were made in 
the sagittal plane at 90° to the long axis of the thoracic aorta with signal output to a high 
resolution, echo-locked wall-tracking system (Wall Track, Pie Medical Systems, 
Maastricht, Netherlands) and data analysed off-line.
After ultrasound, a midline laparotomy was performed and the peritoneum was opened. 
The adipose tissue surrounding the aorta and inferior vena cava was removed with 
dissection forceps and the aorta was exposed. Aortic SBP and DBP were measured by
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intra-aortic probe with Datex Engstron Light Monitor (Datex-Ohmeda Division, 
Instrumentarium Corp., Helsinki, Finland) and aortic blood flow with a transonic 
flowmeter system (HT 207; Transonic Medical, New York, USA). Trunk blood was 
obtained from vena cava and serum prepared by centrifugation and stored at -20 °C until 
required. Serum concentrations of LH, FSH, T and insulin were assayed using kits 
specific for animals. Animals were killed by exsanguination and the thoracic aorta was 
dissected, cleaned of adherent tissue, washed several times and placed in oxygenated 
Krebs buffer solution (NaCl 118.6 mM; KC1 2.8 mM; CaCU 2.5 mM; MgSC>4 1.2 mM; 
NaHC0 3  25.1 mM; KH2PO4 1.2 mM; glucose 5.5 mM), until in-vitro function was 
assessed. The right ovary was also dissected, fixed in formalin and embedded in paraffin 
wax. Serial 6  pm sections were cut from wax embedded ovary and assessed to determine 
the presence of ovarian morphology.
In-vitro endothelial function was assessed as described in Section 4.6. In brief, the 
dilatory response to graded dose ACh was assessed on PE precontracted aortic rings. The 
PE-ACh treatment cycle was repeated in the presence of NG -  nitro-L-arginine methyl 
ester (L-NAME), followed by final treatment with graded doses of SNP. Aortic tension 
was expressed as percentage relaxation, such that the tension induced by 3 pM PE was 
defined as 0% relaxation, and the tension prior to PE treatment was defined as 100% 
relaxation.
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9.2.3 Data and statistical analysis
For in-vivo data, the intra-observer variability was determined by calculating the 
coefficient of variation of repeated measurements. Coefficients of variations below 10% 
were considered to indicate good reproducibility. The average vessel wall movement was 
calculated from readings over three cardiac cycles, and the diametrical compliance (C) 
and stiffness index (P) were calculated as previously described (Section 3.4.2) from this 
data, using the aortic blood pressure and flow estimates taken immediately after 
laparotomy. Statistical significance was tested by analysis of variance (ANOVA) with 
Fisher’s protected least significant difference test. All data are expressed as mean ± SEM. 
All analyses were performed using the statistical package SPSS for Windows (version 
10.05).
9.3 Results
Treatment of female rats with mifepristone had no significant effect on body weight 
(244.8 ± 5.2 vs 238.3 ± 8.3 g, treated vs. controls respectively), SBP (74.4 ± 6.6 vs. 62.0 
± 1.6 mmHg) or DBP (59.8 ± 5.80 vs. 54.3 ± 3.3 mmHg). Hormonal disturbances were 
apparent -  treated rats exhibited increased serum concentrations of LH (15.15 ± 1.46 
IU/L vs. 9.35 ± 2.16 IU/L; p < 0.05) and testosterone (1.81 ± 0.51 nmol/1 vs. 0.47 ±0.10 
nmol/1; p < 0.05). Serum insulin also tended to be elevated (1.44 ± 0.49 mU/L vs. 0.76 ± 
0.22 Mu/L) but this difference failed to attain significance perhaps due to hypervariable 
insulin concentrations in the treated animals. Mifepristone treatment had no effect on 
serum FSH levels (143.5 ± 20.6 ng/ml vs. 150.0 ± 30.1 ng/ml). Mifepristone- treated 
ovaries exhibited an altered morphology relative to controls, as expected, with evidence
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of arrested follicular growth, an increase in the abundance of atretic follicles and 
follicular cysts (Sanchez-Criado et al, 1992; 1993b) (Figure 9.2). Although the histology 
confirmed ovarian morphology, it was difficult to accurately obtain qualitative data due 
to the lack of qualified personnel.
Figure 9.2 Histology of ovaries on day 9 in rats treated with mifepristone 
A -  General view of one ovarian section showing arrested follicular growth
B -  Follicular cyst with massive luteinisation
C -  Increased atretic follicles
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Coefficients of variation for ultrasound estimation of aortic parameters were in nearly all 
cases < 10%, indicating these measurements were made with an appropriate level of 
reproducibility. In mifepristone-treated animals, the mean aortic diameter and blood flow 
were unaffected, relative to the controls, but aortic compliance was reduced by 67%, 
while stiffness index was increased 2.3-fold (Table 9.1).
There was minimal difference in the median and the mean compliance values between the 
mifepristone treated rats and controls. The mean values were compared by ANOVA. 
The median and mean compliance values for each group respectively: Compliance -  
mifepristone treated rats 109.35 vs 140.88 % mmHg'x 10'2; Controls 399.0 vs 426.86 % 
mmHg 'x  10'2. Similarly, the differences in percentage relaxation at each concentration 
of ACh and SNP between the median and mean values were minimal; therefore the mean 
values were plotted.
Table 9.1 Aortic diameter, blood flow and mechanical parameters in mifepristone 
treated rats and control rats (mean ± SEM)
Variable Control
(n = 6)
Mifepristone
(n = 8)
p - value
Diameter, (mm) 1.32 ±0.02 1.44 ±0.04 NS
Blood flow, (ml/min) 37 ±5.1 32.0 ±2.6 NS
Compliance, (%mm Hg'1 x 10’2) 426.86 ± 17.36 140.88 ±6.33 0.05
Stiffness index 0.57 ±0.03 1.30 ±0.07 0.02
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In vitro organ bath assessment of endothelial and smooth muscle function was performed 
to determine whether the changes in aortic compliance and stiffness might be related to 
dysfunction of these tissues. ACh induced a concentration-dependent relaxation in PE 
contracted aortic rings from mifepristone treated and control animals (p < 0.001; Figure 
9.3), however, relaxation was less in mifepristone-treated animals than in controls (p = 
0.002), notably at 0.1 pM and 1.0 pM (Figure 9.3).
ACh-stimulated aortic relaxation is endothelium-dependent, and thought to be due to 
activation of eNOS, producing NO, which diffuses to the underlying smooth muscle 
causing relaxation (Palmer et al, 1987). Indeed L-NAME, which inhibits 80% of eNOS 
activity, considerably impaired ACh-induced relaxation in aortic rings from normal and 
mifepristone-treated animals (p < 0.001 for L-NAME effect in both the mifepristone- 
treated and control groups). This inhibitory effect was, however, less in aortic rings from 
the mifepristone-treated rats than in controls (p < 0.001), notably at ACh concentrations 
of 1 pM and above (Figure 9.3).
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Figure 9.3 ACh-induced relaxation in aortic rings from mifepristone-treated 
(circles) and control (squares) rats, without (filled) and with (unfilled) L-NAME. *p 
< 0.05; **p < 0.005, treated vs appropriate control, by 1 way ANOVA.
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To determine smooth muscle function independent of endothelial NO, the aortic dilation 
was assessed using graded doses of SNP, a non-endothelium dependent NO donor. As for 
ACh, SNP-induced concentration-dependent (p < 0.001, SNP effect by 2-way ANOVA) 
relaxation in aortic rings from mifepristone-treated and control animals (p < 0.001).
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Relaxation was however greater in mifepristone-treated animals compared with controls 
(p = 0.001, mifepristone treatment effect by 2-way ANOVA), notably at 0.01 pM and 0.1 
pM SNP (Figure 9.4)
Figure 9.4 SNP induced relaxation in aortic rings from mifepristone-treated 
(circles) and control (squares) rats. ***p < 0.001, treated vs control, by 1 way 
ANOVA.
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9.4 Discussion
Female rats injected with mifepristone for 7 -  9 days displayed signs similar to those seen 
before in this model (Sanchez-Criado et al, 1992; 1993a, b; Ruiz et al; 1996) and in 
women with PCOS (Goldzieher, 1982; Lakhani et al, 2002; Conway et al, 1989; Franks, 
1989). Ovarian morphology was disrupted -  follicular development was retarded with 
more small follicles and increased follicular atresia; serum LH and testosterone were also 
elevated. The lack of an effect on insulin may be related to the young age of the rats (12 -  
14 weeks) and the short-term nature of the model. Despite this, the mifepristone-injected 
rat model displays may other features seen in the human PCOS women. It provides a 
valid model in which to assess the short-term effects of the associated ovarian and 
endocrine disturbances on aortic function.
Mifepristone treatment modified rat aortic vascular mechanics -  the aortic stiffness index 
was increased and conversely the compliance was decreased. These results are similar to 
those seen in women with PCOS, albeit in other vascular beds (Lakhani et al, 2002; Kelly 
et al, 2003).
In-vitro assessment of aortic endothelial and smooth muscle function revealed significant 
alterations in aortic rings from mifepristone-treated rats. ACh stimulated endothelium- 
dependent NO mediated relaxation was reduced, while the endothelium-independent 
action of SNP on smooth muscle was exaggerated. L-NAME substantially inhibited ACh- 
induced relaxation in control rings, confirming this process to be NO mediated; residual 
relaxation may be non-NO mediated or possibly L-NAME inhibition of eNOS was 
incomplete. Indeed, L-NAME appears to inhibit only 80% of eNOS activity (Li and
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Fostermann, 2000). The inhibitory effect of L-NAME was less pronounced in aortic rings 
from mifepristone-treated animals and the putative non-NO mediated, ACh-stimulated, 
dilatory pathway may be more active in mifepristone-treated animals. These changes in 
endothelial and smooth muscle function in vitro are consistent with the increase in aortic 
stiffness index and decrease compliance noted in vivo.
These results are the first demonstration of in vivo and in vitro of aortic dysfunction in a 
rat model of PCOS. The endothelium synthesizes many vasodilators, NO being the 
primary vasodilator in arteries such as the rat aorta, whereas EDHF is more prominent in 
small arteries (Shimokova et al, 1996; Ge and He, 2000). Prostacyclin was originally 
thought to have a lesser vasodilatory role in aorta than NO (Palmer et al, 1987) and its 
importance may rest in its inhibition of smooth muscle growth and platelet aggregation. 
Furthermore shear stress promotes endothelial prostacyclin synthesis and activates 
receptor-operated non-selective cation channels, increasing intracellular Ca2+ and K+ 
concentrations, stimulating the release of NO and EDHF. The results of this study are 
consistent with the possibility that aortic endothelial eNOS activity and NO synthesis 
may be impaired, and/or NO degradation enhanced in mifepristone-treated rats. In partial 
compensation, the aortic smooth muscle appears to become more sensitive to NO and a 
non-NO mediated, ACh stimulated vasodilatory pathway may be activated. This may 
reflect an increase in endothelial EDHF or prostacyclin release in the mifepristone- 
injected aorta.
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The changes in endothelial behaviour and aortic mechanics may result from the endocrine 
consequences of mifepristone injection. Serum oestradiol is elevated in this model 
(Sanchez-Criado et al, 1993; Ruiz et al, 1996) but this should enhance, not diminish, 
vasodilatory responses since oestradiol stimulates NOS expression and endothelial NO 
synthesis in rat aorta (Goetz et al, 1994; Andersen et al, 1999) and cultured endothelial 
cells (Lantin-Hermasos et al, 1997). In addition, oestradiol enhances ACh induced rat 
aortic relaxation in vitro, probably via increasing NO release (Huang et al, 1998; Teoh et 
al, 2000a) and oestrogen replacement also normalises the femoral artery blood flow 
response to ACh in oophrectomised women (Pinto et al, 1997).
The elevated serum testosterone concentration in mifepristone-treated animals could 
decrease vasodilatory responses (Herman et al, 1997) in line with the results of the 
present study. Indeed in PCOS women, increases in leg blood flow induced by 
methacholine chloride (an ACh mimic) were negatively correlated with testosterone 
levels (Steinberg et al, 1996), albeit the causal link may be with hyperandrogen ism 
associated with hyperinsulinaemia and insulin resistance (Steinberg et al, 1996). Indeed 
in type II diabetes, methacholine chloride-induced leg blood flow is negatively correlated 
with these parameters, perhaps due to the effects on NO degradation and/or smooth 
muscle sensitivity to NO (Williams et al, 1996). In the present study, however, 
mifepristone had not much effect on insulin and sensitivity to SNP was elevated; aortic 
NO degradation might be thought to be disturbed. It is plausible that testosterone 
influences endothelial function directly (Paradisi et al, 2003) as it stimulates aortic ring 
dilation in vitro by enhancing prostanoid but not NO synthesis, independent of androgen
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receptor (Tep-areenan et al; 2003). The non-NO mediated ACh-stimulated vasodilatory 
pathway in mifepristone-treated rats may be due to the elevated serum testosterone 
activating an aortic prostanoid vasodilatory pathway.
Serum progesterone is depressed in PCOS women (Goldzieher, 1981) hence the use of 
mifepristone as a progesterone and glucocorticoid antagonist (Philibert, 1984), to reduce 
progesterone action in a rat model (Sanchez-Criado et al, 1993a). The effects of 
mifepristone on the rat aorta may be due to reduced aortic progesterone or glucocorticoid 
action. Progesterone has a dilatory action on rat aorta (Glusa et al, 1997; Mukerji et al, 
2000; Zhang et al, 2002) due to the blockage of smooth muscle Ca2+ channels (Glusa et 
al, 1997) and/or stimulation of endothelial prostacyclin synthesis with consequent NO 
release (Zhang et al, 2002). These effects do not though involve the mifepristone 
antagonised nuclear progesterone receptor and are non-genomic (Glusa et al, 1997; 
Zhang et al, 2002). Whether mifepristone interacts with a progesterone receptor to inhibit 
vasodilation in vivo is unknown. As it is a progesterone analogue it is possible and might 
explain some of the results in this study. The impact of mifepristone in vitro was thought 
to be minimal, as the aortic rings were repeatedly washed in Krebs buffer before analysis; 
this is known to prevent acute effects of progesterone and thus mifepristone (Zhang et al, 
2002). A long-term effect of mifepristone-progesterone blockade on aortic gene 
expression cannot be ruled out as the cause of the changes seen in the present study. 
However, progesterone treatment over 8 days, albeit at supraphysiological levels, had no 
effect on noradrenaline-contracted aortic rings from ovarectomised rats (Sampaio-Moura 
and Marcondes, 2001). Glucocorticoids inhibit eNOS expression and prostacyclin
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synthesis in rat aorta in a manner blocked by mifepristone (Jeremy and Dandona, 1986; 
Wallerath et al, 1999). Thus mifepristone could promote vasodilation, as is seen in aortic 
rings from male rats (Tep-areenan et al, 2003). In the present study vasodilation was 
inhibited indicating that the anti-glucocorticoid effects of mifepristone had minimal 
influence.
Endothelial impairment occurs in hyperlipidaemia (Shimokowa et al, 1989) whereas its 
association with hyperglycaemia is controversial (Poston and Taylor, 1995; Oltman et al, 
1997). It is possible that the aortic function in this study is the result of metabolic 
modifications related to mifepristone injection. This model is, however, poorly 
characterised at the metabolic level, and it is therefore difficult to address the possible 
involvement at this time.
Changes in aortic mechanics were observed in mifepristone-treated, anaesthetised rats, 
albeit under conditions standardised to remove variability due to the depth of anaesthesia 
and the use of nitrous oxide, which is vasoactive. The changes were therefore considered 
treatment related, but their impact may be modified by the condition of the model i.e. rats 
were anaesthetised. Thus aortic changes did not significantly alter aortic blood flow in 
mifepristone-treated rats. Another methodological caveat is that the mechanical 
calculations relied on ultrasound measurements recorded pre-laparotomy and blood 
pressure estimates made post-laparotomy. Blood pressures may have been modified by 
laparotomy but a consistent level of anaesthesia was achieved in all rats, thus variability 
in blood pressure related to the stress of laparotomy was thought to be minimal.
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In summary, this is the first demonstration that rat aortic mechanical characteristics are 
disturbed in vivo in the mifepristone-treated rat model of PCOS, in a manner comparable 
with human studies (Lakhani et al, 2002; Lakhani et al, 2003). Aortic ring behaviour is 
modified in vitro suggestive of decreased endothelial NO release or elevated NO 
degradation. In compensation, smooth muscle sensitivity to NO is elevated and a non-NO 
mediated ACh stimulated relaxation mechanism appears activated. The latter mechanism 
may be due to increased prostacyclin or EDHF synthesis or release.
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CHAPTER 10
SUMMARY
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10.1 Introduction
The studies described in this thesis were undertaken to evaluate the hypothesis that 
vascular dysfunction is an early consequence of PCOS, and is a prelude to atherosclerosis 
in later life.
To do this, arterial mechanical vascular properties were assessed in young women with 
PCOS, PCO alone, and in controls. The initial studies assessed a measure of downstream 
vascular resistance -  the PI and the effect of inhalation of 5% C 02, a known vasodilator 
stimulus in the ICA (Chapter 5). Subsequent studies discussed in Chapters 6 and 7 
assessed a measure of arterial wall elasticity -  compliance and stiffness index in the ICA 
and the CCA, and a measure of arterial wall integrity -  IMT in the CCA and the CFA in 
these subject groups. Changes in arterial m«chanical properties were noted in PCOS 
women, therefore endothelial function in vivo, at least in the cutaneous microvasculature, 
was investigated in young women with PCOS and in controls, as discussed in Chapter 8. 
This study used non-invasive laser Doppler ultrasound to measure cutaneous 
microvascular perfusion responses to transcutaneous iontophoretic administration of 
endothelial-dependent (ACh) and endothelial-independent vasoactive (SNP) vasoactive 
compounds. To assess the endocrine and metabolic perturbations seen in PCOS on 
endothelial function and arterial wall mechanics, and the interaction between the two 
phenomena, the mifepristone-treated rat model was used, as discussed in Chapter 9. This 
model allowed ultrasound assessment of aortic mechanical properties in-vivo, followed 
by assessment of endothelial and smooth muscle function in-vitro. The purpose of this
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final chapter is to summarise the conclusions of all the studies, the chief limitations and 
consider areas which merit further research.
It should be noted that there are some limitations with respect to the endocrine 
assessment for other causes of hirsutism in women proposed to have PCOS in this thesis. 
Hyperandrogenism is key feature of PCOS, the major sources of hyperandrogenism in 
women are the ovaries and adrenals. Hyperandrogenism arising from the ovary or adrenal 
does not always result in skin manifestations (acne/hirsutism) and, in general, the 
expression of skin presentation is viewed to be a peripheral disorder (Lobo, 2002).
Testosterone and dihydrotestosterone are the most biologically active androgens and are 
derived from the peripheral conversion of androstenedione. In ‘normal’ women, about 
1% of circulating testosterone is unbound, 66% is bound to SHBG and 30% is bound to 
albumin (Dunn et al, 1981). In hirsute PCOS women where total and free testosterone 
levels are within normal range, there is evidence of a possible increase in 5-a reductase 
activity within the hair follicles, which increases the conversion of testosterone to the 
more potent dihydrotestosterone. Skin biopsies from these women revealed increased 5-a 
reductase activity, which correlates with an androgen metabolite, 5a-androstane-3a, 17(3- 
diol-17glucuronide (Paulson et al, 1986).
Rare causes of hyperandrogenism include ovarian tumor -  Arrhenoblastoma also known 
as stromal tumour, gonadal stromal tumour, androblastoma, which secretes testosterone. 
This is a rare tumour and accounts for less than 0.5% of all ovarian tumours. All women
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recruited in this thesis had transvaginal scan and none had any evidence of ovarian 
pathology.
Androgen secreting adrenal tumours is rare; the clinical course of the disease is a good 
indicator for a detailed evaluation. Endocrine stigmata of Cushing’s syndrome are usually 
clinically recognizable. Hypercortisoleamia for obese women with PCOS can be 
differentiated by determination of 24-hour urinary free cortisol levels, which will be 
normal in PCOS women and high in Cushing’s syndrome. Sudden onset and rapid 
progress of clinical hyperandrogenism was not seen in any of the women recruited in the 
studies described in this thesis and none had features of Cushing’s Syndrome -  moon 
face, ‘buffalo hump’ (collection of fat between shoulders) or purple striations on 
abdomen, thighs or breasts, furthermore, the blood pressure was also within normal range 
in all women with PCOS.
The findings of elevated androgen levels also demands exclusion of non-classical adrenal 
hyperplasia (NCAH), which often mimics PCOS (Lobo et al, 1980). A fasting 17- 
hydroxyprogesterone level of > 4 ng/ml should arouse suspicion of NCAH. However, a 
more robust diagnosis can only be confirmed by dynamic test with adrenocorticotrophin 
stimulation following dexamethasone suppression.
During data collection for this thesis, the European definition for the diagnosis of PCOS 
was used which required ultrasound documentation of polycystic ovarian morphology 
mandatory with the presence of clinical manifestations of hyperandrogenism 
(acne/hirsutism/alopecia) and/or menstrual disturbances
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(oligomenorrhoea/amenorrhoea/infertility; Adams et al, 1986; Balen et al, 1995) and not 
the National Institute of Health (1990) definition which requires the exclusion of 
secondary causes NCAH and androgen secreting tumours (Zawadzki and Dunaif, 1992). 
Secondly, the use of 17-hydroxyprogesterone for ‘mild/moderate’ hirsutism was not 
performed and available at the time. Furthermore, it is not possible to perform this test at 
present because all the saved serum samples were lost due to freezer breakdown in the 
Department of Biochemistry. Therefore, it is possible that some women with PCOS may 
have NCAH in association with PCO morphology. However, there is evidence that only 
4 - 7% of women with PCOS may have NCAH (Benjamin and Deutsch, 1986; Azziz et 
al, 2004).
One of the limitations in the human studies in this thesis with respect to 
hyperandrogenism is that the principal biochemical abnormality in women with PCOS is 
often attributed to enhanced androgen production by both the ovaries and adrenals. Other 
causes of hyperandrogenism were not investigated in any of the studies in this thesis 
because none of the women had gross hirsutism or any clinical evidence of Cushing 
syndrome or androgen secreting tumours.
Another limitation regarding the human studies in this thesis was that the evidence for 
ovulation was not assessed in the oligomenorrhoeic subjects. Spontaneous ovulation may 
have occurred in women with PCOS during the time of the examination. This was 
considered unlikely, although possible. If ovulation did occur in a small number of
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women with PCOS, how this may have influenced the vascular mechanical properties is 
not known.
The cycle length of 21 -  35 days used in the controls in this thesis is the same as that used 
in previous studies of PCOS (Conway et al, 1989; Clayton et al, 1992; Rodin et al, 1998). 
It is commonly held that the mean menstrual cycle length is 28 days, with a standard 
deviation of ca. 2 days (Scommegna & Dmowski, 1977). The range 2 1 - 3 5  days defines 
the limits of the normal set of values in that values outside this range are unlikely (p >
0.05) to belong statistically to the normal set of values. In a more clinical justification for 
this range, it has been said that ‘cycles as short as 21 days and as long as 40 days should 
be considered within physiologic limits, unless associated with symptoms or findings 
indicative of pathology’ (Scommegna & Dmowski, 1977).
The 2 1 - 3 5  day menstrual cycle length range, in defining the control subjects in this 
study, may however complicate the interpretation of the results. Since cycle length 
variability is normally due to differences in follicular phase length, subjects with 2 1 - 3 5  
day cycles may have 7 - 2 1  day follicular phases. Serum sampling and assessment of 
vascular parameters at day 4 may, therefore, actually have been at different relative cycle 
times in different subjects, depending on their menstrual cycle length. This may have 
influenced the serum levels of hormones and any hormonally regulated vascular 
parameters measured in this thesis. In mitigation, changes in serum levels of major sex 
hormones are limited in the first third of the follicular phase, albeit other hormones may 
be cycle dependent and influence the vasculature. In addition, the potential variability due
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to the relative timing of sampling/vascular assessment would be expected to increase the 
range of values in the normal and PCO groups, thus tending to reduce the significance of 
any differences between groups, and not to produce spuriously significant results. 
Furthermore, the effect of such variability, if present, would be to skew the data set, 
whereas all data passed a statistical test of normality. In retrospect however, it would 
have been preferable to use a narrower range for ‘normal’ cycle length in order to 
minimise this potential influence on the outcome measures.
As previously, the ratio between fasting plasma insulin and fasting plasma glucose was 
used to assess insulin resistance (Holte, 1996). The hyperinsulinaemic glucose clamp is 
considered to be the ‘gold standard’ and should be the preferred method to measure 
insulin sensitivity. In this test, exogenous insulin is administered as a prime followed by 
constant infusion to maintain physiological suprabasal insulin levels. Simultaneously, 
glucose concentration is monitored frequently and clamped at the euglycaemic or 
isoglycaemic (patients own fasting glycaemia) concentration by glucose infusion at 
variable rates. When a steady rate is attained (within ~ 2 hrs), the exogenous glucose 
infusion rate is equal to the rate of whole body glucose disposal. This method is 
technically complex, requires experience personnel and is invasive (two intravenous lines 
throughout the study and frequent bedside blood samples) (Yildiz and Gedick, 2004).
Simpler methods, in particular indices calculated using fasting plasma concentrations of 
glucose and insulin, as well as data obtained using plasma concentrations of insulin and 
glucose obtained 120 minutes of a standard 75g oral glucose tolerance test have been
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reported for quantifying insulin sensitivity (Radikova, 2003). There is a significant 
correlation (r = 0.63; p< 0.001) between the simpler technique and euglycaemic 
hyperinsulinaemic clamp in assessing insulin sensitivity and provides validation of the 
minimal model which can be adaptable for use in both clinical and research settings (Gutt 
et al, 2000). The commonly used fasting glucose insulin ratio was therefore used as a 
method for assessing insulin sensitivity in this thesis.
All the above mentinoned limitations are important and will be addressed in all further 
future work. Furthermore, where appropriate and possible the more robust 
hyperinsulinaemic glucose clamp method will be the preferred method to measure insulin 
sensitivity, with ethical approval.
10.2 Vascular resistance and vascular reactivity to 5% carbon dioxide 
in women with polycystic ovaries
o This study is the first to demonstrate decreased PI in the ICA in PCOS women, 
suggesting decreased downstream vascular resistance, 
o This study is the first to demonstrate low back pressure in the ICA in 
asymptomatic women with PCO alone, and a difference of similar magnitude 
between PCOS and controls, 
o Within groups, there was a significant decrease in PI and a paradoxical increase in 
Vmax in PCOS women following inhalation of 5% CO2 .
Increased ICA PI is a risk factor for cerebral infarction in patients with type II diabetes 
(Nakatou et al, 2004). However, in PCOS women PI in this vessel was reduced compared
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to controls. This could result either from increased luminal diameter of the ICA or 
decreased downstream vascular resistance and therefore increased blood flow. Although 
it was not possible to measure luminal diameter in this study, since the required software 
was not available on the ultrasound machine within the host Department at the time the 
work was performed, results from a later pilot study indicate there were no differences in 
luminal diameter between women with PCOS, women with PCO alone and controls. 
Thus it is likely that the decreased PI is related to a reduction in downstream cerebral 
vascular resistance in women with PCOS.
The finding of decreased PI in the present study differs from that reported in patients with
type II diabetes (Lee et al, 2000). Lee and colleagues (2000) reported increased PI in the
ICA and middle cerebral arteries in patients with diabetic complications in relation to
those without complications, as well as in controls. This is not an unusual finding
because, compared with health controls, patients with diabetes have more extensive
atherosclerosis of the extracranial and intracranial vessels (Grunett, 1963). The
differences noted in this thesis may suggest that PCOS women have insulin resistance but
no diabetic complications and it would be of interest to assess vascular changes in these
women who may develop type II diabetes in later life. Vascular responses in women with
♦
PCOS may be modulated by oestrogen profile. Oestrogen is known to enhance blood 
flow and the increase in oestradiol concentration from controls through PCO to PCOS 
may suggest its influence on ICA resistance i.e. low PI. However, after controlling its 
effect within multiple regression models, the difference was still significant.
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Non-invasive evaluation of middle cerebral artery blood flow velocity, with transcranial 
Doppler ultrasound, and CC^-induced vascular stimulation has been used in the 
assessment of cerebral vascular reactivity in patients with ICA occlusions (Ringelstein et 
al, 1988; Markus and Cullinane, 2001). In the present study, vascular reactivity was only 
assessed in the extracranial vasculature, possibly suggesting changes distal to the point of 
measurement. There is no published data to suggest that CO2 could act as a 
vasoconstrictor. The paradoxical response to 5% CO2 in the ICA in the present study in 
comparison to Ringelstein et al (1988) and Markus and Cullinane (2001) may reflect the 
concentration of CO2 used (5% vs. 8%), and age of patients (mean age 26.1 vs. 51 years) 
and the technique used in assessing vascular reactivity (spectral colour Doppler 
ultrasound vs. transcranial ultrasound with computer assisted programme). Secondly, this 
response after inhalation of CO2 , suggests some form of neurohumoral dysregulation may 
be the cause of altered reactivity in women with PCOS. However, as previously 
described, Lees (1998) reported similar unexpected finding in the uterine artery of PCOS 
women with glyceryl trinitrate as a vasodilator. Whilst rapidly developing atherosclerosis 
with loss of elasticity and ability to dilate may relate to the loss of vascular reactivity in 
older subjects, this is unlikely to be the cause in younger subjects. Further studies are on­
going using Near-Infrared Spectrophotometry to measure cerebral blood flow and 
vascular reactivity with 5% CO2 in women with PCOS and controls.
As previously described, insulin resistance is a central feature of PCOS and there is 
increasing evidence of type II diabetes in these women (Dunaif, 1997). The importance of 
assessing haemodynamic parameters results from a cross-sectional study which showed
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PI being an independent parameter for estimating previous risk of cerebral infarction in 
patients with type II diabetes (Nakatou et al, 2004).
10.3 Viscoelastic properties and intima-media thickness in women with 
polycystic ovaries
o This is the first demonstration of decreased vascular compliance in the CCA 
and ICA and conversely an increased stiffness index in these vascular beds in 
PCOS women.
o Similar findings were also observed in asymptomatic women with PCO. 
o The IMT was also increased in the elastic CCA and muscular CFA in young 
PCOS women
Alterations of the mechanical properties of arteries -  compliance in relation to risk factors
i.e. hypertension, diabetes, dyslipidaemia, smoking and age (McVeigh, et al, 1991) -  are 
major contributors to cardiovascular morbidity and mortality (Lusis, 2000).
With respect to the evaluation of the vascular elastic properties, the main limitation is in 
the assessment of blood pressure. Ideally blood pressure should be measured from the 
same segment of artery under investigation. Intra-arterial blood pressure recording would 
be difficult to justify in this research project due to its invasive nature. Non-invasive 
assessment of brachial artery blood pressure introduces a small error to the estimation, 
but has been used as the reference point in much published research (Benetos et al, 1993; 
Sonesson et al, 1993; Salomaa et al, 1994). Brachial artery blood pressure was measured 
in all women using an automated device at the start of the procedure with a cuff
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appropriate for the circumference of the arm. Measurements were taken at 2 min intervals 
until the systolic and diastolic blood pressures varied by less than 5 mmHg and the pulse 
rate by 5 beats/min, over two readings and an average of three readings were taken. This 
same technique was used for all the patients and the method is therefore not responsible 
for the observed differences between the groups.
The limitation with duplex scanning is the inaccuracy and inability to recognize the IMT 
in the near wall (Wong et al, 1993; Linhart et al, 2000). Therefore, the IMT is determined 
in the far arterial wall, which in general is significantly thicker when compared with 
histological measurement (Wong et al, 1993; Gamble et al, 1993; Persson et al, 1994). 
Another limitation against the use of duplex determination of the IMT is that there is no 
consensus of where the measurement should be taken. The Edinburgh Artery Study 
(EAS) (Allan et al, 1997) defined the CCA IMT as the maximum value measured from 
both left and right common carotid arteries, 2.0 cm below the bifurcation. The Rotterdam 
study (Bots et al, 1994) used the average value from both left and right CCA, each with 
three recordings obtained from the distal 1.0 cm from the carotid bulb. The 
Atherosclerosis Risk In Community (ARIC) study (Burke et al, 1995) used the average of 
the readings taken from the CCA, the carotid bifurcation and the ICA of both left and 
right sides.
In this thesis, the carotid IMT was measured according to a modified version of the EAS 
study i.e. an average of three readings taken within 2.0 cm of the bifurcation from the 
carotid artery. The use of average reading rather than the maximum reading of IMT has
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the advantage of better reproducibility (Frost et al, 1998) and allows the evaluation of 
observer errors. The coefficient of variations for IMT measurements in this thesis was 8% 
for CCA and 23% for the carotid bulb, respectively. The lack of statistical significance at 
the carotid bulb may be explained by the increased intra-group variation possibly due to 
the anatomical shape of the segment resulting in the inability to produce an adequate 
image. The IMT was not measured in the internal carotid artery due to its localisation i.e. 
the CCA bifurcating behind the mandible, rendering the identification and positioning 
difficult.
There is evidence suggesting that reduced vessel wall compliance (Winer et al, 2001) and 
increased IMT of the CCA (Jerrard-Dunne et al, 2002) are independent risk factors for 
myocardial infarction in young subjects. The mechanism of impaired vascular 
compliance may be genetic in origin and mediated through alterations in the vessel wall 
matrix composition independent of age, gender, smoking, mean arterial pressure, BMI, 
family history of hypertension and activity scores (Brull et al, 2001). Brull et al (2001) 
reported an association between collagen type 1-alpha 1 gene (COL1A1) polymorphism 
and arterial compliance. Furthermore, there is evidence of a possible linkage between 
genetic alteration of angiotensin converting enzyme gene (ACE-ID) and functional large 
artery properties (CCA and CFA) in a white population (Balkestein et al, 2001).
10.4 Skin microcirculation in women with polycystic ovaries
o This is the first demonstration of reduced cutaneous response to ACh 
(endothelial-dependent) but no difference in response with SNP (endothelial- 
independent) in women with PCOS.
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There is some evidence that skin vessel reactivity to SNP and, to a lesser extent, ACh 
decreases with age and is gender dependent (Algotsson et al, 1995). Although skin 
reactivity declined with age in both men and women, women exhibited greater perfusion 
after iontophoresis than men. The influence of age in the present study is unlikely since 
all subjects in the present study were young adults. Although there was no difference in 
serum cholesterol levels and BP (before and after iontophoresis) in women with PCOS in 
relation with controls, there are in-vitro studies to suggest evidence of impaired 
endothelial function in small arteries i.e. skin (as a result of hypertension and 
dyslipidaemia), which do not develop atherosclerotic plaques (Heagerty, 1999).
Steinberg et al (1996) and Paradisi et al, (2001) reported abnormal vascular reactivity 
with infrafemoral infusions of MCh in PCOS women, suggesting impaired endothelial 
function, but did not assess vascular smooth muscle function. The findings of impaired 
perfusion response confirm endothelial dysfunction rather than vascular smooth muscle 
function of small vessels in these women with the syndrome. Although iontophoresis 
only assesses the cutaneous microcirculation, it is effectively a robust surrogate marker of 
vascular function in other vascular beds. Reduced response has been reported in women 
with previous gestational diabetes mellitus (Hannemann et al, 2002) and there is a link 
between pre-eclampsia and maternal coronary heart disease (Ramsay et al, 2002; 2003) as 
well as in heart transplant recipients (Andreassen et al, 1998).
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A limitation of this study is that it only showed that endothelium dysfunction is mediated 
by NO but did not demonstrate other systems localised in the endothelial and smooth 
muscle cells which may regulate microvascular tone. It did not assess the extent to which 
other substances such as prostaglandins and EDHF contribute and act as intermediates in 
relation of the L-arginine/nitric oxide pathway. The goal of this work was to assess 
functional change in skin microcirculation using simultaneous introduction of 
endothelium-dependent ACh and endothelium-independent stimulus SNP in women with 
PCOS and to establish and complement the invasive technique used before for the 
assessment of endothelial function. Whether abnormal endothelial function observed in 
women with PCOS is a more generalised defect rather than an abnormality at the 
endothelial muscarinic receptor level remains to be determined.
The prognostic value of endothelial function independently predicting acute coronary 
events has been reported in patients with and without coronary artery disease by 
measuring change in vascular resistance with ACh and SNP. This provides both 
functional and prognostic information that complements angiographic and risk factor 
assessment i.e. subjects with increased response to ACh had improved survival as did 
those without coronary atherosclerosis in the total population (Halcox et al, 2002). Once 
again the mechanism responsible for these findings is unclear, but genetic factors could 
be contributory. As described before, NO plays an important role in atherogenic events 
(Channon et al, 2000). Polymorphism in the eNOS activity influences the functional 
action of the enzyme and affects the susceptibility of atherogenesis. A recent study has
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demonstrated the 4a allele and eNOS combined genotypes (4a4a + 4a4b/ -786CC + TC) 
are independent predisposing factors for carotid atherosclerosis (Fatini et al, 2004).
10.5 Aortic function in a rat model of polycystic ovary syndrome
o The principal morphological and endocrine features seen in PCOS women 
(Goldzieher, 1962; Conway et al, 1989; Franks, 1989) were replicated in this 
model.
o This is the first in-vivo demonstration of thoracic aortic vascular changes, in 
parallel to those seen in humans, of decreased vascular compliance and an 
increased vascular stiffness index.
o For the first time, an in-vitro study has confirmed endothelial dysfunction in a 
young animal model (15-18 year old female).
Although the findings of abnormal vascular reactivity in the cutaneous microcirculation 
(Chapter 8) and that by Paradisi et al (2001), in the femoral artery suggests endothelial 
dysfunction in women with PCOS relative to controls, PCOS-related vascular 
modifications may result from the influence of endocrine and metabolic disturbances on 
endothelial function, and in the longer term, increase the risk of atherosclerosis. Because 
it is not feasible to assess the mechanism(s) responsible for our findings in human 
subjects, an animal model of PCOS was used to confirm the endocrine, metabolic, 
ovarian morphology, endothelial and mechanical properties seen in women with PCOS. 
Further studies are now planned to use this animal model for assessing the mechanism(s) 
responsible for our findings.
Unfortunately the PCOS-like symptoms do not last beyond three weeks in the 
mifepristone-injected rat model, and it is therefore difficult to determine whether longer 
period treatments would lead to symptoms of metabolic disorder seen in older PCOS 
sufferers. Although the reproducibility of repeated measurements of the vascular 
compliance and stiffness index were made with reasonable levels of reproducibility and 
accuracy, the effect of anaesthesia on the central nervous system and vascular system 
may be different depending on the degree of disease. But the effect of disease seems 
unlikely in this short-term model.
A limitation of the in-vitro study is that local concentration of ACh is unknown, and the 
assumption that the levels at which the differences were significant between mifepristone 
treated rats and controls are significantly less than those required to produce vascular 
effects in-vivo studies, the accuracy of the model in relation with human situation is not 
validated. Secondly, the effects of vasoactive substances such as prostacyclin, EDHF on 
vascular smooth muscle, which are derived and released from the endothelium, were not 
assessed.
As discussed previously, there is no ideal animal model of PCOS. Most of the published 
models involve the administration of sex steroids or, in this case, an antagonist. Although 
using this model we demonstrated many of the endocrine, metabolic and morphological 
features of the syndrome, it is possible that some of the vascular abnormalities found 
resulted from the direct effects of mifepristone or progesterone antagonism. Although 
progesterone has a dilatory effect on rat aorta (Glusa et al, 1997; Mukerji et al, 2000;
219
Zhang et al, 2002), there is no evidence to suggest that it influences vascular compliance. 
The evidence for this lack of effect derived from studies of post-menopausal women 
(Honisett et al, 2003) and one study of a third-generation combined oral contraceptive pill 
(Willekes et al, 1999). There are no published studies relating to the effects of 
mifepristone on arterial compliance. There is therefore no reason to attribute the 
decreased arterial compliance seen in the mifepristone-induced PCOS rat model to a 
direct effect of this drug or progesterone antagonism.
10.6 Final summary
The unique finding in this thesis is that asymptomatic women with PCO had similar, but 
smaller, significantly different changes in Doppler parameter Vmax and vascular 
compliance, seen in women with PCOS in relation to controls; bearing in mind these 
women had normal hormonal and metabolic features. The explanation for this 
observation is that either phenotypic or genotypic factor(s) may be common to both PCO 
and PCOS women. The typical phenotypic appearance common to both asymptomatic 
and symptomatic women with PCO is ovarian morphology. However, this characteristic 
feature seems unlikely to be the cause of observed vascular changes seen in women with 
PCO. Therefore, one can hypothesise that common genotypic risk factor(s), either 
endocrine, metabolic or both, may underlie both PCO and PCOS women. Further studies 
are necessary to confirm or refute this explanation.
The results demonstrate that PCO, per se, accelerates the earlier presentation of 
atherogenesis i.e. the initiation of the ‘disease’, not only in young women with PCOS but
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also in asymptomatic women with PCO. It is now important not to consider PCO, present 
in around 20% of the female population, as a simple, uncomplicated condition with low 
morbidity / mortality. Life style modification by weight management through the 
promotion of exercise and eating habits should be an essential educational approach in 
women with PCO.
There is little doubt that women with PCOS cluster risk factors for cardiovascular disease 
and there is more evidence from experiments in this thesis of both increased macro- and 
micro-vascular disease in young women with PCOS and in a comparable animal model. 
Furthermore the independent associations of PI, vascular compliance, IMT and 
endothelial dysfunction with cardiovascular disease and stroke as well as the genetic 
predisposition suggests that doctors in all specialities should not only be aware of the 
association of PCOS with diabetes, dyslipidaemia and hypertension but also of possible 
long-term cardiovascular/cerebrovascular consequences in these women.
Insulin sensitising agents such as metformin are now widely used to treat infertile women 
with PCOS (Ehrmann et al, 1997; Paradisi et al, 1999) and there is some evidence of its 
beneficial effect on blood pressure, plasma cholesterol, triglycerides (Wulffele et al, 
2004) and haemostasis and vascular function (Grant, 2003). However, the use of 
metformin in a large study by the Diabetes Prevention Program Research Group (2002) 
reported that life style management was more effective than metformin in the reduction 
of type II diabetes in persons at high risk. Furthermore, in a recent 2-year prospective 
study reported that metformin attenuates progression of CCA-IMT in patients with type II
diabetes and did not alter BMI, BP and serum lipids relative to controls (Matsumoto et al, 
2004). Obviously metformin shows potential for short-term gain, and we should not 
overlook the long-term objectives of improving gynaecological and general health over 
many years, including into the menopausal years.
10.7 Suggested topics for future research arising from this work
Human studies
o Insulin resistance is a common feature of PCOS and insulin-sensitising drugs are 
currently being used regularly. Although some doctors are advocating long-term 
treatment (with metformin) for all women with PCOS (Nestler, 2002), this 
practice has been critised (Harbome et al, 2003) on the basis that an association 
between increased cardiovascular mortality and PCOS, let alone the benefits of 
any intervention to prevent this increase, are also unproven. The effects of such 
drugs on vascular mechanics may provide information on the beneficial effects, if 
any, on cardiovascular mortality.
o Insulin resistance, increased incidence of hypertension and dyslipidaemia are all 
associated with abnormal blood rheology (Rillaerts et al, 1989) resulting in 
increased blood viscosity (Lowe et al, 1982) and leading to increased shear stress 
on the vessel wall (Shaaban and Duemickx, 2000). A non-invasive, in-vivo 
technique for the assessment of vessel wall shear stress in atherosclerotic-prone
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haemodynamic profile of women with PCOS would provide and support the 
vascular changes seen in this thesis.
Laboratory research
o Further studies are planned to characterise the endocrinological and metabolic 
changes in the mifepristone rat model and possibly in a larger species (Home 
Office Ethics Approval granted) and to clarify the possible mechanism(s) 
involved.
o Vasodilator action of EDHF on thoracic aortic rings from mifepristone-treated 
rats and control animals. Repeat organ bath experiments with aortic rings pre­
contracted with PE and relaxed with cumulative increments of ACh in the 
presence of L-NAME and indomethacin which blocks the production of NO and 
prostacyclin respectively.
o Measure nitric oxide concentration in either serum or plasma as nitrate/nitrite 
using the established and accurate chemiluminescent technique
o The only active component of the aortic wall is the smooth muscle. There is 
evidence of increased expression of platelet-derived growth factor (PDGF) 
especially [3-receptors and fibronectin (the important factor in the phenotypic 
change of smooth muscle cell from contractile to synthetic with the expression of 
PDGF (3-receptor) from smooth muscle cells and arterial thickness is increased 
after balloon catheter injury before the onset of NIDDM in Otsuka Long-Evans 
Tokushima fatty rats (Tamura et al, 2000). The increased vascular stiffness and
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decreased response to ACh in PCOS model could be attributed to increased 
expression of these vasoactive agents in the smooth muscle wall, leading to 
migration from the media into the intima and their proliferation in the intima, 
typically observed after percutaneous transluminal coronary angioplasty. 
Assessment of PGDF P-receptors and fibronectin from smooth muscle cells of 
mifepristone treated rats may provide the mechanism(s) responsible for macro 
vascular disease.
Mortality studies
o Since the criteria for defining PCOS have been agreed, large, multi-centre, 
collaborative studies with universally accepted definition of PCOS are now 
necessary to establish if any increased risk of cardiovascular mortality is apparent 
in these women.
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APPENDICES
1. 0 Abbreviations used in Excel spread sheets
2.0 Attached CD with Excel spread sheets of:
2.1 Raw data for measurements in Chapter 5
2.2 Raw data for measurements in Chapters 6 and 7 A& B
2.3 Raw data for measurements in Chapter 8
2.4 Raw data for measurements in Chapter 9 A & B
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ABBREVIATIONS
ACCB Average common carotid artery back pressure
ACCPI Average common carotid artery pulsatility index
ACCRI Average common carotid artery resistance index
ACCV Average common carotid artery velocity
ACh Acetylcholine
AICB Average internal carotid arteiy back pressure
AICPI Average internal carotid artery pulsatility index
A1CRI Average internal carotid artery resistance index
AICV Average internal carotid artery velocity
BACKPRCC Back pressure right common carotid artery
BACKPRIC Back pressure right internal carotid artery
BMI Body mass index
CHOL Total cholesterol
DACCPI Difference average common carotid artery pulsatility index
DACCRI Difference average common carotid artery resistance index
DACCV Difference average common carotid artery velocity
DAICPI Difference average internal carotid artery pulsatility index
DAICR1 Difference average internal carotid artery resistance index
DAICV Difference average internal carotid artery velocity
DBP Diastolic blood pressure
DDBP Difference diastolic blood pressure
DDCA Diastolic diameter common carotid artery in PCOS women
DDCCA—N Diastolic diameter common carotid artery in control women
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DDCCA-P Diastolic diameter common carotid artery in PCO women
DDCFA Diastolic diameter common femoral artery in PCOS women
DDCFA-N Diastolic diameter common femoral artery in control women
DDCFA-P Diastolic diameter common femoral artery in PCO women
DDIA Diastolic diameter internal carotid artery in PCOS women
DDIA-N Diastolic diameter internal carotid artery in control women
DDIA—P Diastolic diameter internal carotid artery in PCO women
DLC Diastolic diameter left common carotid artery
DLI Diastolic diameter left internal carotid artery
DRC Diastolic diameter right common carotid artery
DRI Diastolic diameter right internal carotid artery
DSBP Difference systolic blood pressure
FAI Free androgen index
FASTG Fasting glucose
FASTI Fasting insulin
FSH Follicle stimulating hormone
GACCPI Gas average common carotid artery pulsatility index
GACCRI Gas average common carotid artery resistance index
GACCV Gas average common carotid artery velocity
GAICPI Gas average internal carotid artery pulsatility index
GAICRI Gas average internal carotid artery resistance index
GAICV Gas average internal carotid artery velocity
GDBP Gas diastolic blood pressure
GLCCPI Gas left common carotid artery pulsatility index
GLCCRI Gas left common carotid artery resistance index
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GLCCV Gas left common carotid artery velocity
GLICPI Gas left internal carotid artery pulsatility index
GLICRI Gas left internal carotid artery resistance index
GLICV Gas left internal carotid artery velocity
GRCCPI Gas right common carotid artery pulsatility index
GRCCRI Gas right common carotid artery resistance index
GRCCV Gas right common carotid artery velocity
GRICPI Gas right internal carotid artery pulsatility index
GRICRI Gas right internal carotid artery resistance index
GRICV Gas right internal carotid artery velocity
GSBP Gas systolic blood pressure
HDL High density lipoprotein
HT Height
INSRES Insulin resistance index
LC-C Left common carotid artery compliance
LC-S Left common carotid artery stiffness index
LCCB Left common carotid artery back pressure
LCCPI Left common carotid artery pulsatility index
LCCRI Left common carotid artery resistance index
LCCV Left common carotid artery velocity
LI—C Left internal carotid artery compliance
LI-S Left internal carotid artery stiffness index
LDL Low density lipoprotein
LICB Left internal carotid artery back pressure
LICPI Left internal carotid artery pulsatility index
259
LICRI
LICV
LH
L-NAME
MEANBP
N-C-C
N-C-CF
N-C-IC
N-IMT-BULB
N-IMT-C
N-IMT-IC
OEST
PCO
PCO-C-C
PCO-C-CF
PCO-C-IC
PCO-IMT-BULB
PCO—IMT-C
PCO—IMT-CFA
PCOS
PCOS-C-C
PCOS—C—CF
PCOS-C-IC
PCOS—IMT—BULB
Left internal carotid artery resistance index 
Left internal carotid artery velocity 
Luteinising hormone 
Ng -  nitro -  L-arginine methyl ester 
Mean blood pressure
Common carotid artery compliance in control women 
Common carotid artery compliance in control women 
Internal carotid artery compliance in control women 
Intima media thickness o f carotid bulb in control women 
Intima media thickness of common carotid artery in control omen 
Intima media thickness of common femoral artery in control women 
Oestradiol
Polycystic ovary syndrome
Common carotid artery compliance in PCO women 
Common carotid artery compliance in PCO women 
Internal carotid artery compliance in PCO women 
Intima media thickness of carotid bulb in PCO women 
Intima media thickness of common carotid artery in PCO women 
Intima media thickness of common femoral artery in PCO women 
Polycystic ovary syndrome
Common carotid artery compliance in PCOS women 
Common femoral artery compliance in PCOS women 
Internal carotid artery compliance in PCOS women 
Intima media thickness of carotid bulb in PCOS women
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PCOS—IMT—C Intima media thickness of common carotid artery in PCOS women
PCOS—IMT—CF Intima media thickness of common femoral artery in PCOS women
PE Phenylephrine
PROLAC Prolactin
RCCB Right common carotid artery back pressure
RC-C Right common carotid artery compliance
RI-C Right internal carotid artery compliance
RCCPI Right common carotid arteiy pulsatility index
RCCRI Right common carotid artery resistance index
RCCV Right common carotid artery velocity
RC—S Right common carotid artery stiffness index
RI—S Right internal carotid artery stiffness index
RICB Right internal carotid artery back pressure
RICPI Right internal carotid artery pulsatility index
RICRI Right internal carotid artery resistance index
RICV Right internal carotid artery velocity
SBP Systolic blood pressure
SD Standard deviation
SDCA Systolic diameter common carotid artery in PCOS women
SDCCA-N Systolic diameter common carotid artery in control women
SDCCA—P Systolic diameter common carotid artery in PCO women
SDCFA Systolic diameter common femoral artery in PCOS women
SDCFA—N Systolic diameter common femoral artery in control women
SDCFA-P Systolic diameter common femoral artery in PCO women
SDIA Systolic diameter internal carotid artery in PCOS women
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SDIA—N Systolic diameter internal carotid artery in control women
SDIA—P Systolic diameter internal carotid artery in PCO women
SHBG Sex hormone binding globulin
SNP Sodium nitropruside
SLC Systolic diameter left common carotid artery
SLI Systolic diameter left internal carotid arterty
SRC Systolic diameter right common carotid artery
SRI Systolic diameter right internal carotid artery
TRIGL Triglyceride
WHR Waist to hip ratio
WT Weight
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